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Chapter 1
General introduction
A.B.P. Staring
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General introduction 11
Halfway during the 20th century, the development of antipsychotic medications 
revolutionised the care for patients with psychosis. Yet today, efficacy of anti-
psychotic medications is still far from perfect. Positive symptoms may persist 
despite antipsychotic treatment, the effects on cognitive and negative symptoms 
are small, and side-effects are often burdensome (Leucht et al., 2009a). There-
fore, putting means and efforts into developing more efficacious medication, 
if possible with fewer side-effects, is to be applauded. However, effect-sizes of 
the second-generation antipsychotic medications on primary symptoms, in 
comparison to placebo, currently lie around .51 (Leucht et al., 2009b). Note 
that this effect-size is the result of a meta-analysis of controlled trials where 
medication intake was strictly monitored and adherence was probably high. 
However, in the average patient population, non-adherence is common in more 
than half of the patients (Perkins, 2002), and it is associated with poor outcome 
and high costs. In the UK for example, non-adherence to antipsychotic medica-
tion predicted an excess annual cost of more than 5.000 pound of service use 
per patient (Knapp et al., 2004), due to factors such as crisis interventions and 
readmissions. It is therefore plausible, considering that no recent development 
has improved the effects of antipsychotic medications substantially, that current 
intervention and research efforts are most likely to successfully improve out-
come if they target the non-adherence problem. Medications, no matter how 
effective, are not helpful when patients do not use them. Given the fact that 
a mere 58% of the prescribed antipsychotic medications is actually taken by 
patients (Cramer & Rosenheck, 1998), solving the problem of non-adherence 
could theoretically almost double the efficacy of antipsychotic treatment in 
everyday practice.
Research on interventions to improve adherence has been accumulating 
over the past fifteen years, but the results are disappointing. It has become clear 
that non-adherence is no easy target for change. Patient education for example, 
i.e. teaching about the biomedical model of schizophrenia and the necessity 
of medication to control symptoms, does not increase adherence. Other inter-
ventions have produced mixed results. Looking at the scientific literature on 
predictors of non-adherence, it seems that poor insight, denial, the experience 
of stigma, and cognitive dysfunction each are of some relevance. However, 
although these factors are often specifically present in patients with psychosis, 
it is known that non-adherence is also a huge problem across other medical 
and psychiatric disorders. Non-adherence is certainly not confined to the field 
of psychosis. Therefore, non-psychopathological processes probably explain the 
largest part of the non-adherence problem in psychosis. These factors, found 
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in adherence studies in other illnesses, include a natural tendency to quit treat-
ment when symptoms have receded, side-effects, a too complex medication 
regime, not wanting to think about being ill, forgetfulness, a poor alliance with 
the clinician, or maybe a general kind of anti-medication attitude (e.g. Jackson 
et al., 2009; Lingam & Scott, 2002).
In conclusion, treatment non-adherence in psychotic disorders is a big 
problem and we are presently in need of viable theoretical models and effective 
interventions to deal with it.
researCh questions
The first aim of this study was to develop an intervention that would have a 
good chance of improving adherence. For this, we conducted a literature-review 
to develop an empirical-theoretical model as the foundation of Treatment 
Adherence Therapy (TAT; Chapter 2).
The main objective of our research was to find out whether TAT is effective. 
To investigate this, we conducted a multi-centre randomised controlled trial 
(RCT) (Chapter 3). An RCT is to-date the best scientific method available for 
testing the effectiveness of interventions in health care.
We also examined research questions that would contribute to our understand-
ing of the expected mechanisms of TAT. One is that adherence to antipsychotic 
medication may have diverging effects on patients’ quality of life, as good 
adherence is likely to result in symptom-reduction as well as more side-effects 
(Chapter 4). This would mean that structural monitoring of symptoms and 
side-effects is useful for finding an optimal balance for each patient with the 
best chance of improving quality of life, and possibly adherence.
Another issue is that insight into illness may not always be relevant for good 
adherence, but rather in only those patients who have sufficient cognitive abili-
ties to act according to their convictions and beliefs (Chapter 6). If supported, 
this hypothesis would imply that the best strategies for improving adherence 
may be different per patient. Enhancing insight into illness would only be use-
ful for some. However, insight may have negative consequences for self-esteem 
and quality of life, which raises the following dilemma: will improved insight 
into illness produce more benefits than drawbacks? We hypothesized that the 
detrimental effects of insight would depend on the amount of stigma that 
patients attach to the illness (Chapter 5). If supported, this could mean that 
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General introduction 13
reducing self-stigmatization may be helpful in achieving positive consequences 
of insight into illness, while avoiding the detrimental ones.
Another research question was how it might be explained that the patients 
of ethnic minorities often adhere less to treatment than native patients. We 
hypothesized that immigrant patients are more likely to use a ‘sealing-over’ 
recovery style, a factor that is related to lower self-esteem (Chapter 7). Also, as 
a patient’s recovery style may significantly influence the manner in which they 
deal with and think about psychotic episodes as well as how they participate and 
benefit from treatment, we wanted to test if an ‘integrating’ recovery style was 
able to predict the remission of a psychotic disorder, and to compare its effects 
with those of insight into illness and the therapeutic alliance (Chapter 8).
During the execution of the randomised controlled study on TAT, we were 
soon confronted with the problem that some of the most non-engaging patients 
refused participation with the study. Of them, some were either very non-
adherent to antipsychotic treatment or completely refusing medication, while 
at the same time repeatedly experiencing relapses and re-admissions. For them, 
we came up with the idea of using financial incentives to promote adherence 
to depot antipsychotic treatment. A research pilot evaluating this method was 
conducted (Chapter 9).

Chapter 2
Understanding and improving treatment adherence 
in patients with psychotic disorders: a review and a 
proposed intervention.
A.B.P. Staring 
C.L. Mulder 
M. van der Gaag 
J.P. Selten 
A.J.M. Loonen 
M.W. Hengeveld
Current Psychiatry Reviews, 2006, 2, 487-494
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abstraCt
Non-adherence to treatment in patients with psychotic disorders is related to 
higher rates of relapse, hospitalization, and suicide. Important predictors of 
non-adherence include poor social structure, cognitive deficits, negative medi-
cation attitude, side effects, depression, a sealing-over recovery style, feelings 
of stigmatization, denial of treatment need, and lack of insight. Attempts to 
improve adherence have shown that psycho-education alone is not fully effec-
tive, and that motivational interviewing, behavioural strategies, and linking 
a patient’s personal goals to treatment may increase adherence. Based on the 
empirical data reviewed, we formed four clusters of possible causes of non-
adherence, each of which can be targeted by a specific module of our developed 
Treatment Adherence Therapy (TAT). These four modules are: self-enhancement, 
motivational interviewing, medication optimization, and behavioural training. An 
individual patient may benefit from one or more of these modules; and thus the 
contents of TAT vary in accordance with individual causes of non-adherence. 
Basically, TAT aims to help patients work out what they want regarding treat-
ment and then support them in following this through.
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2.1 introduCtion
2.1.1 Definition
Although the term compliance is widely used in the medical literature on psy-
chotic disorders, it has been criticized as implying that the patient is expected 
to passively obey the advice of the clinician (Bebbington, 1995). Indeed, this 
criticism is consistent with definitions of compliance: “the extent to which 
a person’s behaviour coincides with the medical advice he/she has received” 
(Kampman & Lethinen, 1999), or “the extent to which the patient’s behaviour, 
in terms of taking medications, following diets, executing life style changes, 
coincide with the clinical prescription” (Haynhes, Taylor & Sachett, 1979). 
A definition that stresses the agreement reached between doctor and patient 
would seem more desirable (Zweben & Zuckoff, 2002; Kemp et al., 1998). 
The term concordance has been suggested, but then the problem arises that 
agreements with the patient are a necessity for someone to possibly become 
non-adherent. If no agreements are made, one cannot be non-adherent. This 
is not practical as especially those patients with whom no agreements can be 
made should be regarded non-adherent. We will therefore use the term adher-
ence, based on the above mentioned compliance definition of Kampman and 
Lethinen (1999), and simultaneously realise that adherence is not necessarily 
desirable in all cases. As McDonald et al. (2002) put it: “The term adherence is 
intended to be non-judgmental, a statement of fact rather than of blame of the 
prescriber, patient or treatment.”
There are many measures of adherence, most of which concentrate on 
medication adherence, as measured by patient self-report and physician assess-
ment. Both consistently overestimate adherence (Byerly et al., 2007; Churchill, 
1985). Other methods to assess medication adherence include urine and blood 
assays or pill counts, but the first are subject to individual variations in phar-
macokinetics, and with the latter it is unfortunately not possible to tell whether 
the patient has actually taken the medication or thrown it away. Extending the 
concept of adherence to also include a person’s availability for appointments, 
collaboration, and help-seeking behaviour, Tait et al. (2002) introduced the 
term service engagement. We consider this to be a more appropriate operational 
definition of treatment adherence because it encompasses several domains 
(Zweben & Zuckoff, 2002). However, many of the studies reviewed here were 
concerned with medication compliance and not the other aspects covered by 
the term service engagement.
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2.1.2 Prevalence of non-adherence
The prevalence-numbers of non-adherence, as found in various studies, depend 
on the definition of adherence used and the cut-off scores to distinguish between 
adherent and non-adherent behaviour. It is therefore not surprising that a sys-
tematic review of 103 studies found estimates of failure to adhere to treatment 
programs to range from 24% to 90% (Nosé, Berbui & Tasella, 2003). Cramer 
and Rosenheck (1998) found that patients who were prescribed antipsychotics 
took on average 58% of the recommended amount of medication. They also 
concluded that adherence might be lower in patients with psychiatric disorders 
than in those with physical disorders. Perkins (2002), in her review of predic-
tors of non-adherence, concluded that at least 50% of all patients with chronic 
psychotic disorders do not fully comply with treatment. Other studies not 
included in Perkins’ review reported that at least 50% and 75% of patients were 
non-adherent to antipsychotic drug treatment after 1 and 2 years, respectively 
(Bebbington, 1995; Weiden et al., 1991; Weiden, Aquila & Standard, 1996). 
It would thus seem that non-adherence is the norm rather than the exception.
2.1.3 Consequences of non-adherence
Non-adherence obviously prevents treatment from achieving its intended effect. 
Many authors claim that antipsychotic medication is effective for reducing 
(mainly the positive) symptoms in schizophrenic patients (Davis & Andruikaitis, 
1986), but others make a case against it, arguing that the long-term natural course 
of schizophrenia has never thoroughly been investigated, making us unable to 
clearly determine the long term effects of antipsychotic medication (Whitaker, 
2003). However, empirical studies have shown that the risk of relapse is three to 
five times higher after discontinuation of neuroleptic treatment (Fenton, Blyer 
& Heinssen, 1997; Dixon & Lehman, 1995; Robinson et al., 2002; Ucok et al., 
2006; Weiden et al., 2004). The consequences of non-adherence are not only 
worsening of a person’s mental health, but also homelessness, imprisonment, 
violence, and suicide (Torrey & Zdanowicz, 2001). The risk of suicide is about 
3.75 times higher in patients with schizophrenia who are poorly adherent than 
in those who adhere to treatment (Hawton et al., 2005). Zweben and Zuckoff 
(2002) summarized evidence for a relationship between treatment adherence 
and better outcome. Furthermore, they reported that clinicians could become 
frustrated and demoralized by patients who inconsistently attend therapeutic 
activities, and that patients who occupy available slots without fully utilizing 
the offered treatment prevent other, possibly more cooperative, patients from 
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accessing treatment. These last aspects underline the importance of a more 
broadly defined treatment adherence.
2.2 attemPts to imProve adherenCe in Patients with PsyChotiC 
disorders
Given the prevalence and consequences of non-adherence, it is important to 
try to prevent and/or change this behaviour. Although psycho-education may 
seem appropriate, reviews conclude that it is not fully effective (Zygmunt et 
al., 2002; Dolder et al., 2003), because while education increases knowledge, 
it does not increase motivation to adhere to treatment (Kemp & David, 1995). 
For this reason other interventions have been developed and tested, the most 
frequently cited of which is Compliance Therapy (Kemp et al., 1998), which 
consists of four to six sessions dedicated to producing medication cognitions by 
means of cognitive behavioural techniques and motivational interviewing. The 
differences between regular psycho-education and compliance therapy mainly 
consist in that the latter searches for individual motives for (non-)compliance 
and uses specific psychological techniques and metaphors to work from – and 
add to – the patient’s perspective when providing information and correct-
ing misconceptions. A randomised controlled trial in patients with psychotic 
disorders, comparing compliance therapy with supportive counselling, showed 
positive effects on insight, attitudes to treatment, and observer-rated compli-
ance (Kemp et al., 1998). However, the trial had methodological shortcomings, 
such as attrition (only 48 of 75 patients remained after 18 months of follow-up) 
and compliance was estimated using only one item. O’Donnel et al. (2003) 
tried to replicate this study and compared compliance therapy with non-specific 
counselling in a group of 56 patients with schizophrenia. They used blind esti-
mates of compliance but failed to detect an effect. They explained the difference 
in results by arguing that patients with schizophrenia may benefit less from 
compliance therapy than patients with other psychotic disorders.
Byerly et al. (2005a) investigated compliance therapy in 30 patients with 
either schizophrenia or schizoaffective disorder, but found no improvement in 
clinician and patient ratings of adherence. They concluded that patients with 
psychotic disorders might not benefit from this treatment. However, their sample 
was relatively adherent at study entry (an average of 72% medication adherence) 
which may have contributed to a ‘ceiling’ effect (Byerly et al., 2005a). This 
limitation emphasizes that non-adherent patients are the most suitable targets 
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for adherence promoting interventions. Moreover, the study did not include 
a control group, and therefore it was not possible to determine whether the 
intervention prevented the patients from sliding into non-adherence. It is also 
possible that more sessions are needed for a measurable and enduring effect. In 
a large European randomised controlled trial (QUATRO), Gray et al. (2006) 
did not find Adherence Therapy – based on compliance therapy – to be better 
than non-specific counselling in admitted patients with psychotic disorders. 
Again, however, also their patient sample was relatively adherent at study entry. 
Cramer and Rosenheck (1999) reported that providing patients with visual 
feedback of their medication adherence rates, based on an electronic monitor-
ing system, had positive effects in a 7-month controlled trial. However, about 
half of their respondents had mood disorders and the effects were different in 
different diagnostic subgroups. Kozuki et al. (2005) tried a similar intervention 
– Visual Feedback Therapy – in 23 patients with psychotic disorders but did not 
find an effect on adherence.
In their review of interventions to improve medication adherence in schizo-
phrenia, Zygmunt et al. (2002) reached four conclusions: (1) one third of the 
39 included studies reported significant effects; (2) psycho-education by itself 
was not effective; (3) concrete problem solving and motivational techniques 
that link medication adherence to personal goals were common features of suc-
cessful programs; and (4) making adherence a specific target seemed to increase 
the chance of success. The authors emphasized the need for further theoretical 
development. Nosé et al. (2003) conducted a meta-analysis with similar goals, 
including 24 studies (the control condition was ‘care as usual’ in 63%). The 
odds ratio for dichotomous outcomes was 2.59 (95% CI 2.21-3.03) and the 
pooled standardized mean difference for continuous outcomes was 0.36 (95% 
CI 0.06-0.66), thus showing a significant general effect of such interventions. 
Contrasting their findings with the less positive conclusions of Zygmunt and 
others, the authors mentioned differences in study selection. For example, the 
review of Nosé et al. (2003) included studies that measured appointment (not 
solely medication) adherence and they excluded studies that did not measure 
adherence as the primary outcome. The latter selection criterion seems to be 
in line with the conclusion of Zygmunt et al. (2002), that interventions that 
specifically target adherence are more likely to be successful. In their meta-
regression analysis, Nosé et al. (2003) found two factors to be associated with 
greater effect: a short follow-up period – which perhaps means that booster 
sessions are useful – and a diagnosis of schizophrenia. The latter is in conflict 
with the tentative conclusion of O’Donnel et al. (2003).
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2.3 Coming to a new model for imProving adherenCe: 
treatment adherenCe theraPy
Given that theoretical models for improving treatment adherence have so far 
not proved satisfactory (Kemp & David, 1995), and that interventions yield 
at most only moderate effects (Puschner et al., 2005), we sought to develop 
a rationale for a new intervention, based on existing empirical literature on 
predictors and interventions.
Table I summarizes (a) three reviews of predictors of non-adherence in 
patients with psychotic disorders that include studies up until 2002, and (b) 
empirical studies reported in the literature from 2003 onward.
Unfortunately, some of the predictors of non-adherence are not easy to 
change. Age, ethnicity, and gender are beyond the control of practitioners. 
Although a small social network is a predictor of non-adherence, such networks 
cannot easily be expanded. Similarly, although failure to establish a working 
alliance between practitioner and patient is a predictor, it is not always possible 
to form such an alliance despite the best efforts of practitioners – and many 
continuing education programs already include training of the relevant skills.
We developed an intervention model – Treatment Adherence Therapy – that 
consists of four broad techniques (termed ‘modules’), each targeting one of four 
clusters of remaining predictors of non-adherence. The four clusters are as follows:
Cluster A
- cognitive deficits (e.g. forgetfulness, impaired executive function)
- poor social / daily structure
Cluster B
- medication side effects
- negative medication attitude
Cluster C
- a ‘sealing-over’ recovery style1
- expecting only few benefits (low hope)
- depression
1 A ‘sealing-over’ recovery style is a way of coping by minimizing the significance of 
symptoms and the impact of psychosis and showing a lack of curiosity about the 
experience, thereby not integrating the illness into ones self-identity.
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Cluster D
- feelings of stigmatization
- negative, distrusting attitude
- denial of treatment need
- poor insight
With respect to cluster A, forgetfulness, poor executive function, poor atten-
tion, and chaotic thought can cause non-adherence because of difficulties with 
integrating structural treatment procedures into daily life (also depression may 
affect adherence this way because depressed individuals are often forgetful 
(Elbogen et al., 2005)). Although these factors are hard to alter, behavioural 
training can help the individual to cope with them (Boczkowski, Zeichner & 
DeSanto, 1985). Behavioural training, which has proven effective in studies of 
patients with schizophrenia (Zygmunt et al., 2002), consists of specific instruc-
tions and problem-solving strategies, such as reminders, self-monitoring tools, 
cues, family or partner support, reinforcement, and linking medication-use to 
highly frequent behaviours. We included this module in our Treatment Adher-
ence Therapy, but it is only implemented when other barriers to treatment 
(clusters B, C, and D) have been ‘removed’.
Considering cluster B, when it has been established that these causes for 
non-adherence are present, we start with medication optimization. A rather high 
dosage will be prescribed of a (possibly yet untried) antipsychotic medication, 
and then we structurally build down while the patient, the practitioner, and a 
family member each monitor side effects and psychotic symptoms in the patient. 
Every six weeks, the dosage decreases another step. If necessary, this procedure 
can be repeated for up to three different antipsychotic medications. The patient 
finally decides as to which medication and in what dosage he prefers, and to 
aid in his decision he can make usage of the registered symptoms and side 
effects tables. Before start, the procedure of this module is explained in detail 
to the patient, personal choice is emphasized, and some safety arrangements are 
discussed.
We’ve tested these medication optimization in about seven patients, and 
subjectively found that they responded quite positive. One 46-year old woman 
(diagnosis is schizophrenia, paranoid type; she lives alone; and has an affair 
with a man who is also a psychiatric patient) had paranoid delusions of being 
watched and controlled by her neighbours’ machines. She was terrified by this 
and, even while the delusional ideas remained, using antipsychotic medication 
seemed to ‘protect’ her from this fear. However, medication also made her feel 
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less energetic. During her 20-year course of illness she had repeatedly ceased to 
take medication because of this reason. Problems came and went, and she had 
been hospitalized three times in a state of severe decompensation. Now, we pro-
posed to her an experiment to search for her optimal dosage. She started with 
10 mg of olanzopine, then 5 mg, then 3.5, then 2.5, and then 1 mg. These steps 
each lasted six weeks, and she was asked to record her experience of fear and 
energy every day. At 1 mg olanzopine, the fears came back. She was given 10 
mg for one week and then returned to the dosage tried last that still worked well 
enough: 2.5 mg. Currently for two years at this same dosage, she hasn’t been 
afraid nor experienced side-effects. Furthermore, she has discovered this herself 
and now seems to require a lot less persuasion to keep using her medication. In 
one other patient, we used his mother to register symptomatic behaviour during 
the medication dosage module. This also worked well, seemingly because she 
now had more objective data in hands to show to her son the dose-response 
relationship between the antipsychotic medication and his behaviour.
With regard to cluster C, we hypothesized that many patients have not con-
sciously thought about the pros and cons of treatment, about their current goals 
in life, the means to reach them, and about how this relates to their illness and its 
treatment. This is in line with data on recovery styles (McGlashan et al., 1975), 
as these ideas partially overlap: the non-integration (sealing-over) of psychotic 
illness into patients’ lives and self-image is predictive of non-adherence (Tait, 
Birchwood & Trower, 2003). Furthermore, Zygmunt et al. (2002) pointed out 
that linking medication adherence to personal goals was a common feature of 
successful interventions to improve adherence. We use motivational interview-
ing (Barkhof et al., 2006) to achieve this, a technique that has previously been 
used successfully to deal with the problem of non-adherence (Barkhof et al., 
2006; Possidente, Bucci & McClain, 2005). This technique consists of develop-
ing discrepancy; expressing empathy; believing in the patient’s abilities; rolling 
with resistance; avoiding arguments; letting the patient sum up his perceived 
pros and cons; reflection; trying to let patients base their decisions on informa-
tion instead of expectations; recalling goals of treatment that have already been 
reached; emphasizing freedom of choice; and other aspects (Miller & Rollnick, 
2002). We included depression in this cluster of predictors because depression 
may cause non-adherence partially due to a general lack of motivation (Elbogen 
et al., 2005), an aspect amenable to motivational interviewing.
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And finally for cluster D, we hypothesize that some patients are not ready to 
figure out what they want (by the strategy outlined for cluster C), as they ‘fool’ 
themselves with coping strategies that function to maintain some feelings of 
self-esteem. This is needed because their self-esteem is under threat by the pos-
sible acknowledgment that they have a chronic and stigmatized illness, that they 
may require treatment for a long time, that they will need to adapt their lifestyle, 
and that their current life situation is not as they would like it. Evidence for 
this mechanism comes from the finding that the above-mentioned sealing-over 
recovery style is linked to insecure adult attachment, negative self-evaluative 
beliefs, and insecure identity (Tait, Birchwood & Trower, 2003), and thus seems 
to be linked to threatened self-esteem. Self-esteem is known to be particularly 
vulnerable in the face of a chronic psychotic illness (Roe, 2003; Tarrier, 2001). 
Furthermore, patients with schizophrenia, more so than patients with other 
mental disorders (Corrigan, 2004) or diabetes (Lee, 2005), experience stigma 
from family, partners, friends, and colleagues, which has been linked to more 
illness concealment (Lee, 2005), avoidance of help-seeking (Dinos et al., 2004), 
and less positive attitudes toward treatment (Mann & Himelein, 2004). Feelings 
of stigmatization by significant others strongly affects self-esteem (Link et al., 
2001), and avoidant coping styles – e.g. denial of treatment need or sealing-over 
– presumably protect the patient’s feelings. Indeed, it has been found that an 
integrating recovery style is associated with higher levels of discomfort (Bell & 
Zito, 2005), that insight into illness is associated with more feelings of depres-
sion (Trauer & Sacks, 2000; Lysaker et al., 2003), and that having doubt in a 
delusion instead of completely accepting it as the truth is associated with lower 
self-esteem (Feeman et al., 2004). In our model, lack of insight is assumed to 
especially influence adherence when it is caused by denial (for a differentiation 
in the etiology of poor insight into denial and cognitive impairment, see Lysaker 
et al. (2005) or for a review: Cooke et al. (2005)), which is in line with the 
finding that psycho-education by itself is not effective (Zygmunt et al., 2002; 
Dolder et al., 2003) – a lack of information is probably not the problem.
It is, in short, quite understandable that patients diagnosed with a psychotic 
disorder tend to use avoidant coping styles that coincide with / lead to non-
adherence. Our model includes a number of strategies to work on this: positive 
labelling; illness normalization; emphasizing the patient’s own wishes and ideas; 
using metaphors of integration; believing in the patient’s abilities; discussing 
famous people with psychosis; enhancing self-efficacy; and rolling with resis-
tance. Some of these strategies are already included in motivational interviewing 
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(Miller & Rollnick, 2002); the others we refer to as self-enhancement strategies, 
because their goal is to lessen the perceived threat to the patient’s self-esteem.
The model of treatment adherence therapy is summarized in Figure I. A manual 
was written (in Dutch) by which the practitioner can get familiar with the 
intervention protocol, and we also propose that practitioners receive a training 
in the relevant techniques. During the first one or two sessions of treatment 
adherence therapy the practitioner estimates which of the four clusters mostly 
cause(s) non-adherence in the patient he/she is facing. The next step will be to 
apply the corresponding module(s, commencing with the one placed highest in 
figure I). Together, treatment adherence therapy probably takes up around ten 
sessions, but the actual number of sessions depends on the modules that need 
to be applied. Also, we propose two booster sessions to strengthen any pattern 
of achieved behavioural changes.
 
 
    Causes of non-adherence:                        Module to be used: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
D. The patient denies or 
seals over his illness and 
need for treatment, so as to 
protect his self-image. 
C. The patient has not 
yet thought all aspects 
through concerning his 
wishes and treatment, 
and/or lacks motivation. 
Self 
Enhancement 
Motivational 
Interviewing 
A. The patient does 
not posess the skills or 
structure to effectively 
adhere to treatment.  
Behavioural 
Training 
Non-adherence 
B. The patient experiences 
side effects, responds 
negatively to medication. 
Medication 
optimization 
Figure I A model for improving adherence: Treatment Adherence Therapy
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Since two of the proposed modules of treatment adherence therapy 
(behavioural training and motivational interviewing) have already separately 
been investigated by other researchers, and since another module (medication 
optimization) seemed effective during our pilot, we estimate that our interven-
tion has a good chance of improving adherence. Furthermore, we expect that 
using an individualized mix of modules may add significantly to this effect. 
The effects of our proposed add-on intervention will be tested in a multi-centre 
randomised controlled trial, comparing treatment adherence therapy with 
treatment as usual. It should be noted as a limitation, however, that extremely 
low-adherent patients are probably not suitable for this type of intervention, as 
attendance of the sessions is a necessary element. For that group, more assertive 
interventions are called for, such as Assertive Community Treatment (ACT).
2.4 the moral Position of treatment adherenCe theraPy
Given the undesirable consequences of non-adherence on one hand and the 
apparent fact that some patients do not want any treatment for their disorder on 
the other, the question arises whether it is ethical to ‘psychologically’ intervene 
so as to influence patients’ perception and motivation. If we consciously try 
to make patients do something other than their own expressed preference, 
are we then knowingly acting against their will? Miller and Rollnick, in their 
motivational interviewing book, have devoted a chapter on this delicate topic in 
which they struggle with the morally questionable notion that, by using moti-
vational interviewing, the patient may be changed in what he wants (Miller & 
Rollnick, 2002; p161). In our view, however, what is changed are the patient’s 
beliefs about what he wants. More specifically: we hope that these beliefs become 
more accurate. A philosophical analysis of this approach is more thoroughly 
explained in an article by Voerman (2006). Applied to treatment adherence 
therapy, it comes down to the following:
We consider that because the aim of treatment adherence therapy is to help 
patients understand what they want in terms of treatment, the ethical problem 
described above is at least partially solved. Treatment adherence therapy is not 
in conflict with what patients want nor changes what they want, because its 
underlying tenet is that some patients may not know what they want. The goal 
is exactly to help them discover this, by means of making them conscious of 
the pros and cons, asking them to weigh their options, getting them to create 
an integrating picture of their adherence behaviour and personal future goals, 
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and by trying not to evoke resistance while doing so. While patients afterwards 
may still decide they do not want treatment, they will at least have consciously 
thought about relevant aspects; they have been prompted to investigate what 
they really want and hopefully have made an informed decision. The practitio-
ner should then accept a decision of non-adherence in our view, unless there is 
a question of danger and involuntary admission and treatment are called for. 
It is also important to recall that the known consequences of non-adherence 
consist in general patterns in group data, and adherence is not wisely applied 
as an absolute norm for each individual patient. But we do believe that most 
patients wish to function well and that if, after sorting out their feelings about 
the diagnosis and treatment, patients decide they want treatment, they are more 
likely to adhere to that treatment.
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abstraCt
Background
Interventions to improve adherence to treatment in patients with psychotic 
disorders have produced inconclusive results. We developed a new treatment, 
Treatment Adherence Therapy (TAT), whose intervention modules are tailored 
to the reasons for an individual patient’s non-adherence.
Aim
To examine the effectiveness of TAT with regard to service engagement and 
medication compliance in outpatients with psychotic disorders who engage 
poorly.
Method
Randomised controlled study of treatment as usual (TAU) versus TAU + TAT in 
109 outpatients. Most measurements were performed by masked assessors. We 
used intention-to-treat multivariate analyses. (Dutch Trial Registry; NTR1159)
Results
TAU + TAT vs. TAU significantly benefited service engagement (Cohen’s d=.48) 
and medication compliance (Cohen’s d=.43). Results remained significant at 
six-month follow-up for medication compliance. Near-significant effects were 
also found regarding involuntary re-admissions (1.9% vs. 11.8%; p=.053). 
Symptoms and quality of life did not improve.
Conclusions
Treatment Adherence Therapy helps improve engagement and compliance, and 
may prevent involuntary admission.
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3.1 introduCtion
Non-compliance with medication is prevalent in over fifty percent of patients 
with psychotic disorders (Cramer and Rosenheck, 1998; Keith and Kane, 2003; 
Bebbington, 1995; Thomas, 2007; Weiden et al., 1996; Weiden et al., 1991). 
If a patient stops using antipsychotic medication, the risk of relapse increases 
three to fivefold (Dixon and Lehman, 1995; Fenton et al., 1997; Robinson et 
al., 2002; Ucok et al., 2006; Weiden et al., 2004). Also, the risk of suicide has 
been found to be 3.75 times higher in non-compliant patients with schizophre-
nia than in compliant patients (Hawton et al., 2005).
Despite such detrimental consequences, dealing with this problem has 
proven difficult. Psycho-education, for example, is not effective in improving 
adherence (Zygmunt et al., 2002; Dolder et al., 2003; Lincoln et al., 2007). 
On the other hand, there is some evidence that cognitive behavioural therapy is 
effective if it specifically targets non-compliance (Lecompte & Pelc, 1996), and 
a meta-analysis has shown that effective strategies include practical problem-
solving, and motivational techniques that link adherence to personal goals 
(Zygmunt et al., 2002). But while versions of Compliance Therapy and Adher-
ence Therapy, both including these strategies, were shown to be effective in 
some studies (Kemp et al., 1998; Gray et al., 2004; Maneesakorn et al., 2007), 
they did not prove their usefulness in others (O’Donnel et al., 2003; Byerly, et 
al., 2005a; Gray et al., 2006). Research may have failed to detect effects because 
of a small study sample (Byerly et al., 2005a), relative effectiveness of the ‘com-
parator’ intervention (Gray et al., 2006), or because short term positive effects 
may have been lost where only one year outcomes were reported (O’Donnel 
et al., 2003). Based on current knowledge, the updated guidelines of National 
Institute for Health and Clinical Excellence (NICe, 2009) recommend that 
adherence interventions should not be used in patients with schizophrenia.
Adherence interventions may be more effective when they take the large 
variations in causes of non-adherence into account. This randomized controlled 
trial therefore measured the effectiveness of Treatment Adherence Therapy 
(TAT; Staring et al., 2006), in which strategies for improving adherence are 
tailored to patients’ individual situations.
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3.2 method
3.2.1 Design and hypotheses
This rater-blind randomized controlled trial compared a combination of Treat-
ment Adherence Therapy (TAT) with Treatment As Usual (TAU). Our primary 
hypothesis was that TAT would more successfully improve service engagement and 
medication compliance. Our secondary hypotheses were that TAT would be more 
successful not only in preventing voluntary and involuntary re-admission, but also 
in reducing symptoms and improving quality of life. We hypothesized that these 
effects would have four mediators: a reduction in the experience of stigma, better 
therapeutic alliance, increased insight, and a more integrative recovery style.
3.2.2 Procedure
Inclusion criteria were (1) a DSM-IV diagnosis of schizophrenia or schizoaf-
fective disorder, (2) receiving outpatient treatment, (3) mastery of the Dutch 
language, (4) at least some problems with service engagement, as defined by 
an average item-score of 1.25 or higher on at least two subscales of the Service 
Engagement Scale (SES; see primary outcomes). Patients were referred when the 
clinician believed them to meet the criteria. In order to classify patients accord-
ing to DSM-IV (APA, 1994), they were interviewed using the lifetime Com-
posite International Diagnostic Interview, version 2.1 Auto (WHO, 1997). We 
then used the SES to determine whether a patient met the fourth criterion. If 
the patient did meet it, a research assistant asked them to participate and to give 
written informed consent.
At baseline (T0), at the end of the six-month treatment (T1), and at six-month 
follow-up (T2), all respondents and their mental-health professionals participated 
in a structured interview. These were conducted by psychology and medicine 
students who were blind to the patients’ treatment allocations. The students had 
received a two-day training that consisted of interview role-play and of scoring of 
the instruments. After co-rating a live interview conducted by the main researcher 
(AS), they conducted two interviews under supervision. When their ratings were 
sufficiently consistent with those of the experienced researcher, the students con-
ducted interviews independently, but still under supervision every other week.
Within a week of baseline assessment, participants were randomly assigned 
to one of the treatment conditions. This was done according to a lottery system, 
executed by the main researcher. Allocation was not concealed from the par-
ticipants, therapists or researchers. Only the raters were blind to the treatment 
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allocation. Because the risk existed that patients would tell to which group they 
had been allocated, raters were instructed to specifically ask the patient at the 
beginning of the interview to not say this. This was successful; patients did not 
report their allocation.
Patients were paid EUR 20 for each of the three interviews. The study 
design was approved by the Medical Ethics Committee of Erasmus MC Uni-
versity Medical Center.
3.2.3 Treatment Adherence Therapy
Treatment Adherence Therapy is an intervention based on an empirical-
theoretical model described earlier (Staring et al., 2006), in which patient-
determinants of non-adherence are clustered into three groups. The first group 
of determinants is characterized by a patient who denies or seals over his illness 
and has not integrated illness and treatment into life. The second is character-
ized by a patient who is not satisfied with his medication due its side-effects or 
low efficacy. The third is characterized by a patient who lacks the cognitive skills 
or daily structure to participate effectively in the treatment. According to the 
TAT-model, every non-adherent patient will have at least one of these clusters 
present, explaining the non-adherent behaviour.
The first cluster of causes of non-adherence mentioned here – the patient 
denies or seals over his illness and has not integrated illness and treatment into 
life – still consisted of two separate clusters in Chapter 2 of this thesis. When 
re-writing the treatment manual after that publication, based on a small pilot, 
two modules were combined in order to simplify the approach.
The first part of the TAT manual describes the procedure for one or two 
initial sessions which assess individual determinants of non-adherence. Accord-
ing to the clusters of determinants they detected, and after discussion with their 
supervisor, the therapists then filled out a decision-form and chose from the 
three modules available. These are listed here.
(1) The first module was an adapted form of Motivational Interviewing, which is 
intended to explore a patient’s perspective and goals, developing discrepancy 
between current behaviour and future goals, and to help him or her with the process 
of placing the illness and treatment into a coherent life-narrative, while avoiding 
resistance and emphasizing freedom of choice and the patient’s own responsibility. 
To this we added strategies for reducing self-stigmatization, such as the provision 
of a continuum-perspective on the illness, and discussion not only of the stress-
vulnerability model, but also of famous people who have struggled with psychosis.
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(2) The second module was Medication Optimization. Here, a normal 
dosage was prescribed of an antipsychotic medication, and was then optimally 
tailored (which sometimes meant that a dosage was reduced) while the patient, 
the TAT-therapist, and a family member each monitored any side-effects and 
psychotic symptoms in the patient. The dosage was adjusted every six weeks. 
If necessary, this procedure was repeated for various antipsychotics until an 
optimal medical treatment was reached. The patient clearly stated which medi-
cation he preferred, and in which dosage. To aid his decision, he used the log 
he had kept on his symptoms and side-effects. Before the start of this module, 
the procedure was explained to the patient in detail. The options for personal 
choice were emphasized, and some safety arrangements were discussed.
(3) The third option was Behavioural Training, which was provided to help 
individuals to cope with the problems caused by forgetfulness, poor executive 
function, poor attention, and chaotic thought, all of which can cause non-
adherence due to difficulties with integrating structural treatment procedures 
into daily life. Training consisted of specific instructions and problem-solving 
strategies, such as reminders, cues, reinforcement, self-monitoring tools, family 
or partner support, and linking medication-use to highly frequent behaviours. 
The structure of these three modules was hierarchical. Thus, if more than one 
cluster of problems was present in an individual patient, motivational inter-
viewing was conducted first, followed by medication optimization, and then 
by behavioural training. The duration and number of sessions therefore varied 
according to the needs of the patient. In general, it took no more than six months.
Most of the TAT-therapists were psychiatric nurses. They were not the 
patients’ own mental health professional, and gave TAT in addition to TAU. 
They received a full week of training and an hour’s supervision every two weeks 
thereafter. To ensure treatment fidelity, all sessions were recorded and used in 
supervision. Although treatment fidelity was not rated with instruments, each 
executed session was discussed and therapeutic instructions were always given 
for the upcoming session. Tapes were often used to check and maintain the 
relevant therapeutic skills. No significant problems were encountered and the 
therapists were found to be compliant with the instructions given.
3.2.4 Treatment As Usual
Treatment as usual generally consisted of sessions with a psychiatric nurse and 
a psychiatrist when indicated. The sessions varied in frequency and duration, 
but mostly consisted of one or two sessions per month. The contents reflected 
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overall problems the patient might encounter, such as symptoms, social par-
ticipation, work, daily activities, and medication issues. Some patients received 
psycho-education individually or in group sessions. This was recorded.
3.2.5 Primary outcomes: service engagement and medication compliance
Service engagement
We used the Service Engagement Scale (SES), a 14-item rating scale in which 
the service engagement observed is rated by the clinician most familiar with 
the patient. It has four subscales: (1) availability, (2) collaboration, (3) help-
seeking, and (4) medication compliance. As well as having good face validity 
and content validity, it is user-friendly, and has been shown to have good test-
retest reliability in patients with psychotic disorders (Tait et al., 2002). The total 
scale scores were used minus the subscale of medication compliance, because 
this subscale was included in our compiled measure of medication compliance 
(see medication compliance, below).
Medication compliance
We administered a semi-structured interview with the patient to assess medica-
tion compliance by the independent rater. The rater normalized non-compliance 
as well as possible reasons for it, stressed that the obtained information would 
be treated confidentially and not be passed on to the patient’s clinician, and 
inquired about the number of missed doses in the past days and weeks. Such 
an interviewing style has been found to produce a more valid measurement of 
adherence than some of the questionnaires that are used in adherence research, 
such as the Medication Adherence Rating Scale, the Medication Adherence 
Questionnaire, the Drug Attitude Inventory, and the Compliance Rating Scale 
(Kikkert et al., 2010). The score ranged from 0 to 4, with higher scores indicat-
ing more problematic compliance. The scoring method was modelled after the 
Health of the Nation Outcome Scales (Wing et al., 1998).
In this way, we used two different measures of medication compliance: one 
clinician-based (SES subscale) and one rater-based. These two measures were 
standardized, summed, and reversed, thereby creating a compiled measure of 
compliance, in which null scores indicated the average compliance in our study, 
and high scores indicated good compliance. Composite measures of medication 
compliance help reduce the underestimation of compliance that is associated 
with any individual source of information (Kikkert et al., 2008).
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In our baseline data, this compiled measure of medication compliance cor-
related with the positive syndrome of the PANSS (r = -.23) and with side-effects 
of neuroleptics (r = .23) (Staring et al., 2009a). Although relatively small, these 
associations provide some support for the measure’s validity.
3.2.6 Secondary outcomes
Admissions
We documented whether, at the time the study was conducted, patients had 
been readmitted to a psychiatric hospital, and, if so, whether this had been 
voluntary or involuntary.
Symptoms
The Positive and Negative Syndrome Scale (PANSS) (Kay et al., 1987) is a 30-item 
rating scale which is completed by the trained raters. It has three subscales: (1) 
positive syndrome, (2) negative syndrome, and (3) general psychopathology.
Quality of life
We used the self-report EQ-5D, which has been validated in patients with 
schizophrenia (Prieto et al. 2003). On the basis of a Dutch validation study 
(Lamers et al., 2005), the items were linearly transformed into a score ranging 
from -0.33 to 1.00. High scores reflect good quality of life.
3.2.7 Mediators
Insight
We used the self-report 8-item Insight Scale (IS) of Birchwood et al. (1994), 
whose total scores range from 0 to 12. The scale is reliable and valid, and is easy to 
use within this group of patients. To have some indication of the veracity of the 
patients’ response on this scale in our study, we’ve calculated the Pearson correla-
tion between this scale and the insight item of the PANSS (A12) in our baseline 
data. It was -.514 (p<.001), indicating an important overlap between the two.
Recovery Style
Recovery style was measured using the Recovery Style Questionnaire (RSQ; 
Drayton ea., 1998), a 39-item self-report measure. Total scores range from 1 to 6, 
low scores reflecting integration and high scores reflecting sealing-over. Broadly 
defined, a sealing-over patient prefers not to think about his psychotic experience 
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during recovery, while an integrator is interested in the psychotic experience and 
desires to put it into some coherent perspective. The RSQ is reliable and cor-
relates highly with McGlashan’s interview-based measure (Drayton ea., 1998).
Stigma
We used the 12-item ‘perceived devaluation and discrimination’ part of the 
self-report Stigma Scale (SS) (Link et al., 2002). The items cover the patient’s 
perception of common opinions about psychiatric patients, such as ‘Most 
people believe that entering a mental hospital is a sign of personal failure.’ 
Total scores range from 1 to 4, with higher scores indicating greater perceived 
stigmatization.
Therapeutic alliance
The 36-item Working Alliance Inventory (WAI) was used to measure the alli-
ance factor of the therapeutic relationship as it is experienced by the patient 
(Horvath & Greenberg, 1989, 1994; Vervaeke & Vertommen, 1996).
3.2.8 Statistical analyses
Logistic regression analysis was used, with treatment allocation as the dependent 
variable, and with baseline demographics and instrument scores as independent 
variables to test whether the randomization process was conducted successfully. 
Next, we performed an intention-to-treat multivariate analysis (MANCOVA), 
in which primary outcomes were entered as dependent variables, treatment 
allocation as a fixed factor, and baseline SES and compliance scores as covariates. 
The analysis included the effects of the TAT intervention directly after it had 
ended (T1) and after six months of follow-up (T2). Significant outcomes were 
expressed in effect-sizes (Cohen’s d) by dividing the difference in mean scores of 
the two treatment allocations by their pooled standard deviation. For secondary 
outcomes and mediators, similar analyses were used as well as Fisher’s exact tests.
On the basis of the variances, error estimates, and observed effects of the 
first 58 patients who had completed T1, we calculated the minimum sample 
size necessary to achieving a power of .80 for our analyses. For this, we did a 
univariate two-group repeated-measures analysis of variance using the Green-
house-Geisser correction to nominal degrees of freedom. It was concluded that 
at least 46 participants were needed in each treatment allocation to reliably 
detect an effect on the primary outcome measure.
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3.3 results
3.3.1 Participants
We screened 391 people, 195 of whom were identified as meeting the inclu-
sion criteria. Seventy-nine refused to participate, and 116 (59%) decided to 
participate. The 79 patients who declined participation were found to engage 
less with services than those who decided to participate; their respective SES 
total scores were 23.31 versus 20.89 (p<.05; independent samples t-test). Age 
or gender differences were not found. 
Table I portrays the characteristics of the 109 patients who were random-
ized. Figure I shows progression through the trial. Because attrition was so 
small, we have performed the analyses with only the data actually gathered, 
rather than imputing scores for the few patients who died or refused further 
participation.
Table I Respondents characteristics
N 109
Sex 77 patients (71%): male
32 patients (29%): female
Average age at T0 39.0 years (SD=11.6)
Average age of the first 
contact with a mental health 
institution
26.2 years (SD=9.9)
Employment 91 patients (84%): unemployed
18 patients (16%): employed
Ethnicity 49 patients (45%): Dutch
21 patients (19%): second-generation immigrants
39 patients (36%): first-generation immigrants
Diagnoses 76 patients (70%): schizophrenia
- 57 paranoid type
- 11 disorganized type
- 7 catatonic type
- 1 undifferentiated type
33 patients (30%): schizoaffective disorder
- 21 depressive type
- 12 bipolar type
Antipsychotic treatment 20 patients: no antipsychotic agent (completely non-compliant)
14 patients: first-generation oral antipsychotic (mostly zuclopentixol 
and penfluridol)
37 patients: second-generation oral antipsychotic (mostly risperidon 
and olanzapine)
13 patients: first-generation injectable antipsychotic (mostly 
zuclopentixol)
7 patients: second-generation injectable antipsychotic (mostly 
risperidon)
18 patients: two antipsychotic agents combined
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Assessed for eligibility (n=391) 
 
Randomized (n=109) 
 
Excluded (n=275):  
 
Did not meet inclusion 
criteria (n=196) 
 
Refused to participate 
(n=79) 
Allocated to TAU (n=55) 
 
Received TAU (n=55) 
 
Did not receive TAU (n=0) 
Allocated to TAT (n=54) 
 
Received TAT (n=47) 
 
Did not receive TAT because stopped 
after 1 or 2 TAT sessions (n=7) 
 
Lost to 6-month assessment 
- died (n=1) 
- refused interview (n=1) 
- stopped all treatment (n=1) 
 
Lost to 6-month assessment (end of 
TAT)  
- dropped out of the study (n=1) 
 
Discontinued intervention:  
- refused to complete TAT (n=6) 
 
Lost to 12-month assessment 
- died (n=2) 
- stopped all treatment (n=1) 
Received baseline assessment (n=116) 
 
Refused further 
participation (n=7) 
Lost to 12-month assessment 
- dropped out of the study (n=1) 
Primary outcome analysed, intention-to-
treat 
- with 6-month data (end of TAT) 
(n=53) 
- with 12-month data (follow-up) (n=53) 
Primary outcome analysed, intention-to-
treat  
- with 6-month data (end of TAT) 
(n=52) 
- with 12-month data (follow-up) (n=52) 
Figure I Progression through the trial
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3.3.2 Randomization
Results of the logistic regression analysis showed that the randomization proce-
dure was successful; treatment allocation was not significantly predicted by any 
demographic variable, treatment characteristic, or outcome variable at baseline. 
Importantly, the subscriptions of oral and injectable antipsychotic agents were 
evenly distributed between the two treatment allocations. Independent samples 
t-tests produced similar results.
3.3.3 Therapy participation
Seven of the 54 patients who had been allocated to the TAT intervention dropped 
out after one or two sessions, and one had quit the study entirely. While another 
six patients did not complete the intervention, the remaining 40 patients (74%) 
did. Given the basic selection of non-adherent patients, this drop-out rate was 
not surprising. Those dropping out of TAT, did go on to receive treatment as 
usual. Data on the primary outcome measures was gathered successfully for all 
54 patients but one. These data were used for the intention-to-treat analyses.
Forty of the 46 patients who participated in the TAT intervention were 
given the motivational interviewing module. Six of these forty patients also 
received the medication optimization module, and seven behavioural train-
ing. Of the remaining six patients, four received behavioural training, one the 
medication optimization module, and one both. The mean number of TAT 
sessions for the 46 participating patients was 9.89 (st-dev=2.72). This process 
took about six months.
3.3.4 Primary outcomes: service engagement and medication compliance
At baseline, the distributions of the outcome variables were approximately 
normal. As Table II shows, when we controlled for baseline levels in the mul-
tivariate analysis, there were significant differences in service engagement and 
medication compliance between the two treatment conditions at the end of 
the TAT intervention (T1). Cohen’s d was .48 for service engagement and .43 
for medication adherence. These effect-sizes indicate clinical significance and 
can be regarded as medium effects (33). Six months later (T2), Cohen’s d was 
.39 for service engagement and .30 for medication adherence, indicating that 
after six months of follow-up, the effects had reduced somewhat, and now fell 
within the small to medium range. Despite the smaller effect-size, only the 
MANCOVA effects on medication adherence were still statistically significant, 
and not those on service engagement, which is due to differences at baseline.
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3.3.5 Secondary outcomes
Admissions
At baseline, all respondents were in outpatient treatment. Of those allocated 
to the TAT intervention group, four patients (10%) had been re-admitted to a 
psychiatric hospital before T1, and they did not complete the intervention. By 
T2, a total of nine patients had at least once been re-admitted (17%). One of 
these patients (1.9%) had been admitted involuntarily. Of those allocated to 
the control group, more had been re-admitted: nine patients (18%) before T1; 
and by T2, this increased to fourteen patients (28%), six of whom (11.8%) had 
been admitted involuntarily. Fisher’s exact test showed that the difference in 
re-admissions at any time before T2 was not significant (p=.159; 1-sided), and 
that the difference in involuntary admissions tended to significance: 1.9% in 
the TAT group versus 11.8% in the control group (p=.053; 1-sided).
Symptoms and quality of life
The analyses showed no effects on symptoms or quality of life (Table III).
3.3.6 Mediators
The analyses showed no effects of TAT + TAU on insight, stigma, recovery style, 
or therapeutic alliance (Table III).
Table II Results of the intention-to-treat multivariate analysis (MANCOVA) with Service 
Engagement and Medication Compliance as the dependent variables, both directly at the end of 
TAT (T1) and after six months of follow up (T2). Treatment allocation was entered as a fixed-
factor independent variable; baseline Service Engagement and Medication Compliance were 
entered as covariates.
Variable Assessment 
time
TAT group
mean (st-dev)
Control group
mean (st-dev)
Cohen’s 
d
MANCOVA*
F Sig.
Service Engagement 
Scale
T0
T1
T2
14.83 (4.44)
10.87 (6.64)
10.98 (6.70)
15.95 (4.87)
14.02 (6.35)
13.81 (7.67)
.48
.39
4.995
3.561
.028
.062
Medication 
Compliance
T0
T1
T2
-0.09 (1.55)
0.35 (1.58)
0.22 (1.66)
0.02 (1.92)
-0.42 (1.94)
-0.35 (2.17)
-.43
-.30
11.77
4.73
.001
.032
* Results represent the effects of treatment allocation
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3.4 disCussion
3.4.1 TAT: observed effects and participation
The present study compared the outcomes of two treatment conditions – TAT 
versus TAU – and found that TAT enhanced service engagement and medica-
tion compliance more successfully than TAU did. The effects were smaller at six 
months follow-up, yet still statistically significant for medication compliance. 
There was a trend that the patients within the TAT condition were less often 
involuntarily admitted to a hospital (1.9% versus 11.8%) – a difference that 
was almost significant. This can mean that patients in the TAT group were more 
likely to cooperate with their admission and inpatient treatment, whereas those 
in the TAU group tended to be more unwilling to comply with the recommended 
Table III Means and standard-deviations of service engagement, medication compliance, 
symptoms, insight, stigma, recovery style, therapeutic alliance, and quality of life across the 
assessments and treatment allocations
Variable Assessment 
time
TAT group
mean (st-dev)
Control group
mean (st-dev)
MANCOVA*
Secondary 
outcomes
PANSS positive 
syndrome
T0
T1
T2
13.65 (5.37)
12.92 (5.20)
12.76 (5.01)
13.93 (5.40)
13.10 (5.75)
12.90 (4.72)
ns**
ns
PANSS negative 
syndrome
T0
T1
T2
14.17 (6.17)
12.67 (5.37)
14.16 (6.61)
13.73 (5.22)
13.59 (5.40)
14.37 (5.57)
ns
ns
PANSS general 
psychopathology
T0
T1
T2
31.04 (9.75)
29.63 (9.04)
30.22 (8.20)
30.02 (9.43)
27.27 (8.09)
28.44 (8.20)
ns
ns
EQ-5D T0
T1
T2
0.68 (0.27)
0.70 (0.25)
0.69 (0.24)
0.73 (0.25)
0.74 (0.25)
0.70 (0.26)
ns
ns
Mediators Insight Scale T0
T1
T2
8.09 (3.27)
7.79 (3.71)
7.47 (3.57)
7.00 (3.68)
7.07 (3.71)
7.41 (4.12)
ns
ns
Stigma Scale T0
T1
T2
2.74 (0.51)
2.70 (0.35)
2.65 (0.48)
2.77 (0.45)
2.73 (0.53)
2.64 (0.44)
ns
ns
Recovery Style 
Questionnaire
T0
T1
T2
2.57 (1.11)
2.75 (1.23)
2.78 (1.21)
2.79 (1.26)
2.74 (1.18)
2.43 (1.24)
ns
ns
Working Alliance 
Inventory
T0
T1
T2
141.8 (23.2)
145.6 (19.3)
143.8 (24.1)
139.5 (22.3)
141.5 (19.4)
140.7 (18.7)
ns
ns
* Results represent the effects of treatment allocation, with the variable at T0 as a covariate
** Effect of treatment allocation is not significant at the .05 level
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treatment, and to be more likely to meet the dangerousness criteria that qualified 
them for an involuntary admission. This is undesirable, as compulsory admission 
is often an if-all-else-fails measure. Even though it may have positive effects, some 
patients also report negative ones, such as those on therapeutic alliance, family 
relationships, and employment prospects (O’Donoghue et al., 2009). 
The majority of patients found TAT acceptable. In our view, the drop-
out rates from therapy were low (26%), especially when we take account of 
the targeted patients, who are often very difficult to engage in psychological 
treatment. On the basis of the frequent use of motivational interviewing, we 
also conclude that the most common reason therapists judged a patient to be 
engaging poorly with services was due, not to cognitive impairments, but to 
factors such as stigma, denial, and low insight.
3.4.2 Symptoms and quality of life
The absence of an effect on symptoms was unexpected, although other interven-
tion studies have reported similar results (Valenstein et al., 2009). It may be 
that our sample size was too small to detect an effect on symptoms. Also, it may 
be that the duration and/or intensity of TAT was not enough to cause changes 
in symptoms and quality of life, and that we need longer or more intensive 
treatments. Alternatively, it may be that patients in our sample were in fact 
poorly adherent at baseline as a consequence of poor response to antipsychotic 
medication. Better adherence would then not result in large symptomatic 
improvements.
Although adherence improved, this also did not lead to better subjective 
quality of life. Apparently, improving adherence per se did not lead to less 
symptoms or increases in subjective well being in our study. 
3.4.3 Mediators
Despite the effects of TAT on service engagement and medication compliance, 
it is not clear what the main mechanisms of change were. Surprisingly, insight 
into illness, therapeutic alliance, recovery style, and the experience of stigma 
were all unrelated to the effects of TAT. As the baseline means of these variables 
allowed for improvement, given the scale ranges, a ceiling-effect was ruled 
out. One possibility is that our sample size was too small to detect significant 
effects, for example on insight, which did correlate with compliance at baseline. 
Another possibility is that although patients’ views of treatment were changed 
and although patients were trained effectively in adherent behaviour, these fac-
tors were not covered by our mediator measurements. 
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In our study design, TAT was an add-on intervention administered by a 
therapist other than the patient’s own clinician. This has some drawbacks and 
benefits. A drawback may be that TAT did not result in a better therapeutic 
alliance with the patient’s own clinician. As we consider the approach to be 
patient-oriented and respectful of patients’ views, TAT may be more effective 
when it is administered by the patient’s own clinician: it might strengthen the 
alliance in the regular therapeutic relationship, a factor known to positively 
influence outcome (Hewitt & Coffey, 2005). On the other hand, a benefit of 
this choice in design may be that the therapist providing TAT was not con-
fronted with other demanding topics that the patient would need help with, 
nor was the therapist impeded by requests to change or reduce medication, 
which may have interfered with the adherence work.
Because good insight has been associated with depressive symptoms, low 
self-esteem and lower quality of life (Staring et al., 2009a), improved adherence, 
if obtained by enhanced insight, may carry the risk of deteriorating quality of 
life and increasing depression (Rathod et al., 2005). It is therefore noteworthy 
that, although we could not detect any effect of TAT on quality of life, neither 
did we observe a deterioration. While TAT improved service engagement and 
compliance, it seems somehow to have ‘bypassed’ insight. Indeed, the primary 
focus of TAT is not on psycho-education: instead, because it stimulates the 
patient to develop an individual narrative into which treatment can somehow 
be integrated, individual motives for engagement or compliance may some-
times turn out to be different from what clinicians would find appropriate. For 
example, one patient realized that being adherent to treatment could help to 
avoid arguments with his partner, and this motivated him. However, he did not 
recognize that his symptoms and agitation increased whenever he stopped his 
medication, which is what caused the arguments with her.
3.4.4 Limitations and strengths
Seven limitations should be considered. First, the sample size was not large, 
which may have limited the power to detect treatment effects on secondary 
outcomes and mediators. For example, assuming that the observed difference in 
hospitalization rates were non-random and would hold in a larger study, about 
120 patients would be needed in each group for a difference of 18% versus 28% 
to become statistically significant.
Second, our inclusion of many outcome variables may have increased the 
chances of finding a significant result.
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
Treatment Adherence Therapy – RCT 49
Third, the patients who refused to participate in the study were engaging 
less with services than those included. An implication is that interventions such 
as TAT may not be acceptable for patients with very low treatment adherence. 
These may benefit more from assertive treatments and direct incentives to 
motivate them (Claassen et al., 2007; Staring et al., 2010a).
Fourth, our study design distributed attention unevenly between the two 
treatment allocations, which may have produced a bias. TAU mostly consisted 
of one or two sessions per month. Patients receiving TAT were given an average 
of 9.9 sessions on top of this during the course of six months. Thus, patients 
receiving TAT were given about twice the amount of sessions of those receiving 
TAU. Although one study on enhancing adherence did not produce results that 
were more significant than those produced in a control group that received less 
attention (Byerly et al., 2005), another found results indicating that patients 
improved in both the intervention and control group (Gray et al., 2006). It is 
therefore still unclear whether attention by itself can increase adherence, and 
we can not rule out that our results were in part due to an attention bias rather 
than the contents of TAT.
The fifth limitation is that our measure of compliance consisted of the SES 
plus a one-item rating scale. This latter measure has not been validated in other 
studies, and may not be the best available. However, measuring compliance 
is difficult, and a gold standard is certainly lacking (Kikkert et al., 2008). As 
well as self-report and interview measures, methods of measuring compliance 
include pill counts, electronic methods, prescription monitoring, and saliva, 
plasma and urine assay tests (Patel & David, 2007). Each has its advantages and 
disadvantages. Pill counts, for example, are not only time-consuming, but also 
have great potential for inaccuracy. And not only are saliva, plasma, and urine 
tests not possible for all drugs, they are expensive and invasive, and may also 
overestimate adherence for drugs that have a long half-life (Fenton et al., 1997; 
Zygmunt et al., 2002). However, future studies may use such alternative meth-
ods to verify our results. Hopefully, our study overcame some of the difficulties, 
not only because patients were asked about their compliance by interviewers 
who were not involved in the treatment, but also because it was made clear that 
the answers would be used solely for the purpose of this study and would not 
be communicated with care-givers. We are therefore reasonably confident that 
patients felt free to give honest answers on their medication compliance.
Sixth, we did not look at whether conducting the trial had an effect on what 
happened within TAU. The patients’ treatment allocations were known to their 
clinicians. As a result, clinicians may have been more aware of adherence issues 
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and have given the topic more attention, perhaps especially with patients in the 
control group. This may have influenced our results by for example increasing 
the effectiveness of TAU.
The seventh limitation is that, although assessors were blind to the patient’s 
treatment allocation, their clinicians were not. Therefore, the information clini-
cians gave on the service engagement scale was not blinded from the treatment 
allocation, and possible bias in this measure can not be ruled out.
Despite these limitations, the study also had at least four strengths:
(a) it had a well-defined treatment protocol that was based on an empirical-
theoretical model in which strategies were tailored to the patient’s individual 
causes of non-adherence;
(b) it involved an intervention that was applied in routine settings by therapists 
who worked within the institutions;
(c) it used masked, independent assessors of outcome; and
(d) it had relatively high inclusion and follow-up rates of patients with poor 
service engagement.
These are important outcomes, particularly for patients who are non-adherent 
to treatment, and therefore risk future relapse and re-admission. The positive 
findings of TAT are promising and suggest optimism for further exploration. 
An important contributor to the effects may be that, after a patient’s individual 
situation has been assessed, TAT provides various intervention modules.


Chapter 4
Fewer symptoms vs. more side effects? Opposing 
pathways between antipsychotic medication 
compliance and quality of life. 
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abstraCt 
Background 
Non-compliance with medication often has long-term detrimental effects in 
patients with schizophrenia. However, when patients are compliant, it is not 
certain whether they experience short-term improved quality of life. By simul-
taneously reducing symptoms and increasing side-effects, compliance with 
antipsychotics may have opposing effects on a patient’s perceived quality of life.
Aim 
This study aimed to identify any clinical-empirical evidence for two pathways 
between compliance and quality of life.
Method 
To evaluate various pathways between compliance (Service Engagement Scale 
plus a one-item rating), psychotic symptoms (Positive and Negative Syndromes 
Scale), adverse medication effects (Subjective Wellbeing under Neuroleptics 
scale), and quality of life (EQ-5D), we used Structural Equation Modeling on 
cross-sectional data of 114 patients with a psychotic disorder.
Results
Compliance was not directly related to quality of life (r=.004). The best-
fitting model (χ2=1.08; df=1) indicated that high compliance was associated 
with fewer psychotic symptoms (β=-.23) and more adverse medication effects 
(β=.22). Symptoms (β=-.17) and adverse medication effects (β=-.48) were both 
related to lower quality of life.
Discussion
Our results suggest that compliance with antipsychotics has two opposing 
pathways towards quality of life, albeit indirect ones. While compliance was 
associated with less severe psychotic symptoms, and was thus related to higher 
quality of life, it was also associated with more adverse medication effects, and 
was thus related to lower quality of life. However, due to our study design, we 
cannot draw firm conclusions on causality. Two possible clinical implications of 
the results for compliance and interventions are discussed.
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
Two opposing pathways between compliance and quality of life 55
4.1 introduCtion
Many patients with either a somatic or a psychiatric disorder do not comply 
with medication. Based on a review, Cramer and Rosenheck (1998) estimate 
that, on average, patients who have been prescribed somatic medicine use only 
76% of the pills. This percentage is lower in the case of antipsychotics, where 
only 58% of the prescribed medication is estimated to be actually taken. Keith 
and Kane (2003) aptly conclude their review by observing that while compliance 
with medication is difficult for everyone – for example in the field of diabetes, 
high blood pressure, asthma, or birth control – it is particularly difficult for 
people with schizophrenia. Four studies have shown that 50% to 75% of patients 
on antipsychotic medication become non-compliant after one to two years of 
treatment (Bebbington, 1995; Thomas, 2007; Weiden et al., 1996; Weiden et 
al., 1991). Obviously, non-compliance makes it difficult to achieve the effects 
intended for treatment. When a patient stops using antipsychotics, the risk 
of relapse and admission or readmission increases three to five-fold (Dixon & 
Lehman, 1995; Fenton et al., 1997; Robinson et al., 2002; Ucok et al., 2006; 
Weiden et al., 2004). It should be mentioned, however, that in some cases non-
compliance may follow clinical deterioration, which can be due to resistance in 
therapy, making causal attributions on the relationship between non-compliance 
and relapse difficult. In the same way, the risk of suicide may be 3.75 times higher 
in noncompliant patients with schizophrenia than it is in those who are compli-
ant (Hawton et al., 2005), though here it is important to realise that depression 
increases the risk of non-compliance (Elbogan et al., 2005) as well as of suicide. 
Although the long-term consequences of non-compliance are often detrimental 
to patients with schizophrenia, it is less obvious whether those who are compliant 
experience any short-term improvement in their quality of life. While three stud-
ies have found that people suffering from schizophrenia experienced substantially 
lower quality of life than healthy subjects (Carlsson et al., 2002; Reine et al., 
2003; Zissi et al., 1998), few studies have investigated how experienced quality of 
life was affected by compliance with antipsychotics. One study reported an asso-
ciation between compliance and quality of life in first-episode patients (Coldham 
et al., 2002). Another initially found a small positive association that however 
was not borne out by subsequent statistical modelling (Puschner et al., 2006).
Arguably, by reducing symptoms on the one hand and increasing side-effects on 
the other, compliance with medication involves two mechanisms, each affecting a 
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patient’s perceived quality of life in a different direction. Although Puschner et al. 
(2006) did indeed find that better compliance and higher perceived quality of life 
were mediated by a reduction in psychopathology, they did not find that better 
compliance and lower quality of life were mediated by an increase in medication 
side-effects. This may be because they used the Liverpool University Neuroleptic 
Side Effect Rating Scale (LUNSERS, Day et al., 1995) – a good self-report scale 
of side-effects that nonetheless does not make it possible to quantify their overall 
burden on a patient. It has been found in other studies, however, that side-effects of 
antipsychotics are associated with a reduced perceived quality of life (Angermeyer 
and Matschinger, 2000; Yen et al., 2008), and that they are sometimes a reason for 
discontinuing medication (Lambert et al., 2004; Robinson et al., 2002).
The objective of this study was to test the hypothesis that medication com-
pliance has two opposing and indirect associations with a patient’s perceived 
quality of life: (1) that, by reducing psychotic symptoms, better compliance 
is associated with increased quality of life; and (2) that, by increasing adverse 
medication effects, better compliance is associated with poorer quality of life.
4.2 method 
4.2.1 Study population
Participants were respondents in a multi-centre randomised controlled trial 
that took place in the Dutch city of Rotterdam and investigates the effects of 
Treatment Adherence Therapy (TAT). TAT is a tailored intervention in which, 
depending on a patient’s individual reasons or causes of non-compliance, four 
different intervention modules can be applied, for example behavioural inter-
ventions or an adapted form of motivational interviewing. For a more detailed 
description, see Staring et al. (2006). Inclusion criteria were: (1) schizophrenia 
spectrum disorder, (2) receiving outpatient treatment, (3) speaking the Dutch 
language, and (4) at least some problems with service engagement, as defined 
by an average item-score of 1.5 or higher on at least two subscales of the Service 
Engagement Scale (SES; see Measurements, below).
4.2.2 Design and procedure
The study design was approved by the Medical Ethics Committee at Erasmus 
University Medical Centre. Participants had to give written informed consent 
before start. Patients were referred by their clinician; their participation was 
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requested by a research assistant. In baseline assessment before randomization, 
all respondents and their clinicians participated in a structured interview. This 
was conducted by psychology and medicine students who received a sixteen 
hours training that mostly consisted of interview role playing and scoring of 
the instruments. After co-rating a live interview by the main researcher, they 
performed two interviews under supervision. When ratings were sufficiently in 
line with those of the experienced researcher, the students did interviews by 
themselves, while receiving bi-weekly supervision. Among others, we used the 
lifetime Composite International Diagnostic Interview, version 2.1 Auto (WHO 
CIDI, 1997) to assess mental disorders according to the definitions and criteria 
of DSM-IV (APA, 1994). Respondents were paid EUR 20 for participating in 
the interview. These baseline assessments provided the data for this article.
4.2.3 Measurements
Medication compliance
The Service Engagement Scale (SES) (Tait et al., 2002) is a 14-item rating scale 
in which observed service engagement is rated by the caregiver most familiar 
with the patient. The scale has four subscales: (1) availability, (2) collabora-
tion, (3) help-seeking, and (4) medication compliance. The scale has good face 
validity and content validity, is user-friendly, and had good test-retest reliability 
in patients with psychotic disorders (Tait et al., 2002). In this study, only the 
fourth subscale was used as a measure of medication compliance. A high score 
indicates problematic compliance.
As well as the SES, we also assessed compliance in a semi-structured inter-
view with the patient. This score ranges from 0 to 4, with higher scores indicat-
ing more problematic compliance. The method was modeled after the Health of 
the Nation Outcome Scales (HoNOS) (Wing et al., 1998; Mulder et al., 2004). 
Thus, we used two different measures of medication compliance, one 
caregiver-based and one patient-based. Both measures were standardized, 
summed, and reversed, thereby creating a compiled measure of compliance, 
with high scores indicating good compliance. This compiled measure based on 
dual assessment warrants against biased measurements (Kikkert et al., 2008).
Quality of life
To measure quality of life we used the self-report EQ-5D, which has been 
validated in patients with schizophrenia (Prieto et al. 2003). The patient uses the 
EQ-5D to rate health-related quality of life on five dimensions: mobility, self-care, 
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
Ch
ap
te
r 4
58
usual activities, pain/discomfort, and anxiety/depression. On the basis of a Dutch 
validation study (Lamers et al., 2005), the items were linearly transformed into a 
score ranging from -0.33 to 1.00. A higher score stands for better quality of life.
Psychopathology
The Positive and Negative Syndrome Scale (PANSS) (Kay et al., 1987) is a 
30-item rating scale completed by the trained research staff at the conclusion of 
a semi-structured interview. For this study, we used only the positive syndrome 
scale as a measure of psychotic symptoms.
Adverse effects and wellbeing under neuroleptics
To measure the effects of antipsychotics experienced by our patients, we used the 
20-item version of the Subjective Wellbeing Scale under Neuroleptics (SWN) 
(Naber et al., 2001; De Haan et al., 2002). The scale consists of five subscales: 
(1) physical functioning, (2) social integration, (3) mental functioning, (4) 
self-control, and (5) emotional regulation. The SWN covers adverse side-effects 
(Karow et al., 2007), and encompasses patients’ overall experience of the effects 
of antipsychotics. It is important to note that patients are kept unaware of 
the fact that the measurement is concerned with effects of antipsychotics. This 
makes it unlikely that a patient’s general attitude towards medication will play 
a role in the answers. For the purpose of this study, we reversed the total score, 
which ranges from 0 to 100: high scores thus indicate a high level of subjectively 
experienced adverse effects of antipsychotics.
4.2.4 Statistical analyses
Performance parameters of various pathway models were produced and 
compared using Structural Equation Modeling (SEM). We examined four 
competing models: (1) the model of the hypothesis (Figure I), in which the 
direct effect of compliance on quality of life was fixed at 0.00; (2) a model in 
which this effect was not fixed at 0.00, but the effect of psychotic symptoms on 
quality of life was; (3) a model in which the effects of compliance and psychotic 
symptoms on quality of life were both fixed at 0.00, and (4) a model in which 
the effect of compliance on quality of life was not fixed at 0.00, yet the effect 
of adverse medication effects was. By comparing these models, SEM makes it 
possible to identify and estimate the relevance of the various pathways. In all 
four competing models, psychotic symptoms were allowed to be correlated with 
adverse medication effects.
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As measures of model performance, the χ2 test was used to determine the model-
fit. A non-significant p-value (p>0.05) and the ratio of χ2 / df < 1.5 would 
represent an adequate model fit. To provide for reliable evaluations of the model, 
we used the Comparative Fit Index (CFI>0.95; Bentler, 1990), the Tucker-
Lewis Index (TLI>0.95; 1973), the Root Mean Square Error of Approximation 
(RMSEA<0.05), and the Standardised Root Mean Square Residual (SRMR<0.05; 
Jöreskog, 1971). As the models were not necessarily structured hierarchically, 
we also used three information criteria (AIC, BIC, ABIC), for each of which 
goes: the smaller, the better. As individual measures of performance we used the 
standardized regression coefficient including the corresponding P-values.
4.3 results
4.3.1 Patient characteristics
A total of 195 patients were asked to participate in the randomised controlled 
trial described above. Seventy-nine of them declined to participate. Of the 
remainder, two were too disorganized in thought and speech to be able to 
complete the questionnaires. The remaining 114 completed the baseline 
assessments. Lifetime diagnoses: 79 of these patients (69%) met the criteria 
of schizophrenia (60 paranoid type, 11 disorganized type, 7 catatonic type, 
and 1 undifferentiated type), and 35 (31%) met the criteria of schizoaffective 
disorder (22 depressive type and 13 bipolar type). Eighty-one patients (71%) 
 
negative 
association 
does not affect 
negative 
association 
increases 
reduces 
Psychotic symptoms  
Medication 
compliance 
Adverse medication 
effects 
Quality of life 
Figure I The hypothesis. Compliance does not directly influence quality of life. It lessens psychotic 
symptoms, a process that increases quality of life. Also, it exacerbates the adverse effects of 
neuroleptics, a process that reduces quality of life.
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were male, and 33 (29%) female. Fifty-one patients (45%) were native to the 
Netherlands, 42 (37%) were first-generation immigrants, and 21 (18%) were 
second-generation immigrants. Most of the first-generation immigrants were 
from Suriname (24 patients), and the Dutch Antilles (six patients). As the 
Dutch language is spoken throughout both Suriname and the Dutch Antilles, 
performing the interviews with these immigrants did not produce problems. 
The remaining twelve first-generation immigrants also spoke Dutch, as this was 
a requirement for participation in the study. However, no specific measures 
were taken to ensure that the instruments were culture-sensitive.
One-hundred-and-two patients (90%) were not married or living with 
a partner. The majority were unemployed (95 patients; 83%). Mean age at 
first contact with a mental health institution was 25.8 years (SD=9.3); mean 
age at baseline assessment was 38.3 years (SD=11.5). Although following 
outpatient treatment, 21 patients were not, despite medical advice, taking 
antipsychotic medication (18%), and were thus totally non-compliant. Thirty-
four patients(28%) were being treated with first-generation antipsychotics, and 
61 (54%) with second-generation antipsychotics. Nineteen patients (17%) 
were using two different antipsychotics simultaneously. Average scores on the 
Positive and Negative Syndrome Scale (PANSS; Kay ea., 1987) were as follows: 
positive symptoms 13.7 (SD=5.40), negative symptoms 14.0 (SD=5.72), and 
general psychopathology 30.4 (SD=9.65).
4.3.2 Results concerning the hypothesis
As expected, significant correlations show that compliance was not only 
negatively associated with psychotic symptoms, but also positively associated 
with the perceived adverse effects of neuroleptics (Table I). Compliance was 
not significantly correlated with quality of life. Both psychotic symptoms and 
adverse medication effects had significant negative associations with perceived 
quality of life Table I).
Table I Correlations, means and standard deviations of the study variables
Pearson correlations Medication 
Compliance
Psychotic 
symptoms
Adverse medication 
effects
Quality of life 
Psychotic symptoms -.23*
Adverse medication effects .23* .27**
Quality of life .004 -.30** -.53**
Mean 0.00 13.74 33.26 0.71
SD 1.72 5.40 15.32 0.26
** Correlation is significant at the .01 level (two-sided)
* Correlation is significant at the .05 level (two-sided)
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In models 2, 3, and 4, the χ2 / df parameter was higher than 1.5, indicating a 
lack of fit with the data (Table II). Considering the p-value, model 4 should 
be rejected. Model 3, too, was nearly rejected, as the p-value was slightly above 
0.05.
In terms of the highest scores on the relevant parameters, the hypothesis 
model—model 1—had the best performance. The details of this model, pre-
sented in Table III and in Figure II, suggest that compliance has two indirect 
pathways towards quality of life. High compliance was associated with fewer 
psychotic symptoms (β=-.23) and more adverse medication effects (β=.22). 
Symptoms and adverse medication effects were both related to quality of life 
(β=-.17 and β=-.48, respectively).
4.4 disCussion
4.4.1 Compliance and quality of life
Our results suggest that compliance with antipsychotics in patients with a 
psychotic disorder involves two different and indirect pathways towards quality 
of life. While compliance seems to reduce psychotic symptoms—which may 
increase quality of life—compliance also seems to increase adverse medication 
effects—which may reduce quality of life. This finding is largely in line with 
an earlier study which found not only (1) that compliance with antipsychotics 
had no direct effect on quality of life, but also (2) clinical-empirical evidence 
for an indirect effect through a reduction of psychotic symptoms (Puschner et 
al., 2006). However, in their study, Puschner et al. (2006) did not find that an 
increase in medication side-effects mediated between better compliance and 
lower quality of life. This may be attributed to the fact that their side-effects 
measure (LUNSERS) did not cover the overall burden of adverse antipsychot-
ics effects. Our measure, on the other hand, emphasized subjective wellbeing, 
which is important from the patients’ perspective (Naber et al., 2001; De Haan 
et al., 2002). The results of our study are also in line with findings in which the 
side-effects of antipsychotics were associated with a lower perceived quality of 
life (Yen et al., 2008; Angermeyer & Matschinger, 2000).
As well as the associations we had expected, we found psychotic symptoms to 
be significantly associated with adverse effects of antipsychotics. One possible 
explanation is that patients with severe psychotic symptoms are prescribed 
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higher doses of antipsychotics, which in turn exacerbates adverse medication 
effects. A second possible explanation is that patients with severe psychotic 
symptoms are more likely to report feeling distressed, which is then reflected in 
their answers on the scale for adverse medication effects. A similar relationship 
was found in the study by Puschneret al. (2006), though the authors themselves 
did not comment on it.
4.4.2 Limitations
Our study had three main limitations. The first is our restricted sample size with 
mainly male participants (71%), in addition to which we excluded patients 
with very high service engagement—an exclusion criterion in the multi-centre 
randomised controlled trial addressing patients with moderate compliance. 
Neither is it likely that we included patients with very poor service engagement, 
who may have refused to participate or who may not have been in outpatient 
Table III SEM results of the hypothesis model tested
b1 se2 b / se β3
Effects of compliance on: Psychotic symptoms -0.71 0.29 -2.45 -0.23
Adverse medication effects 2.06 0.82 2.45 0.22
Effects of psychotic symptoms on: Quality of life -0.01 0.00 -2.12 -0.17
Effects of adverse medication effects on: Quality of life -0.01 0.00 -5.89 -0.48
Psychotic symptoms’ association with: Adverse medication effects 26.62 7.74 3.44 0.33
1) unstandardized regression coefficient
2) standard error of the unstandardized regression coefficient
3) standardized regression coefficient
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- 0.48 
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Figure II Results of the best fitting model (model 1) of the SEM analyses, presenting the 
standardized regression coefficients
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treatment. For these reasons, the service engagement of respondents in this 
study probably lay in the middle range. This makes it difficult to generalize our 
findings to patients with very high or very low compliance and future studies 
on the topic may try to include these patient groups, by for example including 
inpatients.
The second limitation is that our measure of compliance consisted of the SES 
plus a one-item rating scale. This latter measure has not been validated, and 
may not be the best available. However, measuring compliance is difficult, and 
a gold standard is certainly lacking (Kikkert et al., 2008). As well as self-report 
and interview measures, methods of measuring compliance include pill counts, 
electronic methods, prescription monitoring, and saliva, plasma and urine assay 
tests (Patel & David, 2007). Each has its advantages and disadvantages. Pill 
counts, for example, are not only time-consuming, but also have great potential 
for inaccuracy. And not only are saliva, plasma, and urine tests not possible for 
all drugs, they are expensive and invasive, and may also overestimate adherence 
for drugs that have a long half-life (Fenton et al., 1997; Zygmunt et al., 2002). 
However, future studies may use such alternative methods to verify our results. 
Hopefully, our study overcame some of the difficulties, not only because patients 
were asked about their compliance by interviewers who were not involved in 
the treatment, but also because it was made clear that the answers would be 
used solely for the purpose of this study and would not be communicated with 
care-givers. We are therefore reasonable confident that patients felt free to give 
honest answers on their medication compliance.
Finally, because our study used cross-sectional data, we cannot draw firm 
conclusions about the directions of causality. The causal interrelationships of 
the relevant variables would almost certainly be identified in longitudinal and 
intervention studies. However, to our knowledge, no studies have experimen-
tally increased compliance and examined its effects on quality of life.
4.4.3 Clinical implications
Overall, our results may have two implications for clinical practice. The first is 
that, with regard to the effects of medication, the balance between symptom 
reduction and adverse effects is associated with the benefit a patient perceives 
in terms of improved quality of life. Generally, however, when evaluating the 
antipsychotic medication with which they have been prescribed, patients do 
not balance side-effects and symptoms as separate issues. Instead, they describe 
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drugs as ‘good’ or ‘terrible’—an indication of the total impact of the treatment 
on their perceived quality of life (Carrick et al., 2004). In clinical practice, 
it may therefore be useful to measure psychotic symptoms and side-effects 
repeatedly, to communicate about the measurements with the patient, and to 
work together with each individual patient to establish which antipsychotic 
(and dosage) is the most suitable. Such repeated measurements may enhance 
compliance, simultaneously helping the patient to distinguish between the 
ways in which medication not only reduces symptoms but also creates adverse 
effects. This method has been described elsewhere as part of an intervention for 
improving compliance (Staring et al., 2006).
The second implication is that outpatients who are compliant with the 
antipsychotics prescribed may not gain any improvement in perceived short-
term quality of life. This means that their motives for compliance may not lie 
in the perception of short-term experienced benefits. They may have several 
other motives for being compliant—to gain partner or family support (Patel & 
David, 2007), to achieve a good relationship with the clinician (Fenton et al., 
1997, Lacro et al., 2002), or possibly because they acknowledge the long-term 
consequences of non-compliance, such as the risk of relapse and admission 
or readmission. Interventions for improving compliance should try to focus 
on those motives, for example by helping patients to reflect on the long-term 
consequences of non-compliance. Examples of such interventions are compli-
ance therapy and motivational interviewing, though there is no conclusive 
evidence on their effectiveness in this field as yet (Barkhof et al., 2006; Rusch 
and Corrigan, 2002). It may be that, despite the efforts of clinicians, some 
patients with severe cognitive deficits are unable to reflect on the more distant 
consequences of non-compliance, or to behave in accordance with them. A 
possible strategy for improving compliance in such patients is by applying a 
form of contingency management, a method intended to gradually transform 
compliance into a rewarding behaviour by providing patients with an incentive 
immediately after they have taken their medication. This method has been used 
to enhance compliance with medications whose effects are not immediately 
rewarding (Rounsaville et al., 2008); our results suggest that antipsychotics fit 
this category of medicine. We should add that, in assertive outreach involv-
ing people with severe mental illness, money has been used as an incentive to 
improve compliance, and the results of an empirical exploration were promising 
(Claassen et al., 2007).

Chapter 5
Stigma moderates the associations of insight with 
depressed mood, low self-esteem, and low quality of 
life in patients with psychosis. 
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H. Duivenvoorden 
C.L. Mulder
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abstraCt 
Background
Good insight into illness in patients with schizophrenia is related not only to 
medication compliance and high service engagement, but also to depression, 
low self-esteem, and low quality of life. The detrimental effects of insight pose 
a problem for treatment.
Aim
To investigate whether the negative associations of good insight are moderated 
by perceived stigma.
Method
Respondents were 114 patients with schizophrenia spectrum disorders. We 
used Analyses of Variance (ANOVA) and Structural Equation Modeling (SEM) 
to test moderation.
Results
Good insight was associated with high service engagement and high compli-
ance. Also, good insight was associated with depressed mood, low quality of 
life, and negative self-esteem. This association was strong when stigma was high 
and weak when stigma was low. SEM showed that the constrained model per-
formed significantly worse than the unconstrained model, in which detrimental 
associations of insight were free to vary across stigma groups (χ2 = 19.082| df 
= 3 | p<.001).
Conclusions
Our results suggest that the associations of insight with depression, low quality 
of life, and negative self-esteem are moderated by stigma. Patients with good 
insight who do not perceive much stigmatization seem to be best off across 
various outcome parameters. Those with poor insight have problems with 
service engagement and medication compliance. Patients with good insight 
accompanied by stigmatizing beliefs have the highest risk of experiencing low 
quality of life, negative self-esteem, and depressed mood. A clinical implication 
is that when it is attempted to increase insight, perceived stigma should also be 
addressed.
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5.1 introduCtion
In patients with schizophrenia, insight into illness is associated with fewer 
symptoms, better psychosocial functioning, and better compliance with anti-
psychotic medication (Francis and Penn, 2001; Kuzoki et al. 2005; Lacro et 
al. 2002; Lysaker et al., 1998, 2002; Mohamed et al., 2009; Perkins 2002; 
Rittmannsberger et al. 2004). Insight has been regarded as a necessary con-
dition for anticipating needs, developing realistic goals (Lysaker et al., 2001; 
Young and Ensign, 1999) and promoting positive social and health outcomes 
(McEvoy, 1998; McGorry and McConville, 1999). However, there appears to 
be a downside. Recent studies show that insight is both cross-sectionally and 
longitudinally related to depression, hopelessness, lower self-esteem (Cooke et 
al., 2007; Karow and Pajonk, 2006; Lincoln et al., 2007a; Mohamed et al., 
2008) and lower quality of life (Hasson-Ohayon et al., 2006; Kravetz et al., 
2000; Pyne et al., 2001; Schwartz, 2001). These opposing effects of insight are 
reflected by diagnosed individuals who express the belief that they have two 
choices: either to accept their diagnosis and life as a “chronic case,” or to reject 
the diagnosis and retain some semblance of control (Barham and Hayward, 
1998).
If insight leads to an impoverished sense of self, worse quality of life, and 
pessimism about the future, should attempts be made to increase it? More 
understanding is needed of the psychological processes at work. To a greater 
extent than those with other mental disorders, patients with schizophrenia 
experience stigma from family, partners, friends, and colleagues (Corrigan, 
2004; Lee, 2005). Lysaker et al. (2006) argued that negative outcome of insight 
depends on the internalization of stigmatic beliefs, on the meaning that patients 
attach to their illness. While some patients believe that they no longer have the 
ability to achieve valued social roles, others disagree, remain hopeful and engage 
in active coping (Lysaker et al., 2005). A similar idea was published by Williams 
(2008), who based a description of post-diagnostic identities for patients with 
schizophrenia on two dimensions: (1) the amount of identification with the 
community of people with severe mental illness, and (2) the amount of stigma 
that is internalized in the self-narrative. Patients with high identification but 
low internalized stigma are assumed to be socially active and not experience 
diminished self-esteem. The hypothesis that good insight is related to negative 
outcome only when it is accompanied by stigmatizing beliefs was recently sup-
ported (Lysaker et al. 2006).
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To the best of our knowledge, the study by Lysaker et al. (2006) is the only 
one to have tested this hypothesis. Although it was well conducted, specific ele-
ments of its design limit the extent to which its findings can be generalized. For 
instance, their sample was relatively small (n=75), and its estimate of insight was 
based solely on a single item of the Positive and Negative Syndrome Scale. Also, 
a subscale of the Quality of Life Scale was used to reflect social functioning, but 
general quality of life was not included. And although its analyses included a 
scale of hopelessness, no measure of general depressive mood was used.
We investigated the same hypothesis as Lysaker et al. (2006), though using 
a larger sample, different outcome variables, other instruments, and more 
advanced statistical analyses. We hypothesized that service engagement and 
medication compliance are high in patients with good insight, independently 
of stigmatic beliefs. However, we also expected that stigma moderates the det-
rimental effects of insight.
5.2 method
5.2.1 Study population
Participants were respondents in an ongoing multi-centre randomised con-
trolled trial that investigates the effects of an intervention targeting service 
engagement in the Dutch city of Rotterdam (Staring et al., 2006). Inclusion 
criteria were: (1) schizophrenia spectrum disorder, (2) outpatient treatment, 
and (3) some problems with service engagement, as defined by an average item-
score of 1.5 or higher on at least two subscales of the Service Engagement Scale 
(see measurements section).
5.2.2 Design and procedure
We used a cross-sectional design. The study design was approved by the Medical 
Ethics Committee at Erasmus University Medical Centre. Patients were referred 
by their clinician, and asked by a research assistant to participate. Participants 
had to give written informed consent. The inclusion period lasted from March 
2005 until September 2008. Respondents were assessed on the basis of a struc-
tured interview, conducted by trained and supervised psychology and medicine 
students. To assess mental disorders according to the definitions of DSM-IV 
(APA, 1994), the lifetime Composite International Diagnostic Interview, ver-
sion 2.1 Auto (WHO, 1997) was used. Respondents were paid EUR 20 for 
participating in the interview.
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5.2.3 Measurements
Insight
The self-report 8-item Insight Scale (IS) of Birchwood et al. (1994) was used. 
There are three subscales: (1) awareness of illness, (2) re-labeling symptoms to 
illness, and (3) need for treatment. Total scores range from 0 to 12. The scale is 
reliable and valid, and is easy to use within this group of patients (Birchwood 
et al., 1994).
Stigma
We used the 12-item “perceived devaluation and discrimination” part of the 
self-report Stigma Scale (SS) by Link et al. (2002). The items cover the patient’s 
perception of common opinions about psychiatric patients, such as “Most 
people believe that entering a mental hospital is a sign of personal failure.” 
Total scores range from 1 to 4, with higher scores indicating more perceived 
stigmatization. Other parts of the Stigma Scale were not used, as they measure 
behavioural reactions on perceived stigma, such as secrecy or withdrawal.
Service engagement and medication compliance
The Service Engagement Scale (SES) (Tait et al., 2002) has 14 items on which 
the caregiver who is most familiar with the patient rates the observed service 
engagement. It has four subscales: (1) availability, (2) collaboration, (3) help-
seeking, and (4) medication compliance. The scale has good face validity and 
content validity, is user-friendly, and had good test-retest reliability in patients 
with psychotic disorders (Tait et al., 2002). Total scores range from 0 to 42, 
high scores indicating problematic service engagement. In this study, the total 
score was used to reflect service engagement, and the fourth subscale was used 
to reflect medication compliance.
On the basis of a semi-structured interview with the patient, we also used a 
one-item rating scale to assess medication compliance. This item ranged from 0 
to 4, high scores indicating problematic compliance.
In other words, because measuring compliance is difficult (Kikkert et al., 
2008), we used two measures of compliance, one caregiver-based and one 
patient-based, hoping that this would provide a valid indication.
Quality of life
The self-report Euro-QOL with five dimensions (EQ-5D) was used, which 
has been validated in patients with schizophrenia (Prieto et al., 2003). Five 
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dimensions are rated: mobility, self-care, usual activities, pain/discomfort, and 
anxiety/depression. Items are calculated into a weighed total score that ranges 
from -0.33 to 1.00, based on a Dutch validation study (Lamers et al., 2005). 
Higher scores represent better quality of life.
Self-esteem
We used the 20-item Self-Esteem Rating Scale-Short Form (SERS-SF) (Lecomte 
et al., 2006). This self-report scale has two subscales, supported by factor 
analysis: positive and negative self-esteem. Each subscale ranges from 10 to 70; 
high scores indicate high positive or high negative self-esteem. The scale has 
good internal consistency, good test-retest reliability, and adequate convergent 
validity in patients with schizophrenia (Lecomte et al., 2006).
Depressed mood
The depressed mood item of the Positive and Negative Syndrome Scale (PANSS) 
(Kay et al., 1987) was used. PANSS is a 30-item rating scale completed by 
trained research staff at the conclusion of a semi-structured interview. The 
depressed mood item provides a rating from 1 to 7, higher scores reflecting 
higher levels of depressed mood.
5.2.4 Statistical analyses
We conducted an Analysis of Variance (ANOVA) to gain a view of our data. 
Then we used Structural Equation Modeling (SEM) in a multiple-group 
approach that would allow us to test the moderator hypothesis.
For the ANOVA, we constructed three groups, the first consisting of patients 
with poor insight, the second of patients with good insight and low stigma, and 
the third of patients with good insight and high stigma. A score of eight or 
higher on the Insight Scale (IS) was taken to reflect good insight, and all scores 
below this point to reflect poor insight. A score of 2.70 or higher on the Stigma 
Scale (SS) was seen as an indication that a patient perceived a lot of stigma. The 
groups were compared for outcome variables using one-way analyses of variance 
(ANOVA) with post-hoc Bonferroni, using SPSS 15.0. Bonferroni’s correction 
was used to correct for multiple testing.
Next, we used Structural Equation Modeling (SEM) to compare two 
models, both in which the continuous measure of insight was used to pre-
dict service engagement, compliance, depressed mood, quality of life, and 
self-esteem. Stigma was dichotomized using the same cut-off score as with the 
ANOVA, dividing the participants into two groups: those with low and those 
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with high stigma. An unconstrained model and a constrained model were then 
analyzed. In the latter, the effects of insight on depressed mood, quality of life 
and self-esteem were constrained to be equal across both stigma groups. In the 
unconstrained model, these effects were free to differ across the stigma groups. 
If the constrained model significantly worsened the model fit in comparison 
to the unconstrained model, this would be evidence of different relationships 
between insight and detrimental measures across the two stigma groups (Frazier 
et al., 2004). In other words, it would be evidence that the detrimental effects of 
insight depend on whether patients perceive much stigma or not. We compared 
the models using a chi-square test, in which the degrees of freedom are equal 
to the difference in degrees of freedom for the test statistics of the two models. 
As measures of model performance, we used the χ2 test (Jöreskog, 1993) 
to determine the adequacy of the model-fit. A non-significant p-value (p>0.05) 
and the ratio of χ2/df < 1.5 would represent an adequate model fit. To pro-
vide for reliable evaluations of the model, we used the Comparative Fit Index 
(CFI>0.95; Bentler, 1990), Tucker-Lewis Index (TLI>0.95; 1973), Root Mean 
Square Error of Approximation (RMSEA≈0.05; Steiger, 1990), and Stan-
dardised Root Mean Square Residual (SRMR<0.05; Jöreskog, 1971). We used 
the M-Plus 5.0 program.
5.3 results
5.3.1 Patient characteristics
A total of 195 patients were asked to participate. Seventy-nine refused. As no 
data was available on those who refused, it was not possible to analyze biases 
due to selective participation. Two patients of those willing to participate were 
too disorganized to be able to complete the questionnaires. The remaining 114 
completed the baseline assessments (Table I).
5.3.2 Effects of insight
The ANOVA results (Table III) showed that Bonferroni’s correction should be 
used for a maximum of three dimensions, which means that our alpha-criterion 
for each test was divided by three, resulting in an alpha of .017. Results indicated 
that service engagement and medication compliance were significantly more 
problematic in patients with poor insight than in those with good insight. The 
effect was independent of stigma for service engagement and caregiver-based 
compliance. On patient-based compliance, the post-hoc analysis clustered 
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patients with good insight and high stigma together with those who were low 
compliant and those who were high compliant. In short, mostly irrespective 
of the level of stigma, the ANOVA supported the hypothesized associations of 
insight with service engagement and compliance.
As to the detrimental associations, ANOVA showed that the group with good 
insight and high stigma scored significantly worse than both other groups on 
negative self-esteem (F = 14.52; p<.001) and quality of life (F = 7.52; p<.01); 
and this group also scored significantly worse on depressed mood than the 
group with poor insight (F = 5.93; p<.01). The group with good insight and low 
stigma scored significantly better on negative self-esteem and quality of life than 
the group with good insight and high stigma. Finally, the poor insight group 
scored significantly better on depressed mood, negative self-esteem and quality 
of life than the group with good insight and high stigma, though not better 
than the group with good insight and low stigma. There were no significant 
differences with regard to positive self-esteem. We therefore did not include 
positive self-esteem in subsequent analyses.
Table I Respondents characteristics
N 114
Sex 81 patients (71%): male
33 patients (29%): female
Average age 38.3 years (SD=11.5)
Average age of the first contact with a mental 
health institution
25.8 years (SD=9.3)
Employment 95 patients (83%): unemployed
19 patients (17%): employed
Ethnicity 51 patients (45%): Dutch
42 patients (37%): first-generation immigrants
21 patients (18%): second-generation immigrants
Diagnoses 79 patients (69%): schizophrenia
- 60 paranoid type
- 11 disorganized type
- 7 catatonic type
- 1 undifferentiated type
35 patients (31%): schizoaffective disorder
- 22 depressive type
- 13 bipolar type
Average PANSS positive syndrome score 13.7 (SD=5.4)
Average PANSS negative syndrome score 14.0 (SD=5.7)
Average PANSS general psychopathology score 30.4 (SD=9.7)
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In the SEM, we included insight as the predictor, and service engagement, 
compliance (both measures), depressed mood, quality of life, and negative self-
esteem as outcome variables. Although the parameters discussed in the methods 
section show that the constrained model did not fit the data well (Table IV), the 
Table III ANOVA results comparing patients with (1) poor insight, (2) good insight and low 
stigma, and (3) good insight and high stigma
(1)
Poor
Insight 
(n=50)
(2) Good
insight and
low stigma 
(n=37)
(3) Good
insight and
high stigma 
(n=27)
ANOVA Group 
Comparisons 
(Bonferroni)
Problematic service 
engagement (SES)
22.9
(SD=6.18)
19.1
(SD=5.56)
18.4
(SD=6.05)
6.88** 1 > 2,3
Problematic medication 
compliance (SES-4)
6.32
(SD=3.21)
3.84
(SD=2.76)
4.19
(SD=2.90)
8.62*** 1 > 2,3
Problematic medication 
compliance (one item) 
1.84
(SD=1.73)
1.00
(SD=0.97)
1.11
(SD=0.93)
4.87** 1 > 2
Depressed mood (PANSS 
G6) 
1.90
(SD=1.20)
2.51
(SD=1.52)
3.07
(SD=1.77)
5.93** 1 < 3
Quality of life (EQ-5D) 0.76
(SD=0.23)
0.75
(SD=0.20)
0.55
(SD=0.30)
7.52** 1,2 > 3
Positive self-esteem (SERS-
SF) 
52.1
(SD=9.99)
51.3
(SD=11.84)
47.7
(SD=9.58)
1.62 ns
Negative self-esteem
(SERS-SF) 
26.7
(SD=9.90)
30.9
(SD=14.69)
42.5
(SD=12.92)
14.52*** 1,2 < 3
*** P < .001
** P < .01
* P < .017 (the alpha-criterion for each test due to Bonferroni’s correction)
Table IV SEM fit to the data parameters of both the unconstrained and the constrained model 
Model description χ2 df p χ2/df CFI TLI RSMEA SRMR
Unconstrained model: all effects 
of insight are unconstrained 
across both stigma groups
7.73 6 0.26 1.29 0.99 0.93 0.07 0.06
Constrained model: the effects 
of insight on depression, quality 
of life, and negative self-esteem 
are constrained as equal across 
the stigma groups
26.81 9 0.002 2.98 0.90 0.54 0.19 0.11
A non-significant p-value (p>0.05) and the ratio of χ2 / df < 1.5 represent adequate model fit. For 
good model fit, the Comparative Fit Index (CFI) should also be higher than .95, the Tucker-Lewis 
Index (TLI) higher than 0.95, the Root Mean Square Error of Approximation (RMSEA) around 
0.05, and ideally, the Standardised Root Mean Square Residual (SRMR) should be lower than 
0.05.
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unconstrained model had a very good fit. The constrained model was significantly 
worse than the unconstrained model (χ2 = 19.082; df = 3; p<.001), indicat-
ing that the associations of insight with depressed mood, quality of life, and 
negative self-esteem were unequal between the two stigma groups. The results of 
the unconstrained model are presented in Table V. The detrimental associations 
of insight with depression, quality of life, and negative self-esteem were more 
pronounced in the patients with high stigma than in those with low stigma.
We also explored the observed results of insight on a subscale level, comparing the 
same type of models as before, though using the subscales as three independent 
variables: (1) awareness of illness, (2) re-labeling symptoms to illness, and (3) need 
for treatment. Results showed that the constrained model significantly worsened 
the fit to the data (χ2 = 27.59; df = 9; p<.01), indicating that stigma moderates 
the detrimental effects of the insight subscales. When stigma was low, no large 
effect of any insight subscale was found on either depressed mood, quality of life, 
or negative self-esteem. When stigma was high, the subscale ‘need for treatment’ 
had the largest detrimental effects on depressed mood and quality of life, and the 
subscale ‘awareness of illness’ had the largest effect on negative self-esteem.
Table V SEM results of the unconstrained model
Effects of insight on: b1 se2 b / se3 β4
Low 
stigma 
group
Problematic service engagement (SES) -0.62 0.16 -3.75 -0.36
Problematic compliance (SES-4) -0.39 0.09 -4.61 -0.40
Problematic compliance (one item) -0.11 0.04 -2.74 -0.26
Depressed mood (PANSS G6) 0.10 0.04 2.44 0.25
Negative self-esteem (SERS-SF) 0.75 0.36 2.10 0.19
Quality of life (EQ-5D) -0.01 0.01 -0.96 -0.10
High 
stigma 
group
Problematic service engagement (SES) -0.63 0.18 -3.58 -0.33
Problematic compliance (SES-4) -0.32 0.08 -3.84 -0.38
Problematic compliance (one item) -0.08 0.04 -1.95 -0.20
Depressed mood (PANSS G6) 0.14 0.04 3.30 0.30
Negative self-esteem (SERS-SF) 1.77 0.35 5.08 0.48
Quality of life (EQ-5D) -0.03 0.01 -3.70 -0.32
1) Unstandardized regression coefficient
2) Standard error of the unstandardized regression coefficient
3)  When this parameter is above [2], it indicates an effect. Large absolute values indicate large 
effects. 
4) Standardized regression coefficient
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5.4 disCussion
5.4.1 Effects of insight
Our results support the hypothesis that insight is associated with medication 
compliance and service engagement. This is consistent with earlier studies 
(Mohamed et al., 2008; Perkins 2002; Rittmannsberger et al. 2004). Our results 
also support the hypothesis that good insight is associated with low quality of 
life, depressed mood, and negative self-esteem, mainly when it is accompanied 
by stigmatizing beliefs. In patients who had good insight yet did not have many 
stigmatizing beliefs, these negative associations were either not observed or were 
smaller. The results therefore show that perceived stigma is a moderator of the 
detrimental associations of insight in patients with a psychotic disorder.
The results indicate that the patients, who have good insight into their 
illness and do not perceive much stigmatization, are best off. Those with poor 
insight have problems with service engagement and compliance, and are unable 
to optimally benefit from treatment. On the other hand, those with good insight 
and many stigmatizing beliefs about psychiatry, despite their engagement with 
services and compliance with medication, have the highest risk of experiencing 
low quality of life, negative self-esteem, and depressed mood.
Our findings are in line with those of Lysaker et al. (2006) and with the 
post-diagnostic identities as formulated by Williams (2008). Patients, when 
realizing that they have a psychotic disorder may or may not internalize the 
stigma and stereotypes which hold that people diagnosed with schizophrenia 
are damaged and deserving of low status. Those who internalize stigma may 
think that they are unable to achieve valued social roles. This reaction has been 
described as an engulfed post-diagnostic identity (Williams, 2008).
5.4.2 Clinical implications
Our findings support the notion that it is desirable to enhance insight as 
long as self-stigmatization is also addressed. If psycho-educational programs 
included a focus on aspects of stigma and illness-normalization, and if physi-
cians were more alert to such questions, it might be possible to improve insight 
without risking a deterioration in mood, self-esteem, and quality of life. The 
effects of psycho-educational programs on insight nonetheless remain unclear. 
Although a meta-analysis showed that psycho-education increases knowledge 
about schizophrenia (Lincoln et al., 2007b), it is not clear whether patients 
apply the knowledge to themselves (Kemp and David, 1995; Sevy et al., 2004). 
Unfortunately, very little literature describes other attempts to enhance insight. 
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Henry and Ghaemi (2004) showed that atypical antipsychotic medication has a 
small positive effect on insight. Cognitive behavioural therapy addresses insight 
– though not explicitly – by re-labeling voices as harmless symptoms of the 
disease, or by restructuring paranoid thought content (Turkington et al., 2002). 
It seems equally difficult to reduce self-stigmatization. Link et al. (2002) 
tested a 16-session group intervention in which patients who were instructed on 
the effects of social stigma were provided both with an outlet to discuss personal 
experiences, and with behavioural strategies for dealing with the social conse-
quences of stigma. However, this produced no effect on stigma, self-esteem, or 
depressive symptoms (Link et al., 2002). Another study examined the effects 
of group therapy that focused on reducing engulfment, perceived stigma, and 
symptoms. Although the results were promising, this produced no significant 
improvement, possibly due to a lack of statistical power (McCay et al., 2006; 
McCay et al., 2007). New approaches for supporting patients that struggle with 
their post-diagnostic identities are being discussed (Williams, 2008).
5.4.3 Limitations
The first of the four limitations of this study is that the sample composition 
limited the possibilities for generalizing the results. Not only were most of the 
participants men (71%), patients with very high service engagement were not 
in this study, as this was an exclusion criterion of the randomised controlled 
trial. It is also probable that patients with a very low service engagement were 
not included in the study, either because they had refused to participate, or 
because they were not in outpatient treatment.
The second limitation is that we used only a single PANSS item to measure 
depressed mood, and made no detailed measurement of the symptoms distinc-
tive of a depressive episode.
The third limitation is that our study used cross-sectional data, which 
makes it impossible to draw conclusions on directions of causality. It may be, for 
example, that negative self-evaluating beliefs cause patients to be more vulner-
able to stigma, rather than the other way around. Longitudinal or intervention 
studies should tell us more about causal relationships.
The final limitation is that not all relevant variables were included in this 
study. Some cognitive dysfunctions, for example, are known to be related to 
insight (Simon et al., 2009) and may affect outcome, such as compliance, global 
functioning, and quality of life.

Chapter 6
Why do schizophrenia patients with poor insight still 
take antipsychotics? Memory deficits as a moderator 
between adherence belief and behaviour.
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abstraCt
Background
While lack of insight is often a strong predictor of antipsychotic non-adherence, 
there is considerable inconsistency in the literature that has not been adequately 
explained. We hypothesized that verbal memory deficits may be an important 
moderator in the association between insight and adherence.
Method
Based on cross-sectional data, outpatients treated with antipsychotics for a 
psychotic disorder were divided into those with (n=59) and without (n=53) 
severe verbal memory deficits.
Results
Poor insight was only associated with medication non-adherence in the patient 
group with relatively good memory (r=.43; p<.01). There was no relationship 
between poor insight and non-adherence in patients with severe memory 
deficits (r=.08; ns). Structural Equation Modelling analysis revealed significant 
moderation (χ2=4.72; df=1; p<.05).
Conclusions
The association between poor insight and poor adherence was only present in 
patients with intact memory. There may be two groups with low insight: patients 
with cognitive deficits, who do not understand their illness, and patients who 
use denial as coping. The latter group may oppose treatment because it conflicts 
with their beliefs. The first group, however, may reflect less critically and be 
more willing to comply with medical advice. When these patients are non-
adherent, other risk factors than insight may be more relevant.
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6.1 introduCtion
Non-adherence with medication is highly prevalent in patients with psychotic 
disorders (Cramer and Rosenheck, 1998; Keith and Kane, 2003; Bebbington, 
1995; Thomas, 2007; Weiden et al., 1996; Weiden et al., 1991). When a patient 
stops using antipsychotic medication, the risk of relapse increases three to five-
fold (Dixon and Lehman, 1995; Fenton et al., 1997; Robinson et al., 2002; 
Ucok et al., 2006; Weiden et al., 2004). Similarly, the risk of suicide has been 
found to be 3.75 times higher in non-adherent patients with schizophrenia 
than in adherent patients (Hawton et al., 2005), though it should be noted that 
depression increases the risk of non-adherence (Elbogan et al., 2005) as well as 
of suicide. Despite the detrimental consequences of non-adherence, no inter-
ventions have dealt very successfully with this problem (Staring et al., 2006).
‘Lack of insight’ refers to a common observation that many patients with 
schizophrenia do not acknowledge the existence of a mental health problem or 
recognize the need for treatment. Although there are many theories about the 
underlying reasons for this finding, ranging from psychological defences against 
stigma to neurologic impairments analogous to anosognosia, there is a general 
agreement that poor insight is a major risk factor for poor medication adher-
ence. However, there is a great deal of variability in the research literature about 
the magnitude of this association (Acosta et al., 2008; Kuzoki et al. 2005; Lacro 
et al. 2002; Mohamed et al., 2008; Perkins 2002; Rittmannsberger et al. 2004), 
and some studies have not found any association whatsoever (McCann et al., 
2008; Tait et al., 2003; Yen et al., 2005). While this is perhaps not surprising 
given differences in setting, methods, and definition of insight and adherence, 
another possible explanation is that certain kinds of cognitive deficits might 
disrupt any association between attitude about the illness (insight) and behav-
ioural outcomes that are influenced by such an attitude (medication adherence).
It has been suggested that there are two groups of patients with low insight: 
those with severe neurologic impairments, who do not really understand their 
illness or overview its symptoms and consequences, and those with psychologic 
defences against stigma, who may deny being ill at all (Lysaker et al., 2003; 
Startup, 1996). It is plausible that the latter group refuses treatment, as that 
would mean accepting the illness, and thus these patients may be very non-
adherent. Patients in the first group, however, despite having low insight, may 
be more willing to comply with their clinician’s advice, as doing so does not 
really interfere with their own ideas. They may reflect less critically, accept their 
clinician’s judgement, and comply with medical treatment as well as they can. 
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Thus, lack of insight may be more predictive of low adherence in those patients 
who use denial as coping, than in patients with severe cognitive impairments. 
Other research of interest is that on metacognition in schizophrenia. A 
range of studies have suggested that cognitive impairment is related to difficul-
ties in thinking about thinking, which may play a major role in making it 
difficult for patients with schizophrenia to construct a meaningful picture of 
their own mental illness (Wiffen & david, 2009). Again, in such a group it is 
less that illness is denied and more that things about one’s own thinking are dif-
ficult to consider and as such may be less linked to behaviour. Non-adherence 
as a deliberate behaviour may therefore occur less in this group.
Because of these reasons, and although cognitive impairments have often been 
investigated as potential determinants of poor insight (e.g. Aleman et al., 2006), 
it may be useful to look at cognitive deficits in a new role: as a moderator of 
the association between insight and adherence. In this light, a relevant neu-
rocognitive measure appears to be verbal memory, which has repeatedly been 
associated with different types of functional outcome in schizophrenic patients, 
for example adherence (Donohoe et al., 2001; Green, 1997; Heinrichs et al., 
2007; Kim et al., 2006). Acquisition—the first stage of memory processing—is 
often particularly impaired (Toulopoulou and Murray, 2004). Because acquisi-
tion deficits underlie an impaired ability to organize and store information in 
a useful manner, they may affect patients’ actions due to a limited ability to 
transform insight into beneficial treatment behaviours such as adherence.
We wished to establish whether insight is associated with adherence in patients 
with severely impaired verbal memory (acquisition) in the same way as in 
patients without severely impaired verbal memory. In other words, we tested 
the hypothesis that verbal memory deficits moderate the association between 
insight and adherence in patients with a psychotic disorder. We expected that 
in patients with poor verbal memory, the link between insight and adherence 
would be less prominent than in patients with relatively intact verbal memory. 
6.2 material and methods
6.2.1 Study population
Participants were those who enrolled in a multi-centre randomised controlled 
trial that took place in the Dutch city of Rotterdam and investigated the effects 
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of an intervention targeting service engagement (Staring et al., 2006). Inclusion 
criteria were: (1) receiving outpatient treatment, (2) a diagnosis of schizophre-
nia or a related psychotic disorder, and (3) at least some problems with service 
engagement as defined by an average item-score of 1.5 or higher on at least 
two subscales of the Service Engagement Scale (SES; see Measurements, below). 
The only exclusion criteria was not speaking the Dutch language. Patients with 
severe cognitive deficits were not excluded.
6.2.2 Design and procedure
The study design was approved by the Medical Ethics Committee at Erasmus 
University Medical Centre. Patients were referred by their clinician; their par-
ticipation was requested by a research assistant. Participants had to give written 
informed consent. In baseline assessment all respondents and their clinicians 
participated in a structured interview. This was conducted by trained and 
supervised psychology and medicine students, who used the lifetime Composite 
International Diagnostic Interview (CIDI), version 2.1 Auto (WHO, 1997) 
to assess mental disorders according to the definitions and criteria of DSM-IV 
(APA, 1994) as well as the Positive and Negative Syndrome Scale (PANSS; 
Key et al., 1987). Respondents were paid 20 Euros for participating in this 
interview. Baseline assessments provided the data for this article.
6.2.3 Measurements
The patients’ demographics were collected. Using a method based on Hollings-
head (1975), socioeconomic status was measured by converting education and 
profession into a single score (range: 1-6), with high scores indicating high 
socioeconomic status.
Insight
To measure insight into illness and treatment, we used the self-report Insight 
Scale (IS) of Birchwood et al. (1994), which consists of eight items that are filled 
out by the patient. It has three subscales: (1) awareness of illness, (2) re-labeling 
symptoms to illness, and (3) need for treatment. The total score ranges from 0 
to 12, high scores indicating good insight. The scale is sufficiently reliable and 
valid, and is easy to use within this group of patients (Birchwood et al., 1994). 
To have some indication of the veracity of the patients’ response on this scale 
in our study, we’ve calculated the Pearson correlation between this scale and the 
insight item of the PANSS (A12) in our data. It was -.514 (p<.001), indicating 
an important overlap between the two.
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Verbal memory
Learning and memory deficits were measured using a Dutch version of the 
Auditory Verbal Learning Test (AVLT) (Saan and Deelman, 1986; Rey, 1964). 
It consists of five successive presentations by the researcher of a list of 15 words 
followed by the participant’s free recall on each trial. After interference tasks 
have been performed during 15 to 20 minutes, retention of the list is measured. 
We calculated (1) the total number of words immediately recalled over five 
trials (Adjusted Acquisition Score [AAS]), and (2) the number of words recalled 
after the 15 to 20 minute delay (Adjusted Delayed Recall Score [ADRS]), and 
corrected them for age, sex, and level of education. For the reasons specified 
in our introduction (above), we used the AAS as a measure of verbal memory 
(acquisition learning).
Medication adherence
Medication adherence was assessed with two different measures of medication 
adherence, one caregiver-based and one patient-based.
The caregiver assessment is derived Service Engagement Scale (SES) (Tait 
et al., 2002), which is a 14-item rating scale in which observed service engage-
ment is rated by the caregiver most familiar with the patient. The scale has 
good face validity and content validity, is user-friendly, and had good test-retest 
reliability in patients with psychotic disorders (Tait et al., 2002). The SES has 
four subscales: (1) availability, (2) collaboration, (3) help-seeking, and (4) 
medication adherence. In this study, the fourth subscale was used as a measure 
of medication adherence. The range is 0 to 12, with higher scores indicating 
poorer medication adherence.
We also administered a semi-structured interview with the patient to 
assess medication compliance by the independent rater. The rater normalized 
non-compliance as well as possible reasons for it, stressed that the obtained 
information would be treated confidentially and not be passed on to the 
patient’s clinician, and inquired about the number of missed doses in the past 
days and weeks. Such an interviewing style has been found to produce a more 
valid measurement of adherence than some of the questionnaires that are used 
in adherence research, such as the Medication Adherence Rating Scale, the 
Medication Adherence Questionnaire, the Drug Attitude Inventory, and the 
Compliance Rating Scale (Kikert et al., 2010). The score ranged from 0 to 
4, with higher scores indicating more problematic compliance. The scoring 
method was modelled after the Health of the Nation Outcome Scales (Wing 
et al., 1998).
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Both measures were standardized, summed, and reversed, thereby creating 
a compiled measure of adherence, with high scores indicating good adherence. 
Composite measures of medication adherence help reduce the underestimation 
of adherence that is associated with any individual source of information (Kik-
kert et al., 2008). Our two independent adherence scores had a correlation of 
.540 (p<.001), indicating important overlap.
Symptoms
The Positive and Negative Syndrome Scale (PANSS) (Kay et al., 1987) is a 
30-item rating scale which is completed by the trained raters. It has three 
subscales: (1) positive syndrome, (2) negative syndrome, and (3) general psy-
chopathology.
6.2.4 Statistical analyses
First, we split the participants into better and worse memory based on the average 
value (-9.11) of the AAS, where low scores reflect a severe impairment in verbal 
memory (acquisition learning). Splitting the respondents this way produces two 
groups of about equal size and allows for testing the moderator hypothesis with 
Structural Equation Modelling (SEM) (Frazier et al., 2004). Using independent 
samples t-tests and Pearson correlations, the groups were compared for cur-
rent levels of insight into illness and need for treatment and cross-sectional 
(current) medication adherence. The main moderator hypothesis was tested 
with a multiple-group approach with SEM (Frazier et al., 2004). With this 
method, the continuous measure of insight was used to predict adherence, and 
an unconstrained model was compared to a constrained model. In the latter, the 
association of insight with adherence was constrained to be equal across both 
memory groups. If the constrained model significantly worsened the model fit, 
this would be evidence of moderation, i.e. different relations between insight 
and adherence across the two verbal memory groups (Frazier et al., 2004). As 
measures of model performance, we used χ2 tests (Jöreskog, 1993) to determine 
the extent of the model fit. Sufficient model fit is indicated by a non-significant 
p-value (p>0.05) and a χ2 / df ratio of < 1.5. To obtain reliable indices of 
the model fit, we also used the Comparative Fit Index (CFI>0.95; Bentler, 
1990), the Tucker-Lewis Index (TLI>0.95; 1973), the Root Mean Square Error 
of Approximation (RMSEA≈0.05; Steiger, 1990) and the Standardised Root 
Mean Square Residual (SRMR<0.05; Jöreskog, 1971). For these analyses, the 
M-Plus 5.0 program was used.
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6.3 results
6.3.1 Patient characteristics
Between January 2006 and September 2008, a total of 195 patients met our 
inclusion criteria for the study. Of the 195, 116 (59%) agreed to participate and 
112 completed the study procedures.
Lifetime diagnoses with the CIDI were as follows: 77 patients (69%) met 
the criteria of schizophrenia and 35 (31%) met the criteria of schizoaffective 
disorder. Seventy-nine (71%) were male, 33 (29%) female. One-hundred-and-
one patients (90%) were not married or living with a partner; 11 (10%) were. 
The majority (93, 83%) were unemployed. The mean age of first contact with a 
mental health institution was 25.8 years old (SD=9.3). The mean age at baseline 
assessment was 38.4 years old (SD=11.6).
The medication status at the time of the assessment was as follows: 27 
(23%) patients were prescribed first-generation antipsychotics, 49 (42%) were 
prescribed second-generation antipsychotics, 19 patients (16%) were prescribed 
both, and 21 patients (18%) were refusing all medication. The average scores 
on the Positive and Negative Syndrome Scale (PANSS) were total symptoms 
58.2 (SD=17.1), positive symptoms 13.7 (SD=5.38), negative symptoms 14.0 
(SD=5.73), and general psychopathology 30.3 (SD=9.71).
6.3.2 Associations between insight and adherence
The two groups split into better and worse memory were compared on demo-
graphic and symptom measures. The primary between-group symptom difference 
was that the worse memory group had significantly greater negative symptoms on 
the PANSS than the better memory group (15.3 versus 12.6; t = 2.58; p < .05).
Average insight and adherence differed between the two memory groups 
(see Table I). Patients in the worse memory group had higher (better) total 
insight scores (t = 2.51; p < .05). The group difference was greatest for the ‘need 
for treatment’ subscale (t = 3.51; p < .01). The patients in the worse memory 
group were also more adherent with their antipsychotic medication (t = 3.20; 
p < .01). However, this group did not show any significant correlation between 
insight and adherence (see Table II).
In the group with better memory, insight was significantly and positively related 
to adherence (r = .43; p < .01). Figure I shows that when insight was good, 
adherence scores were roughly equal between patients with better memory 
and those with worse memory. Patients with better memory whose insight was 
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good were significantly more adherent than those with better memory and poor 
insight (t = 3.86; p < .001). However, the adherence of those who combined 
worse memory with good insight was not significantly different from that of 
their peers with poor insight.
The SEM analysis included adherence as outcome variable, and the continuous 
total insight score as predictor. The unconstrained and the constrained models 
were both analyzed on their goodness of fit to the data. The results showed that 
Table I Adherence and insight scores in (1) patients with worse memory and in (2) patients with 
better memory
Group 1: patients 
with worse 
memory (n=59)
Group 2: patients 
with better 
memory (n=53)
Independent 
samples t-test
Adherence 1 0.46
(SD=1.35)
-0.54
(SD=1.95)
t = 3.20**
Insight Scale total score 2 8.3
(SD=3.1)
6.7
(SD=3.7)
t = 2.51*
Insight subscale 1: illness awareness 2.5
(SD=1.5)
2.1
(SD=1.7)
ns
Insight subscale 2: symptom awareness 2.7
(SD=1.5)
2.4
(SD=1.4)
ns
Insight subscale 3: need for treatment 3.1
(SD=1.1)
2.3
(SD=1.4)
t = 3.51**
1) The average of this compiled measure is zero. Higher scores indicate better adherence. 
2) This scale ranges from 0 to 12, with higher scores indicating better insight. 
* Significant at the .05 level (2-tailed)
** Significant at the .01 level (2-tailed)
Table II Correlations of insight and adherence in (1) patients with worse memory and (2) patients 
with better memory
Pearson correlations Group 1: 
Patients with worse 
memory (n=59)
Group 2: 
Patients with better 
memory (n=53)
Equality test for the 
correlations of the two 
groups, using Fischer’s Z 
transformation
Total insight score with 
adherence 
.08 .43** Z = -1.95; p < .05
Subscale (1) illness awareness 
with adherence
.18 .52*** Z = -2.03; p < .05
Subscale (2) symptom 
awareness with adherence
-.14 .12 Z = -1.34; ns
Subscale (3) need for 
treatment with adherence
.16 .39** Z = -1.29; ns
** Significant at the .01 level (2-tailed)
*** Significant at the .001 level (2-tailed)
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the unconstrained model had a good fit – because it had zero degrees of freedom, 
no parameters needed to be estimated. The effect of insight on adherence in 
the second model was constrained to be equal across the two memory groups. 
Applying this constraint significantly reduced the fit of the model: χ2=4.72; 
df=1; p<.05 (see Table III). This meant that the effect of insight on adherence 
was not equal across the two groups, thus providing evidence for a moderator 
effect of memory impairments on the association between insight and adherence.
Table IV summarizes the results of the unconstrained model. It shows a pattern 
similar to that in Table II: insight in patients with better memory was associated 
with adherence, which was not the case in patients with worse memory.
Table III Structural Equation Modelling fit to the data parameters for the unconstrained and the 
constrained models 
Model description χ2 df p χ2 / df CFI TLI RSMEA SRMR
Unconstrained model: the effect of 
insight on adherence is unconstrained 
(i.e. allowed  to differ) across both 
memory groups
0.00 0 - - 1.00 1.00 0.00 0.00
Constrained model: the effect of insight 
on adherence is constrained as equal 
across both memory groups
4.72 1 .030 4.72 0.59 0.18 0.26 0.10
Sufficient model fit is represented by a non-significant p-value (p>0.05) and the ratio of χ2 / 
df < 1.5. Also, for good model fit, the Comparative Fit Index (CFI) should be higher than .95, 
the Tucker-Lewis Index (TLI) should be higher than 0.95, the Root Mean Square Error of 
Approximation (RMSEA) should be lower than 0.05, and the Standardised Root Mean Square 
Residual (SRMR) should be lower than 0.05.
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Group one: worse memory (n=59)
Group two: better memory (n=53)***
Figure I Comparisons of those with good and poor insight on adherence in (1) patients with worse 
memory and (2) patients with better memory
*** The difference in adherence between poor and good insight is significant at the .001 level (two-
sided independent samples t-test).
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When both adherence measures were looked at separately, similar results were 
found. That is, in the group with worse memory no significant correlations 
were found between insight and either adherence measure, while in patients 
with better memory the correlations between insight and both patient-based 
adherence (r=.33; p<.05) and caregiver-based adherence (r=.43; p<.01) were 
significant.
6.4 disCussion
6.4.1 Insight, memory, and adherence
Our results support the hypothesis that severe verbal-memory deficits moder-
ate the association between poor insight and non-adherence in patients with 
a psychotic disorder. Although poor insight was clearly associated with non-
adherence in patients with relatively intact verbal memory, this was not the case 
in patients with severely impaired verbal memory.
Memory is an essential link needed to change intent to action. In this study, 
the action is antipsychotic non-adherence. The lack of relationship between 
lack of insight and medication non-adherence in the poor memory group only 
is consistent with our hypothesis. An alternate explanation is that the greater 
severity of negative symptoms in the poor memory group is such that motiva-
tion for non-adherence is diminished.
In contrast, the relationship between poor insight and poor medication 
adherence was clearly present in the better memory group. Therefore, the com-
bination of intact memory and poor insight is a strong predictor of medication 
non-adherence.
Paradoxically, a higher number of patients with deficits in verbal memory 
acknowledged the need for treatment, and also seemed to be more adherent 
than those without such deficits. This was not expected, as three other studies 
have found the opposite direction with greater cognitive deficits being associated 
Table IV Structural Equation Modelling results of the unconstrained model
Effects of insight on adherence in: b1 se2 b / se β3
Patients with worse memory (n=59) 0.04 0.06 0.62 0.08
Patients with better memory (n=53) 0.22 0.07 3.45 0.43
1) Unstandardized regression coefficient
2) Standard error of the unstandardized regression coefficient
3) Standardized regression coefficient
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with worse adherence (Donohoe et al., 2001; Heinrichs et al., 2007; Kim et al., 
2006). Differences in the patient samples may explain this. Despite reasonable 
similarities on most characteristics of patient samples in all four studies—such 
as average age, duration of illness, and male/female ratio—our own patients, all 
of whom were outpatients, seemed to have fewer current psychotic symptoms 
than those in the three other studies, some of whom were still in the clinic. 
While the average PANSS positive scale in our study scored a mere 13.7, those 
in the other studies were 20.1 (Heinrichs et al., 2007), 15.5 (Donohoe et al., 
2001), and 18.6 (Kim et al., 2006).
We therefore speculate that, when psychotic symptoms are prominent, a 
deficit in verbal memory will increase confusion and disorganisation, which 
will impair adherent behaviour. But when psychotic symptoms are more or less 
under control, patients with such a deficit may fail to reflect on their condi-
tion; they may accept the clinician’s judgement without much resistance, and 
subsequently improve on acknowledging need for treatment and on adherent 
behaviour. In contrast, patients without such deficits may become more con-
scious of the past and future consequences of their disorder; they may resist 
the diagnosis, denying the need for treatment and thus collaborating poorly. 
Denial has been proposed as a cause of lack of insight and there is evidence that, 
as a coping style, it is characteristic of patients without cognitive impairments 
(Lysaker et al., 2003).
If this indeed explains our results, it may provide an alternative explanation 
for the strong association between adherence and insight in patients without 
cognitive deficits. If insight is low due to denial, adherence may suffer as a 
result, whereas if insight is not affected by denial, adherence may largely be 
independent of insight. In other words: denial of illness and denial of need 
for treatment may lead to poor adherence, while—as we have observed in our 
patients—other causes of a lack of insight, such as cognitive deficits, may not 
lessen a patient’s readiness to comply with treatment.
Finally, patients with memory deficits had high scores on negative symptoms. It 
may be that, independently of their insight into illness, they were aware of their 
poor functioning, and therefore scored high on their acknowledgement of the 
need for treatment, and also on adherence.
6.4.2 Limitations
The first group of limitations concerns the possibility that the sample composi-
tion restricted the scope for generalizing our results. First, the sample was a 
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relatively small and most participants were men. Second, patients with very 
high service engagement were excluded, as this was an exclusion criterion of 
the multi-centre randomised controlled trial whose baseline measurements we 
used. Third, patients with very poor service engagement are unlikely to have 
been included either, as they may have refused to participate or may not have 
been in outpatient treatment. As a result, the level of service engagement of 
most respondents probably lay in the middle range.
The next limitation is that we based a distinction in the patient sample on 
the average of verbal memory scores. This was quite arbitrary, and was done for 
the lack of a better cut-off. It did not seem useful to base a cut-off on scoring 
below or above the average norm of the AVLT, as most patients scored below 
this point. Neither did this seem desirable, as mild impairments may not greatly 
affect the ability to benefit from insight. However, it does imply that another 
choice may yield slightly different results.
Another limitation is that, as no neurocognitive parameters other than 
verbal memory were measured, we were unable to regard the relevance of verbal 
memory’s effects in comparison to other possibly important neurocognitive 
parameters. It may for example well be that our findings reflect the relevance of 
general cognitive impairments rather than verbal memory deficits persé.
Finally, our study was performed with cross-sectional data, which makes it 
impossible to draw conclusions on the directions of causality. Longitudinal and 
intervention studies should be able to tell us more about the causal relationships 
at work.
6.4.3 Clinical implications
Our results suggest that patients with an impaired ability to organize and store 
information may derive little benefit from good insight. But neither, when it 
comes to adherence with antipsychotics, do they seem to be greatly hampered 
by a lack of insight. If adherence is poor in these patients, behavioural interven-
tions are probably enough to overcome it. Various interventions are possible: 
reminders, the simplification of dosing frequency and polypharmacy use, the 
involvement of family members in treatment, or the use of types of contingency 
management such as financial incentives. For a more detailed description of 
such interventions, see Patel and David (2007), Velligan et al. (2007), and 
Masand and Narasimhan (2006).
Patients with relatively intact memory may be more likely to respond 
to interventions that address problems with medication attitudes or insight. 
Examples include cognitive therapy and other approaches based on principles 
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of motivational interviewing. These interventions comprise various elements: 
information on the illness and treatment is provided, symptoms are re-labelled, 
adherence is linked to the patient’s personal goals, the pros and cons of antipsy-
chotic medication are discussed, and resistance is avoided as much as possible. 
For a more detailed description, see publications such as Rathod et al. (2005), 
Patel and David (2007), and Possidente et al. (2005).
Using different approaches for increasing adherence, based on patient char-
acteristics such as cognitive ability and insight, may increase the effectiveness of 
these interventions.
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abstraCt
Background
Surinamese, Antillean, and Moroccan immigrants in the Netherlands have a 
higher risk of developing schizophrenia. Subsequently, they engage less with 
services and have poorer outcome, which may be due, among others, to poor 
psychological adjustment (recovery style). We tested three hypotheses: (1) 
recovery style predicts service engagement; (2) immigrants with schizophrenia 
tend to use a sealing-over recovery style more than natives do; and (3) lower 
self-esteem may help explain more sealing-over in immigrants.
Methods
We used a cross-sectional design to analyze the data of 172 patients on recovery 
style, service engagement, and self-esteem.
Results
Sealing-over was associated with low service engagement (r=.279; p<.01), but 
not with low self-esteem. First-generation (not second-generation) immigrant 
patients had lower service engagement (ANOVA; F=3.082; p<.05), but they did 
not differ from natives with regard to recovery style or self-esteem.
Conclusions
Sealing-over predicted low service engagement. However, lower service engage-
ment in immigrant patients than in natives was not attributable to sealing-over 
or low self-esteem. Based on earlier research, low self-esteem may contribute to 
the development of schizophrenia in a relatively high number of immigrants, 
but after onset, it may be equally common in native patients, and not lead to 
more sealing-over in immigrants.
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7.1 introduCtion
In the early 1980s the Netherlands started seeing itself as a country of immigra-
tion, with substantial numbers of immigrants who were likely to stay rather 
than return to their home countries. Categories of migrants were minorities 
from the former Dutch colonies, as well as low-skilled labour migrants and 
their family members from Turkey, Morocco, and various other countries. In 
the year 2009, 20% of the Dutch population consisted of migrants, and this 
percentage is rising (Statistics Netherlands). The largest groups currently consist 
of people coming from Surinam, the Dutch Antilles, Morocco, and Turkey. 
They have mostly settled in the urban areas of the Netherlands, where their 
numbers frequently concentrate in a specific neighbourhood (NISR, 2009a).
Similar to what has been observed in other Western countries (Harrison et al., 
1997; Schier et al., 2001; Cantor-Graae & Selten, 2005), immigrants to the 
Netherlands from Surinam, the Dutch Antilles, and Morocco have an increased 
risk for developing schizophrenia (Selten et al., 2001). Risk factors may include 
discrimination, childhood adversity, insecure identity, and low self-esteem 
(Veling et al., 2007a, 2008a, 2008b; Cantor-Graae, 2007), which are related 
to immigrant status in the Netherlands in various ways. For example, unem-
ployment and crime rates are higher in non-Western immigrants, and housing 
perspectives can be limited (Statistics Netherlands; NISR, 2009a). Also, par-
ticipation in education and achievements are often lower in immigrants, due to 
low socio-economic status, language problems, and high percentage of single-
parent families (NISR, 2009b), although large variations exist. Furthermore, 
non-Western immigrants may be the subject of discrimination based on their 
ethnic background, race, and skin colour. This may come in many forms, such 
as interpersonal experiences of racist insults or violence, but also in structural 
discrimination by institutions, as in employment policies or access to education 
or housing facilities.
Some specific issues include for example that the Moroccans have a very 
different culture, language and religion than the Dutch, giving rise to difficul-
ties, e.g. on the topic of women’s rights and social participation. And while 
the Surinamese and Antilleans all speak Dutch in their countries of origin, 
facilitating their integration in the Netherlands, they have a cultural history 
that is entwined with slavery, which may have had an impact on their cultural 
self-esteem and perception of Dutch natives.
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When people of ethnic minorities develop schizophrenia, they are generally less 
compliant with medication and tend to engage less with mental health services 
than native patients (Cuffe et al., 1995; Emsley et al., 2002; Opolka et al., 
2003; Valenstein et al., 2006), with adverse consequences (Staring et al., 2006). 
This pattern may be due to the socio-economic disadvantages and discrimi-
nation issues described earlier. Another possibility is that active engagement 
with mental health services is prevented by cultural taboo or culture-specific 
conceptions of illness and treatment – for example: ‘Djinn’ (spirits), ‘l’ayn’ (evil 
eye), and Islamic healings for Moroccans; ‘Brua’ (magic) for Antilleans; and 
‘Winti’ for Surinamese Hindus. Moreover, language difficulties may complicate 
contacts with clinicians for Morrocans.
Alternatively, the factors that are thought to contribute to the high inci-
dence of schizophrenia in immigrants may also play a role in their low service 
engagement. In other words, after onset of the illness, disadvantages that have 
contributed to their higher risk of developing schizophrenia may continue to 
weaken their ability to use coping skills and to benefit from treatment. One 
field of research indeed points in that direction: some of the risk factors (e.g. low 
self-esteem, insecure identity, childhood adversity) are related to the concept of 
a sealing-over recovery style rather than to an integrating one (McGlashan et al., 
1975, 1976). ‘Integrators’ are patients who are more likely to see their psychotic 
experience as something that is part of them, has arisen from their life context, 
which they are responsible for, and may be used as a source of information 
about themselves, conflicts, relationships and behaviour (McGlashan, 1987). 
In contrast, individuals who seal over tend to distance themselves from their 
psychotic experiences, viewing them as causally independent, globally negative, 
interruptions to their lives. It has been found that a sealing-over style predicts 
poor service engagement (Startup et al., 2006; Tait et al., 2003) and that an 
integrating style is predictive of better outcome and functioning at long-term 
follow-up (McGlashan, 1987; Thompson et al., 2003).
A sealing-over style has been associated with more adverse childhood 
experiences (Drayton et al., 1998; Tait et al., 2004), suggesting that recovery 
style may arise out of individual’s life context rather than their psychotic experi-
ence. Integration allows for investment in relationships, affect tolerance, and 
acknowledgment of symptoms (Bell & Zito, 2005), while patients who seal 
over make more negative self-evaluations and have a more insecure identity 
than an integrator (Drayton et al., 1998; Tait et al., 2004). As anticipating loss 
and experiencing shame predict later depression, sealing-over may be motivated 
by defending against these emotions (Iqbal et al., 2000).
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
Recovery style, service engagement, and ethnicity 101
Immigrant patients with schizophrenia may be at specific risk for sealing-over 
styles due to the possibly disruptive migration process, adverse circumstances in 
their countries of origin, cultural taboo and shame, single-parent families and 
attachment difficulties, various forms of discrimination, lower socio-economic 
status in the Netherlands, language problems, insecure cultural identities, and 
lower self-esteem. A high prevalence of the sealing-over style may therefore explain 
part of the observed problem that immigrants portray low service engagement.
This study tested three hypotheses: (1) that recovery style predicts service engage-
ment, (2) that immigrants with a schizophrenia-spectrum disorder tend to use a 
sealing-over recovery style more than native patients do, and (3) that lower self-
esteem may help explain part of the greater sealing-over in immigrant patients.
7.2 method
7.2.1 Study population
For testing the second hypothesis, we used the combined data of two separate 
study populations (study A and B), each of which included a measurement 
of recovery style. The other hypotheses were tested only in study A, since this 
study included measures of service engagement and self-esteem.
Study A
Patients in study A were the respondents in a multi-centre randomized con-
trolled trial in Rotterdam, the Netherlands. The trial investigated the effects 
of an intervention promoting treatment adherence (Staring et al., 2006). The 
highly urbanized Rotterdam is home to many people from ethnic minorities, 
most of them originating from Surinam, the Dutch Antilles, and Morocco. 
Inclusion criteria were (1) having schizophrenia or schizoaffective disorder, 
(2) outpatient treatment, (3) being able to speak Dutch, and (4) having some 
problems with service engagement, as defined by at least two subscales of the 
SES (see instruments, below) having an average item-score of 1.25 or higher.
Study B
Patients in study B were the respondents in MATCH, a multi-centre randomized 
controlled trial in Amsterdam and Haarlem, the Netherlands, that investigated 
the effect of Motivational Interviewing (Miller & Rollnick, 2002) on adherence 
to antipsychotic medication in patients with schizophrenia and schizoaffective 
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disorders. As with study A, these cities are home to many people from ethnic 
minorities, especially Surinamese and Antilleans. Inpatients and outpatients 
were included. Inclusion criteria were (1) the presence of schizophrenia or 
schizoaffective disorder, (2) recent clinical deterioration due to medication 
non-adherence, (3) ability to speak Dutch, and (4) some improvement (CGI-I 
> 2) after restarting the medication.
7.2.2 Design and procedure
We used a cross-sectional design. Our definition of “immigrant” was the same as 
that used by Statistics Netherlands, a first-generation immigrant being someone 
born abroad, and a second-generation immigrant being someone whose mother 
or father was born abroad (one parent being enough). The country of origin is 
then the mother’s place of birth, unless she was born in The Netherlands, in 
which case it is the father’s.
Study A was approved by the Medical Ethics Committee at Erasmus Uni-
versity Medical Centre. Patients were referred by their clinician, and asked by 
a research assistant to participate. Participants had to give written informed 
consent. Respondents were assessed on the basis of a structured interview 
conducted by trained and supervised psychology and medicine students. To 
assess mental disorders according to the definitions of DSM-IV (APA, 1994), 
we used the lifetime Composite International Diagnostic Interview, version 2.1 
Auto (WHO, 1997). Respondents were paid EUR 20 for participating in the 
interview. Baseline assessments provide the data for this article.
Study B was approved by the Medical Ethics Committee at Amsterdam 
University Medical Centre. Participants had to give written informed consent. 
To assess mental disorders, baseline assessments included the Structured Clini-
cal Interview for DSM-IV Diagnoses (SCID). Assessments were performed 
by trained psychiatrists, psychologists, and supervised psychology students. 
Respondents were paid for travel expenses. The RSQ (see instruments, below) 
was included only in the one-year follow-up assessments, which were used for 
the purpose of this article.
7.2.3 Instruments
Recovery Style
In study A and B, recovery style was measured on the basis of the Recovery 
Style Questionnaire (RSQ; Drayton et al., 1998), a 39-item self-report measure 
designed to reflect categories consistent with those developed by McGlashan et 
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al. (1975). It produces six classifications: (1) integration, (2) towards integrat-
ing, (3) mixed picture in which integration dominates, (4) mixed picture in 
which sealing-over dominates, (5) towards sealing-over, and (6) sealing-over. 
The RSQ is reliable, and correlates highly with McGlashan’s interview-based 
measure (Drayton et al., 1998).
Service engagement
In study A, the Service Engagement Scale (SES) (Tait et al., 2002) was used. This 
14-item rating scale is used by the clinician or therapist most familiar with the 
patient to rate the service engagement they observe. There are four subscales: (1) 
availability, (2) collaboration, (3) help seeking, and (4) medication adherence. 
The scale has good face value and content validity, is user-friendly, and had good 
test-retest reliability within a group of patients with psychotic disorders (Tait 
et al., 2002). Higher scores indicate more problems with service engagement.
Self-esteem
In study A, we used the 20-item Self-Esteem Rating Scale–Short Form (SERS-
SF) (Lecomte et al., 2006), a self-report scale with two subscales supported by 
factor analysis: positive and negative self-esteem. Each subscale ranges from 10 
to 70, high scores indicating high positive or high negative self-esteem. The 
scale has good internal consistency, good test-retest reliability, and sufficient 
convergence validity in patients with schizophrenia (Lecomte et al., 2006).
7.2.4 Statistical analyses
All data were analyzed with SPSS 15.0. To compare native patients with first and 
second-generation immigrant patients, we used analysis of variance (ANOVA) 
with post-hoc Turkey HSD. To test the associations between recovery style, ser-
vice engagement, and self-esteem, we calculated Spearman’s Rho correlations.
7.3 results
7.3.1 Patient characteristics
Of the total of 195 patients who were asked to participate in study A, 79 refused 
and 116 decided to participate. Two patients were too disorganized in thought 
and speech to be able to answer the questionnaires, and one refused to be tested. 
A total of 113 completed the baseline assessments.
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Of the 218 patients who were asked to participate in study B, 61 refused 
and 39 were excluded for other reasons, such as low IQ (<70) or new informa-
tion on not meeting the inclusion criteria. A total of 118 patients decided to 
participate. During the intervention period, 16 patients dropped out. At one 
year follow-up –when RSQ data were collected – 72 patients completed the 
assessments. However, as the RSQ data of 13 patients were incomplete, 59 cases 
were included in the analyses.
Table I shows the patient characteristics. Most of the first-generation immi-
grants were from Suriname (37) and the Dutch Antilles (9). As Dutch is 
Table I Respondents characteristics
Study sample A B
N 113 59
Sex 80 patients (71%): male
33 patients (29%): female
49 patients (83%): male
10 patients (17%): female
Average age 38.2 years (SD=11.5) 35.5 (SD=9.5)
Average age at first 
contact with a mental 
health institution
25.8 years (SD=9.3) 27.6 years (SD=7.7)
Employment 94 patients (83%): unemployed
19 patients (17%): employed
46 patients (78%): unemployed
13 patients (22%): employed
Ethnicity 50 patients (45%): Dutch 
42 patients (37%): first-generation 
immigrants
   - 24 Surinamese
   - 6 Antillean
   - 2 Moroccan
   - 10 other
21 patients (18%): second-generation 
immigrants 
   - 8 Surinamese
   - 3 Cape Verdean
   - 10 other 
26 patients (44%): Dutch
25 patients (42%): first-generation 
immigrants
   - 13 Surinamese
   - 3 Antillean
   - 3 Moroccan
   - 6 other
8 patients (14%): second-generation 
immigrants
   - 7 Surinamese
   - 1 Turkish
Diagnoses 79 patients (69%): schizophrenia
   - 60 paranoid type
   - 10 disorganized type
   - 7 catatonic type
   - 1 undifferentiated type
35 patients (31%): schizoaffective 
disorder
46 patients (78%): schizophrenia
   - 33 paranoid type
   - 4 disorganized type
   - 2 catatonic type
   - 5 undifferentiated type
   - 2 residual type
13 patients (22%): schizoaffective 
disorder
Clinical status 113 patients (100%): outpatients
PANSS positive 
syndrome 
13.6 (SD=5.3) 14.2 (SD=5.6)
PANSS negative 
syndrome 
13.9 (SD=5.7) 15.8 (SD=6.6)
PANSS general 
psychopathology 
30.3 (SD=9.6) 31.1 (SD=10.0)
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spoken throughout these countries, there were no problems in performing the 
interviews with them. Although the remaining first-generation immigrants also 
spoke Dutch, as this was a requirement for participation in the studies, no spe-
cific measures were taken to ensure that the instruments were culture-sensitive. 
As only three of all the immigrants were from Western countries, the rest, 
by definition, were from non-Western countries. Separate analyses conducted 
with the three Western immigrants and without them did not produce different 
findings. Below are the results of the analyses including all immigrants.
7.3.2 Recovery style, service engagement, and self-esteem
Although first-generation immigrants tend slightly towards a sealing-over recov-
ery style (Figure I), ANOVA did not reveal significant differences for recovery 
style or self-esteem between native and first and second-generation immigrant 
patients (Table II). However, it did show that native patients were engaging more 
with services (SES) than the first-generation immigrants (ANOVA; p<.05). At a 
subscale level, the difference in SES scores was caused mainly by the availability 
subscale (F = 7.282; p < .01), indicating that native patients (mean score 2.49) 
were more available for services than both the first-generation ones (3.98) and 
the second-generation immigrant ones (4.43).
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Figure I Recovery styles in native patients and first and second-generation immigrant patients with 
a schizophrenia-spectrum disorder (study populations A and B combined; n=172)
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As Table III shows, a more sealing-over recovery style was significantly associated 
with low service engagement, though not with positive or negative self-esteem. 
The correlation of recovery style with the SES total score was caused mainly by 
the correlations with the help-seeking subscale and the medication-adherence 
subscale.
As most immigrants were from Suriname, we conducted the ANOVA again, 
now using a distinction between native patients, patients from Suriname (first 
Table II Differences between immigrant and native patients with regard to recovery style (RSQ), 
service engagement (SES), and self-esteem (SERS-SF)
Mean scores (1) 
Native 
patients
(2) First-
generation 
immigrant 
patients
(3) Second-
generation 
immigrant 
patients
ANOVA 
results
Group 
comparisons 
(Turkey HSD)
RSQ total score
(studies A and B)
2,80 3,09 2,59 F = 2.002
Sig. = .138
n.s.
SES total score 
(study A)
19,1 22,2 21,4 F = 3.082
Sig. = .050
1 < 2
SES availability score 
(study A)
2.49 3.98 4.43 F = 7.282
Sig. = .001
1 < 2,3
SES collaboration score 
(study A)
4.84 5.48 5.14 F = 1.249
Sig. = .291
n.s.
SES help-seeking score 
(study A)
6.55 7.69 7.19 F = 1.827
Sig. = .166
n.s.
SES medication-adherence score 
(study A)
5.24 5.07 4,67 F = .236
Sig. = .790
n.s.
SERS-SF positive score 
(study A)
50,5 51,1 51,2 F = .049
Sig. = .952
n.s.
SERS-SF negative score 
(study A)
29,0 34,1 33,0 F = 1.670
Sig. = .193
n.s.
Table III Associations of recovery style (RSQ) with self-esteem (SERS-SF) and service engagement 
(SES), including both immigrant and native patients (study A)
Spearman’s Rho  correlations RSQ
SES total score .279**
SES availability score .000
SES collaboration score .178
SES help-seeking score .220*
SES medication-adherence score .203*
Positive SERS-SF -.083
Negative SERS-SF -.037
* p < .05
** p<.01
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and second generations combined, n=52), and other immigrant patients. The 
results of the analyses were the same, producing no differences with regard to 
recovery style or self-esteem, although native patients scored best on the SES 
availability subscale.
7.4 disCussion
7.4.1 Hypothesis one: recovery style predicts service engagement. 
The results of this study replicated the clinically significant finding that a seal-
ing-over recovery style is predictive of low service engagement in patients with 
psychotic disorders (Tait et al., 2003; Startup et al., 2006). Patients who employ 
this recovery style may be more avoidant and require extra attention to help 
them engage with treatment. Talking about psychotic experiences (McCabe et 
al., 2002) and urging patients to take an interest in them may be helpful.
7.4.2 Hypothesis two and three: immigrant patients tend to use a sealing-over recovery style 
more than native patients do, and lower self-esteem may help explain this.
As expected, immigrant patients with schizophrenia were observed to engage 
less with psychiatric services than native patients. This finding is consistent 
with other studies which found membership of an ethnic minority group to be 
associated with low medication compliance and service engagement (Emsley et 
al., 2002; Opolka et al., 2003; Valenstein et al., 2006). The greatest difference 
in our study – on the availability subscale – indicated that immigrant patients 
kept appointments with their mental health professional less often, as well as 
were more avoidant in making them.
However, the observed difference in service engagement between immigrant 
and native patients was not attributable to more sealing-over, as no significant 
differences with respect to recovery styles were found. Also, our results did not 
show any difference in either positive or negative self-esteem between native 
and immigrant patients with schizophrenia. This is an intruiging finding, since 
it has been found that discrimination may indirectly contribute to the increased 
incidence of schizophrenia in ethnic minorities, via lower self-esteem (Veling et 
al., 2008a). Low self-esteem has indeed been found as a risk-factor for developing 
paranoid delusions (Bentall et al., 2001) and maintaining psychotic symptoms 
(Garety et al., 2001). Possibly, migrants may more often develop schizophrenia 
due to general lower self-esteem in comparison to the native general popula-
tion, but once the illness has developed, self-esteem may be equally low in both 
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native and immigrant patients and therefore does not explain subsequent lower 
service engagement.
As we could not produce evidence for more sealing-over in immigrant patients, 
other explanations are needed for their observed low service engagement. It may 
be related to their cultural backgrounds. For example, if an immigrant’s views of 
his illness are not consistent with Western medical concepts, he may sometimes 
stop short of seeking help from at a mental health institution whose treatment 
is based on those concepts. It is indeed known that immigrant patients with a 
psychotic disorder in the Netherlands often seek alternative treatments that are 
related to their cultures of origin – such as Islamic, Winti, or Hindu healings 
– (Hoffer, 2005). But it is unknown whether this leads to greater avoidance of 
meanstream mental health institutions. Another possibility is that it may be less 
common in some cultures as it is in the Netherlands to plan and keep appoint-
ments with professionals that are strictly timetabled by date and time. As well as 
causing misunderstanding and frustration, this may lead mental-health profes-
sionals to believe that such patients are not engaging properly with services.
Looking at other factors rather than cultural background, discrimination 
on the side of the treatment institutions may prevent migrants to properly 
access services. Also, practical obstacles can reduce immigrants’ chances to 
benefit from health services, such as low socio-economic status (e.g. not being 
able to pay for additional costs or make time for frequent service visits that 
may accompany the treatment of schizophrenia), the family-structure with 
often only a single parent to take care of income as well as the children, and 
language difficulties. In other fields of health care in the Netherlands, language 
competence and self-reported health status (need factor) were both shown to 
have large impacts on service use across various immigrant groups (Denktas 
et al., 2009). Similarly, Fassaert et al. (2009) reported that language ability is 
important for health care use among Moroccans and Turks in the Netherlands. 
They also found that acculturation was associated with service use, although 
there was heterogeneity across ethnic and gender groups.
Most of these explanations, however, are speculative for patients with 
schizophrenia and should be studied further. And as language difficulty is 
not present in Surinamese and Antillean patients with schizophrenia in the 
Netherlands, it does not explain their low service engagement. So despite the 
knowledge that ethnicity is a risk-factor for low medication adherence and low 
service engagement in schizophrenia, the reasons for this are yet to be empiri-
cally established.
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7.4.3 Limitations
The first of the four limitations of this study is that the sample composition 
limited the possibilities for generalizing the results. Not only were 75% of the 
participants men, neither study included patients with very high service engage-
ment: in study A, this was an exclusion criterion, while study B included patients 
who had experienced a recent clinical deterioration due to non-adherence. It 
is also likely that patients with a very low service engagement had not been 
included in either study population because they had refused to participate. To 
ensure that their samples represented everyday practice, however, both stud-
ies had made considerable efforts to ensure that all eligible patients would be 
included. As a result, there were few exclusion criteria, and even fairly psychotic 
or disorganised patients were included.
The second limitation is that the immigrant patients in our study samples 
originated from various countries. As there may be considerable differences 
between them, they should not be seen as having similar characteristics. 
Although we analyzed the patients from Surinam in a separate analysis, our 
sample size did not allow for reliable sub-analyses with other immigrant groups. 
It may be that our results were dominated by the characteristics of the patients 
from Surinam, and that this limited the generalizability of our findings.
The third limitation is that we took no specific measures to ensure that the 
instruments we used were culture-sensitive. This may have led some immigrant 
patients to understand concepts relating to the instruments differently than 
native patients. Similarly, although the ability to speak Dutch was an inclusion 
criterion, various immigrant patients may have had a poorer mastery of this, 
and thus have had problems filling out the questionnaires. However, this limita-
tion may not be the most important, as most immigrants were from Surinam 
and the Dutch Antilles, where Dutch is spoken and written.
Finally, because our study used cross-sectional data, we cannot draw conclu-
sions on the direction of causality. It is more likely that the causal interrelation-
ships of the relevant variables will be identified in longitudinal and intervention 
studies. 

Chapter 8
Recovery style predicts remission at one-year follow-
up in outpatients with psychosis
A.B.P. Staring 
M. van der Gaag 
C.L. Mulder
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abstraCt
Background 
While people with schizophrenia often use avoidant strategies rather than 
active coping ones, it is largely unknown how their coping style contributes to 
remission of the illness. The concept of recovery style – either sealing-over or 
integrating – reflects an important distinction. Broadly defined, a sealing-over 
patient prefers not to think about psychotic experiences during recovery, while 
an integrator is interested in the psychotic experience and desires to place it into 
some coherent perspective.
Aim
To examine whether recovery style predicts remission at one-year follow-up.
Method 
As part of a randomised controlled trial, data was collected at baseline with 
regard to recovery style (RSQ), insight (IS), therapeutic alliance (WAI), and 
symptoms (PANSS) in 103 patients with psychotic disorders. To measure 
remission status, symptoms were assessed at six and twelve months (PANSS). 
Logistic regression analyses were used to test whether recovery style predicted 
remission, and also to control for baseline symptom levels, insight, and alliance. 
Results
The final model showed that an integrating recovery style increased the odds of 
remission 5.66-fold (95% C.I.: 1.65-19.40). Insight and therapeutic alliance 
were not predictive. While remission was also predicted by positive symptom 
levels at baseline, this did not influence the effect of recovery style.
Conclusions 
Independently of symptom levels, insight or therapeutic alliance, an integrating 
recovery style strongly increased the odds of remission at one-year follow-up. 
These findings provide support for the development of interventions such as 
motivational interviewing and cognitive therapy, designed to promote psycho-
logical adjustment to psychosis.
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8.1 introduCtion
Over recent years, consensus-defined standards for clinical status and improve-
ment in patients with schizophrenia have become increasingly common. 
Remission criteria for schizophrenia have been introduced with the intent to 
facilitate insight into the etiology and the course of disease, and to standardize 
comparisons across treatments (Andreasen et al., 2005; Van Os et al., 2006). 
The use of these criteria has underlain renewed efforts to identify predictors 
of remission, such as cognitive performance (Helldin et al., 2006); baseline-
negative symptoms (Petersen et al., 2008); duration of untreated psychosis 
(Emsley et al., 2006; Petersen et al., 2008); early symptomatic improvement 
(Emsley et al., 2006; Jager et al., 2009); having intimate relations and being 
married (Bankole et al., 2008; Emsley et al., 2006); and lifetime traumatic 
events (Bankole et al., 2008).
While people with schizophrenia often use avoidant coping strategies rather 
than active coping strategies, the way in which their coping style contributes to 
remission of the illness is largely unknown (Tait et al., 2003). The concept of 
recovery style – either sealing-over or integrating – reflects an important distinc-
tion in coping with psychosis. Broadly defined, a sealing-over patient prefers not 
to think about his psychotic experience during recovery, while an integrator is 
interested in the psychotic experience and desires to place it into some coherent 
perspective (McGlashan, Docherty, Siris, 1976). Evidence also suggests that an 
integrating recovery style predicts higher service engagement (Tait, Birchwood, 
Trower, 2003), fewer symptoms at one-year follow-up (Thompson, McGorry & 
Harrigna, 2003), and better long-term functional outcome (McGlashan, 1987). 
In this study, we used the recent remission criteria for schizophrenia (Andreasen 
et al., 2005) to test whether an integrating recovery style would predict remis-
sion at one-year follow-up. We also compared the effects of recovery style with 
those of the therapeutic alliance and insight into illness, to which it may be 
related, especially as insight and alliance are both known to influence the course 
of treatment and predict outcome (e.g. Emsley, Chiliza & Schoeman, 2008; 
Hewitt & Coffey, 2005).
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8.2 method
8.2.1 Study population
Participants were the respondents in a multi-centre randomised controlled trial 
conducted in the Dutch city of Rotterdam to investigate the effects of Treat-
ment Adherence Therapy (TAT). This tailored intervention allows four different 
intervention modules – such as behavioural interventions or an adapted form 
of motivational interviewing – to be applied according to a patient’s individual 
reasons or causes of non-compliance. For a more detailed description, see Star-
ing et al. (2006). The four inclusion criteria were (1) schizophrenia spectrum 
disorder (DSM-IV), (2) receiving outpatient treatment, (3) mastery of the 
Dutch language, and (4) at least some problems with service engagement, as 
defined by an average item-score of 1.5 or higher on at least two subscales of the 
Service Engagement Scale (Tait et al., 2002).
8.2.2 Design and procedure
Patients were referred by their clinician and asked by a research assistant to 
participate. Participants had to give written informed consent. All participants 
were assessed at baseline (To), six months (T1), and twelve months (T2). The 
assessments consisted of structured interviews with the respondent and his/her 
clinician. The assessment interviews were performed by students in psychology 
and medicine, who had received two days’ training in role play and in scoring 
of the measurement instruments. After co-rating a live interview by the main 
researcher, they performed two interviews under supervision. When their ratings 
were sufficiently consistent with those of the experienced researcher, the students 
did interviews independently, but still under supervision every other week.
To assess mental disorders according to the definitions and criteria of DSM-
IV (APA, 1994) we used various interviews including the lifetime Composite 
International Diagnostic Interview, version 2.1 Auto (WHO CIDI, 1997). 
Respondents were paid EUR 20 each time they participated in an interview. 
The study design was approved by the Medical Ethics Committee at Erasmus 
University Medical Centre.
8.2.3 Measurements
Psychopathology and remission
The Positive and Negative Syndrome Scale (PANSS) (Kay et al., 1987) 
is a 30-item rating scale which is completed by trained research staff at the 
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conclusion of a semi-structured interview. There are three subscales: (1) positive 
syndrome, (2) negative syndrome, and (3) general psychopathology. Remission 
was defined as a score for both T1 and T2 of three or lower on the proposed 
eight PANSS-items (Andreasen et al., 2005; Van Os et al., 2006), as such scores 
would suggest that the relevant symptoms had been in remission for at least six 
months.
Recovery Style
Recovery style was measured using the Recovery Style Questionnaire (RSQ; 
Drayton et al., 1998), a 39-item self-report measure designed to reflect cat-
egories consistently with the categories developed by McGlashan et al. (1975). 
It produces six classifications: (1) integration, (2) towards integrating, (3) a 
mixed picture in which integration dominates, (4) a mixed picture in which 
sealing-over dominates, (5) towards sealing-over, and (6) sealing-over. The RSQ 
is reliable, and correlates highly with McGlashan’s interview-based measure 
(Drayton et al., 1998).
Insight
We used the self-report 8-item Insight Scale (IS) of Birchwood et al. (1994), 
which has three subscales: (1) awareness of illness, (2) re-labeling symptoms to 
illness, and (3) recognition of need for treatment. We used total scores in the 
analyses, which range from 0 to 12. The scale is reliable and valid, and is easy to 
use within this group of patients (Birchwood et al., 1994).
Therapeutic alliance
The 36-item Working Alliance Inventory (WAI) was used to measure the alli-
ance factor of the therapeutic relationship as it is experienced by the patient 
(Horvath & Greenberg, 1989; Vervaeke & Vertommen, 1996). The WAI has 
two factors or subscales: the bond subscale or emotional component, and the 
contract subscale, which consists of agreements on tasks and goals. It has good 
validity and reliability (Horvath & Greenberg, 1994; Vervaeke & Vertommen, 
1996).
8.2.4 Statistical analyses
Logistic regression analysis was used, with one-year follow-up remission as 
the dependent variable. In the first block, baseline scores on the three PANSS 
subscales and the treatment allocation (in light of the RCT design) were entered 
into the model in order to control for them.
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In the next block, recovery style was added to the model. On the basis of 
the sample’s mean score, the recovery-style variable was dichotomized into seal-
ing over (score 0) and integrating (score 1). This was done in order to facilitate 
clinical interpretations of the results. However, all analyses were also performed 
with the original RSQ total score.
In the third block, we added the IS and the WAI to the model in order to 
see whether they predicted remission, and whether this in any way influenced 
the predictive power of recovery style. By then, however, there would be seven 
independent variables in the equation, and the number of events (remission) 
per variable should not be lower than ten (Peduzzi et al., 1996). As it was 
unlikely that this criterion would be met, we performed a last analysis in which 
all non-significant variables were deleted in order to produce the final regression 
model for predicting remission, and also to see whether any significant observa-
tions would still hold. For all analyses, SPSS 15.0 was used.
8.3 results
8.3.1 Patient characteristics
A total of 195 patients were asked to participate. Seventy-nine refused. As no 
data was available on those who refused, the biases caused by selective participa-
tion could not be analyzed. Two patients in the group of patients who were 
willing to participate were too disorganized to be able to complete the question-
naires. The remaining 114 completed the baseline assessments. Eleven patients 
were subsequently lost to follow-up; one had died as a consequence of physical 
health problems, and ten refused to participate any further. The analyses for the 
present study were conducted on the remaining 103 patients (Table I).
8.3.2 Predicting remission
As Table II shows, an integrating recovery style was associated both with fewer 
negative symptoms and with better insight into illness. At one-year follow-up, 
22 of the 103 patients (21.4%) had been in remission for at least six months.
In the first block of the logistic regression analysis, the proportion of 
explained variance (Nagelkerke R Square) was .289, and the only significant 
independent variable was the PANSS positive-syndrome subscale (Wald=9.89; 
Exp(B)=.748; p<.01). When recovery style was added in the second block, 
the explained variance increased to .385. Positive symptoms (Wald=7.88; 
Exp(B)=.766; p<.01) and recovery style (Wald=6.93; Exp(B)=5.391; p<.01) 
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Table I Respondents characteristics
N 103
Sex 72 patients (70%): male
31 patients (30%): female
Average age at T0 39.0 years (SD=11.6)
Average age at first contact with a mental health 
institution
26.0 years (SD=9.6)
Employment 86 patients (84%): unemployed
17 patients (16%): employed
Ethnicity 45 patients (43%): Dutch
19 patients (19%): second-generation immigrants
39 patients (38%): first-generation immigrants
Diagnoses 74 patients (72%): schizophrenia
- 57 paranoid type
- 10 disorganized type
- 6 catatonic type
- 1 undifferentiated type
29 patients (28%): schizoaffective disorder
- 19 depressive type
- 10 bipolar type
PANSS positive syndrome (mean and standard 
deviation)
13.7 (SD=5.4)
PANSS negative syndrome (mean and standard 
deviation)
14.0 (SD=5.7)
PANSS general psychopathology (mean and 
standard deviation)
30.4 (SD=9.6)
Table II Pearson correlations of the study variables at baseline
Pearson 
correlations
PANSS 
positive 
syndrome
PANSS 
negative 
syndrome
PANSS general 
psychopathology
Recovery Style 
(RSQ) (high = 
sealing-over)
Insight (IS) 
PANSS negative 
syndrome
.316**
PANSS general 
psychopathology
.623*** .512***
Recovery Style 
(RSQ) (high  = 
sealing-over)
.172 .264** .101
Insight (IS) .057 .054 .191 -.277**
Therapeutic Alliance 
(WAI) 
.100 .072 -.035 -,027 .008
*. Correlation is significant at the .05 level (2-tailed) 
**. Correlation is significant at the .01 level (2-tailed)
***. Correlation is significant at the .001 level (2-tailed)
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both significantly predicted remission. In the third block, insight and thera-
peutic alliance were added. Although the explained variance increased to .417, 
none of the new variables added significantly to the model.
In the final model, all non-significant variables were deleted, leaving only 
positive symptoms and recovery style. As there were 22 events of remission, 
the number of events per variable was higher than ten, and the results were 
thus expected to be reliable (Peduzzi et al., 1996). As Table III shows, posi-
tive symptoms and recovery style together predicted 35.6% of the variance of 
remission status at one-year follow-up. Recovery style had an Exp(B) of 5.66, 
which means that a patient’s use of an integrating recovery style was estimated 
to increase by a factor of 5.66 the odds that he or she would be in remission at 
one-year follow-up (95% C.I.: 1.65-19.40).
In order to test the stability of the results, all analyses were also performed with 
the RSQ total score, without dichotomizing it. The results were comparable 
(e.g. the final effect of recovery style was WALD=5.676; Exp(B)=.544; p<.05). 
8.4 disCussion
8.4.1 Recovery style and remission
The most important finding of this study is that the use of an integrating recov-
ery style by patients with schizophrenia or a schizoaffective disorder strongly 
increased their odds of being in remission at one-year follow-up. This was 
independent of symptom levels, insight into illness, and therapeutic alliance.
This finding is in line with other studies that have shown the bearing of a 
patient’s recovery style on their engagement with treatment and their recov-
ery from psychosis (Tait, Birchwood, Trower, 2003; Thompson, McGorry 
& Harrigna, 2003; McGlashan, 1987). It seems that an integrating recovery 
style allows patients to invest in relationships, tolerate affective states, and 
acknowledge symptoms (Bell & Zito, 2005), and that this may be crucial for 
Table III Results of the final logistic-regression model, with remission at one-year follow-up as the 
dependent variable
Model summary 2 Log likelihood:
79.609
Cox & Snell R Square:
.231
Nagelkerke R Square:
.356
Variables in the equation B S.E. Wald Sig. Exp(B) 95% C.I. of Exp(B)
PANSS positive syndrome -.234 .080 8.508 .004 .791 .676 – .926
Recovery style 1.733 .629 7.591 .006 5.656 1.649 – 19.398
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engaging effectively with treatment, achieving sustainable symptom remission, 
and constructively adapting one’s life after a psychotic episode.
Some studies have found that remission in schizophrenia was predicted by a 
patient’s having intimate relations, being married (Bankole et al., 2008; Emsley 
et al., 2006) and lacking lifetime traumatic events (Bankole et al., 2008). It 
may be that the influence of these factors is mediated by recovery style. It is 
known, for example, that patients with a sealing-over recovery style perceive 
their parents to be less caring – suggesting that the roots of sealing-over may 
in part stem from insecure attachment in childhood (Drayton et al., 1998). 
Similarly, Tait et al. (2004) found sealing-over to be associated with negative 
early childhood experience, insecure adult attachment, negative self-evaluative 
beliefs, and insecure identity. They concluded that a sealing-over recovery style 
denotes a person’s low personal resilience in adapting to psychosis, and reflects a 
history of attachment difficulties that is still manifest in current adult relation-
ships (Tait et al., 2004). The connection between sealing-over and lower social 
competence has also been supported by empirical evidence (Modestin et al., 
2004). It may thus be that a patient’s recovery style mediates both the negative 
impact of traumatic lifetime events on the remission of schizophrenia and the 
positive effect of marriage and intimate relationships.
We did not find that insight into illness or therapeutic alliance were predictive of 
remission at one-year follow-up, despite the fact that other studies have shown 
these concepts to be of important clinical significance (e.g. Emsley, Chiliza & 
Schoeman, 2008; Hewitt & Coffey, 2005). It may be that our sample size was 
too small to detect their influence. On the other hand, other studies have sup-
ported the notion that recovery style is more predictive for the course of illness 
than insight is (Tait et al., 2003). From this point of view, it is important to 
note that although our study found an association between insight and recovery 
style, the two are not synonymous. It is possible for patients to seal-over with 
or without insight, e.g. ‘I know I am ill but it was just one of those things and 
I want to forget about it and move on.’ (Tait et al., 2003).
We did not find that negative symptom levels at baseline were predic-
tive of remission, which contrasts with the findings of Petersen et al. (2008). 
However, because we also found negative symptoms to be associated with the 
use of a sealing-over recovery style, our statistical model may have pre-empted 
the effects of negative symptoms, allowing the results to be dominated by 
those of recovery style. Indeed, in the first block of the regression analysis, 
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negative symptoms almost had a significant effect on remission (Wald=2.919; 
Exp(B)=.890; Sig=.088).
8.4.2 Limitations
The main limitations of this study involve issues of sample-composition, which 
therefore limit the options for generalizing the results. For example, our sample 
size was not large, and the number of remissions at one-year follow-up was 
only 22. Similarly, most of the participants were men (70%). Also, due to an 
exclusion criterion of the randomised controlled trial, the study did not include 
patients with very high service engagement. And neither is it probable that 
patients with a very low service engagement were included in the study, either 
because they were not in outpatient treatment, or because they had refused 
to participate, a factor that is likely to be related to a sealing-over recovery 
style. Although the latter may have introduced a bias in our sample, we made 
considerable efforts – including offering financial incentives – to ensure that 
all eligible patients would be included and the sample would thus represent 
everyday practice. This means that there were few exclusion criteria and that 
even fairly disorganized or psychotic patients were included.
8.4.3 Strengths
As far as we know, this is the first study to use the recently defined criteria 
to examine the influence of recovery style on the remission of schizophrenia 
at follow-up. One important methodological strength is the low attrition rate 
(9.6%). Another is that by comparing the effects of recovery style with the 
effects of clinically related and important concepts, such as insight and thera-
peutic alliance, we have also helped disentangle the psychological processes that 
are most relevant to recovery from a psychotic episode.
8.4.4 Clinical implications
Our results indicate that long-term remission may be promoted by helping 
patients to use a more integrating recovery style, for example by talking with 
them about their psychotic experiences, and by urging them not only to take 
an interest in these experiences during recovery, but also to place them in a 
coherent perspective within the self-narrative.
Although it can be difficult to change a patient’s recovery style, empirical 
evidence shows that it is not solely a trait characteristic (Tait et al., 2003). 
Recovery styles may vary at different stages of the recovery process. During 
the acute phase, for example, patients may be integrating, attempting to cope 
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constructively with the challenge of the new situation. But during the course of 
clinical recovery, when the opportunity for reflection begins, they may employ 
more sealing-over. This means that an effect may be achieved by interventions 
that focus on a constructive recovery style and on talking about psychotic expe-
riences. One illustration of this is the finding that getting patients to write about 
the most stressful aspects of their psychotic episode (emotional disclosure) helps 
reduce psychosis-related post-traumatic stress symptoms (Bernard et al., 2006).
Because vulnerable self-esteem is related to greater sealing-over (Drayton 
et al., 1998), patients who employ sealing-over may be those who experience 
greater loss and shame in their psychosis. In order to help them achieve greater 
integration, it may therefore be useful to address self-stigmatization and self-
esteem. Rather than providing neurobiological explanations and telling a patient 
only that he has an incurable brain disease, strategies for this might include 
normalizing psychotic experiences within the stress-vulnerability model and 
within the range of sub-clinical psychotic symptoms in the general population. 
Important contributions to altering recovery style and to achieving remission 
may also be made by interventions intended to improve a patient’s self-esteem 
(e.g. Tarrier, 2001).
In general, the findings of this study confirm that psychological adjustment 
to psychosis should be promoted through the development of interventions 
such as motivational interviewing and cognitive therapy.

Chapter 9
Financial incentives to improve adherence to 
medication in five patients with psychotic disorders. 
A.B.P. Staring 
C.L. Mulder 
S. Priebe
Psychopharmacology Bulletin, in press
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
Ch
ap
te
r 9
124
abstraCt
Objective
Non-adherence to antipsychotic medication is common and increases the risk of 
psychotic relapse. A promising intervention may be a strategy wherein financial 
incentives are offered.
Methods
In a pilot study in The Netherlands, five patients with schizophrenia were 
offered financial incentives for a duration of one year to improve adherence to 
medication. Adherence and hospital days were measured.
Results
The percentage of accepted depot injections increased from an average of 44% 
in the previous year to 100% in the year when financial incentives were offered. 
While patients had been hospitalised for an average of 100.2 days in the previous 
year, only one was re-admitted for 17 days during the year of the intervention. 
Conclusions
The differences in adherence before and after the intervention were large and 
of clinical significance. However, randomised controlled trials are required to 
provide conclusive evidence on the effectiveness of offering financial incentives 
and potential consequences.
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9.1 introduCtion
Non-adherence to antipsychotic medication in schizophrenia is high (Weiden, 
2007; Cramer & Rosenheck, 1998) and is associated with a three to five times 
increased risk of relapse (Fenton et al., 1997; Ucok et al., 2006; Weiden et al., 
2004). Developing effective interventions for improving adherence is a major 
challenge to mental health care. In the UK, Claassen et al. (2007) used financial 
incentives to improve the adherence to antipsychotic maintenance medication 
in five formerly non-adherent patients. Results were promising, yet no other 
studies have since been published.
We conducted a pilot study to test the feasability of using financial incen-
tives to improve adherence and explore potential benefits for patients in an 
Assertive Community Treatment (act) team.
9.2 methods
9.2.1 Procedure
Patients were gathered in Rotterdam, The Netherlands. Written informed 
consent was obtained from all patients after providing them with a complete 
description of the study. The intervention was over a one year period and the 
study was conducted from July 2008 to October 2009. A Medical Ethics Com-
mittee (METIGG, The Netherlands) approved the study (ref-number: 8208; 
CCMO number: NL22014.097.08).
9.2.2 Intervention: financial incentives for adherence
Patients received ten to twenty Euro cash (fifteen to thirty US $) for each depot 
injection of antipsychotic medication. The amount of money depended on the 
frequency of the depot. Ten Euro were offered for a depot administered every 
two weeks, 15 Euro for a depot every three weeks, and 20 Euro for a depot every 
four weeks.
9.2.3 Respondents
Inclusion criteria were (1) a diagnosis of schizophrenia or schizoaffective disor-
der, (2) being treated in the act-team for a period of one year or more, (3) the 
prescription of depot antipsychotic medication, (4), non-adherence, as defined 
by either not accepting all depot injections or repeated resistance and discus-
sion when accepting the medication, (5) having been admitted to a psychiatric 
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hospital in the past year as a consequence of non-adherence (as assessed by the 
responsible clinician).
Six patients were asked to participate out of which one refused and five 
decided to participate. Two patients were native to The Netherlands. The others 
were first-generation immigrants; one from Suriname, one from Turkey, and 
one from the Dutch Antilles. For more details, see Table I.
9.2.4 Measurements
For both the year before and the year during which the intervention was applied, 
the following data were collected from the patients’ files: (1) the number of 
administered depot injections as compared to the prescribed one; and (2) the 
number of days the patient spent in psychiatric in-patient treatment. Further-
more, we designed a short questionnaire to capture the views of patients, their 
relatives and clinicians (workers in the act-team) on the experiences with offer-
ing financial incentives.
9.3 results
9.3.1 Depot acceptance and hospital days
As Table I shows, all five patients accepted every depot injection of antipsy-
chotic medication during the year of the intervention. During the year before 
the intervention, adherence was much lower. Patient B had previously always 
Table I Hospital days and depot acceptance both before and during the intervention
One year before the 
intervention
One year during the intervention
Patient 
(sex; age)
DSM-IV diagnosis Hospital 
days
Depots accepted* Hospital 
days
Depots accepted*
A (male; 23 
yrs)
Schizophrenia, 
paranoid subtype
76 45% 0 100%
B (male; 24 
yrs)
Schizophrenia, 
paranoid subtype
260 0% 17 100%
C (male; 21 
yrs)
Schizophrenia, 
paranoid subtype
89 20% 0 100%
D (male; 43 
yrs)
Schizophrenia, 
paranoid subtype
14 100% 0 100%
E (male; 34 
yrs)
Schizophrenia, 
disorganised subtype
62 55% 0 100%
* This is the percentage of depot injections that were effectively given to the patient in comparison 
to what was officially prescribed, counting only the outpatient days.
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declined a depot injection of antipsychotics, despite the fact that mental health 
professionals had often tried to motivate him because of his poor compliance 
with oral medication and his recurring and severe psychotic relapses.
The number of days patients spent in psychiatric in-patient care decreased 
during the intervention. Only one of the five patients was admitted whilst being 
offered financial incentives. However, the same patient (B), during the period 
of the intervention, had been in detention for 195 days for domestic violence 
while being in a psychotic state. Thus, the incentives improved adherence, but 
the medication did not sufficiently control his psychotic symptoms.
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Figure I Depots accepted one year before and one year during the intervention
* This is the percentage of depot injections that were effectively given to the patient in comparison 
to what was officially prescribed, counting only the outpatient days.
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Figure II Hospital days one year before and one year during the intervention
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9.3.2 Views of patients, relatives and clinicians
In the short questionnaire on the experiences with the intervention all five 
patients considered the intervention to be a good project. The reasons they gave 
were “I don’t like the injection, but money makes it better,” “Money keeps me 
motivated,” and “The depot injections keep me balanced.” When prompted, 
two patients said that they perceived financial incentives as a voluntary and 
non-coercive measure, two patients did not know what to think about this, and 
one indicated that he perceived financial incentives as a coercive measure, say-
ing that “I have to take the medication anyway.” All patients said that they spent 
the money on food and on cigarettes, and one patient also bought household 
products. It was observed, however, that at least one patient had spent some 
of the money on cannabis. All five patients stated that the amount of money 
was too low. None of them, however, had asked for more money during the 
intervention. All five patients said that they preferred receiving cash to other 
systems of reward such as vouchers for food, sports activities, etc.
Three patients either had no relatives or did not allow us to interview them 
in this study. The two interviewed relatives – two mothers – indicated that they 
considered financial incentives to be a good measure, saying that “There can 
never be enough research” and “This project is in the best interest of both the 
patient and his parents.” They considered the amount of money to be sufficient, 
and they preferred the reward of money over vouchers.
During the intervention, two patients had repeatedly asked for their depot 
injections sooner than scheduled, which was always declined. Despite this, 
no clinician reported a negative impact on the therapeutic relationship. Two 
patients complained about side-effects, and one expressed concerns that the 
depot injection could kill him, after watching a TV program in which someone 
died as a result of medication.
No other patient in the care of the team complained about unequal treat-
ment or demanded to be paid for taking their medication as well.
9.4 disCussion
The pilot results are promising and seem to indicate that offering financial 
incentives can increase adherence with depot antipsychotic medications and, 
as a consequence, reduce the risk of relapse in patients with schizophrenia that 
are treated in an ACT-team. The difference in adherence and clinical outcomes 
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
Financial incentives for adherence – a pilot 129
with the total prevention of further hospitalisations in four out of five patients 
is substantial. The benefits of such changes for the patients concerned and their 
relatives as well as the reduction of service costs appear to justify the interven-
tion.
The positive results are consistent with findings of a previous study in the 
UK (Claassen et al., 2007). Unlike that previous study, we also assessed experi-
ences of patients, relatives, and clinicians. Overall, experiences were positive, 
cash incentives were preferred to vouchers, other patients did not ask to be 
offered incentives as well, and no negative impacts on therapeutic relationships 
were noted. However, the reported experiences also indicated potential problems 
with offering incentives. Some patients felt they should receive more money 
and the issue of a coercive nature of the intervention was raised. Some of these 
issues are linked to ethical considerations about offering financial incentives to 
change health behaviour in general (Prendergast et al., 2006) and particularly 
for improving medication adherence in patients with schizophrenia which have 
been discussed elsewhere (Claassen, 2007; Claassen et al., 2007).
9.5 ConClusions
The differences in adherence before and after the beginning of the intervention 
were large and of clear clinical significance. However, randomised controlled 
trials are required to provide conclusive evidence on the effectiveness of offer-
ing financial incentives and potential consequences (Priebe et al., 2009). Such 
research should distinguish between an effect on adherence itself and a positive 
impact of the medication.

Chapter 10
General discussion, conclusions, and 
recommendations.
A.B.P. Staring
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10.1 short summary of the findings
The main objective of this study was to find ways to improve treatment adher-
ence in patients with psychotic disorders. In Chapter 2, based on a literature-
review, three clusters of possible causes of non-adherence are summarized, each 
of which can be targeted by a specific module of our developed Treatment Adher-
ence Therapy (TAT). Our multi-centre randomised controlled trial showed that 
this intervention was effective in improving treatment adherence (Chapter 3). 
It was also shown that adherence to antipsychotic medication has diverging 
effects on patients’ quality of life, as good adherence is associated with symptom-
reduction as well as side-effects (Chapter 4). Also, insight into illness was not 
always relevant for good adherence, but rather in only those patients who have 
sufficient cognitive abilities (Chapter 6). Furthermore, the detrimental effects 
of insight depended on the amount of stigma that patients attach to the illness 
(Chapter 5).
We hypothesized that immigrant patients were more likely to use a sealing-
over recovery style, which might explain their observed low service engagement, 
but this was not supported (Chapter 7). We did find, however, that an inte-
grating recovery style strongly predicted the remission of a psychotic disorder 
(Chapter 8).
Finally, we did a pilot study on using financial incentives to promote adher-
ence to depot antipsychotic medications. The results indicated that it may be a 
very effective method (Chapter 9).
10.2 motivations for adherenCe and intervention strategies
The results that are reported in Chapters 3 and 4 indicate that good adherence 
to antipsychotic medication does not, on average, improve patients’ short-term 
quality of life. In other words, patients report that they do not feel much better 
or happier with their lives. We know that antipsychotic medications generally 
do not produce immediate pleasant effects, and this is unlike some other medi-
cations, for example benzodiazepines. Rather, the first thing that patients often 
experience is a range of unpleasant side-effects. Therefore, those who keep using 
their medication for a prolonged time, as prescribed, probably do so because 
they have some other short-term reason (e.g. to sleep better, avoid arguments, 
or reduce certain symptoms), or because they have insight in the long-term 
consequences of non-adherence, such as the increased odds of relapse and 
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re-admission. Thus, in order to achieve adherence in non-adherent patients, it 
seems useful to create awareness of the short-term and long-term consequences 
that are of personal significance from a patient’s perspective. This is indeed 
what we have explored, and our intervention strategies in Treatment Adherence 
Therapy (TAT) are aimed at developing a personal narrative in which these 
consequences intrinsically motivate patients to adhere to treatment (Chapters 
2 and 3).
However, some well motivated patients may still find it difficult to adhere 
to medication because of a lack of self-control. For them, the solution is rather 
straightforward: give them depot injections of the medication, or support them 
with various behavioural strategies to make it easier to use oral medication, such 
as reminders, cues, self-monitoring tools, family or partner support, and linking 
medication-use to highly frequent behaviours.
Other patients, even after talking about all relevant consequences, still con-
sider medication as not helpful. Several causes can be imagined: Is this opinion 
based on a balance of pros and cons? Do they experience adverse effects? It 
seems best to start a period of testing medication types and dosages in order to 
examine what works best for an individual patient, and to develop his aware-
ness of effects and side-effects. We have done so by the module medication 
optimization in TAT. Some of these patients may finally decide that there is no 
suitable antipsychotic medication with benefits outweighing the side-effects. 
Clinicians could probably best support this decision of non-adherence (except 
when danger is involved and involuntary measures are needed). This group of 
patients may actually be larger than is generally expected (Chapter 3). Many 
of the non-adherent patients may have decided to become non-adherent as 
a consequence of not responding well to antipsychotic medication, and this 
may have produced part of the frequently observed associations – mentioned 
throughout this thesis – between non-adherence and an increased risk of relapse 
and re-admission (Dixon & Lehman, 1995; Fenton et al., 1997; Robinson et 
al., 2002; Ucok et al., 2006; Weiden et al., 2004)
Other patients may change their opinions and acknowledge that antipsy-
chotic medication helps them control symptoms and prevent social exclusion. 
However, there may be patients who do not change their opinions and 
who are still frequently non-adherent despite the observed medication benefits 
and despite recurrent involuntary admissions. For them, it may be important 
to realise that cognitive dysfunction, positive symptoms, and perception biases 
may incapacitate them to judge their own situations well and to behave in 
accordance with beliefs (Chapter 6). In these cases, providing incentives for 
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adherence seems a good option. This might be a better option than the threat 
of involuntary admission in a psychiatric hospital ward. Providing incentives is 
probably more effective, less traumatic, and less expensive (Chapter 9).
The abovementioned vignettes of patient perspectives on the use of antipsy-
chotic medication are helpful in developing a heuristic model for improving 
adherence behaviour, as is integrated in Treatment Adherence Therapy (TAT; 
Chapter 2).
10.3 the effeCts of treatment adherenCe theraPy
The multi-centre randomised controlled trial in this thesis has supported the 
hypothesis that Treatment Adherence Therapy (TAT) enhances service engage-
ment and medication adherence in patients with psychotic disorders. The effect 
on medication adherence remained significant at six-month follow-up. Also, 
there was a trend that the patients receiving TAT were less often involuntarily 
admitted to a hospital. These results contrast with the lack of significant 
improvements in some of the other attempts to improve adherence (e.g. Gray et 
al., 2006), and may be due to the model of TAT in which intervention strategies 
are tailored to patients’ individual situations. However, we could not detect any 
effects of TAT on symptoms, quality of life, insight, recovery style, therapeutic 
alliance, or the experience of stigma.
The effects of TAT on adherence, although still significant, were somewhat 
reduced at six-month follow-up. This is in keeping with the findings of a meta-
analysis (Nosé et al., 2003), where length of follow-up was negatively associated 
with treatment effect on adherence. Thus, the benefit of this type of interven-
tion is less evident with increasing length of follow-up. Until more long-term 
data has become available, clinical interventions should be implemented in 
practice as short-term measures, and may need frequent and routine repetition 
for enduring effects.
Based on the frequent use of motivational interviewing, it can be concluded 
that the most common reason therapists judged a patient to be poorly engaging 
with services in the TAT study was related to factors such as stigma, denial, and 
low insight. Behavioural training and medication optimization were less often 
employed. This pattern may be the result of the way clinicians referred patients 
for the study. Clinicians may have primarily focussed on those patients who 
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would openly resist their diagnosis and treatment, and they may have failed to 
detect non-adherence when it was a consequence of cognitive problems such 
as forgetfulness, or in those instances where patients secretly disposed of the 
medication because they believed it was not helpful or produced too many side-
effects. It is indeed known that clinicians often underestimate non-adherence 
(Byerly et al., 2007). This mechanism may have produced a bias in our study 
sample, limiting the possibility to generalize the findings.
In our study design, TAT was an add-on intervention administered by a thera-
pist other than the patient’s own clinician. As we consider the approach to be 
patient-oriented and respectful of patients’ views, TAT may be more effective 
when it is administered by the patient’s own clinician. Such an approach might 
strengthen the alliance in the regular therapeutic relationship, a factor known 
to positively influence outcome (Hewitt & Coffey, 2005).
10.4 why did symPtoms not imProve?
Despite the effects of TAT on service engagement and medication adherence, 
we did not detect symptomatic improvements. Interestingly, some other inter-
ventions have yielded similar results: adherence to antipsychotic medications 
improved, yet psychiatric symptoms did not (Kemp et al., 1996; Velligan et al., 
2008; Valenstein et al., 2009). What’s going on?
One possibility is that the adherence-measurements used were not valid and 
failed to reflect the true adherence of patients. This is unlikely, however, because 
other outcome measures did in fact show some improvement, for example on 
functioning (Kemp et al., 1996; Velligan et al., 2008), as well as a near signifi-
cant effect on involuntary admissions in the TAT study.
Another explanation for the lack of symptomatic improvement is that the 
sample sizes were too small to detect a not very large effect. Maybe then, the 
duration and intensity of the interventions were not enough to cause large 
changes in symptoms, and that we need longer or more intensive treatments.
Alternatively, it may be the case that referred patients were actually poorly 
adherent at baseline as a consequence of insufficient improvement with antipsy-
chotic medication. Non-adherent patients might have a more malignant course 
of the illness, leading to both non-adherence and poor outcome. Somewhat 
related to this explanation is the possibility that symptoms were relatively 
under control at baseline and that, despite incomplete adherence, patients 
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may have had already gained the maximum benefit from their antipsychotic 
treatment. In both these scenarios, creating better adherence would not have 
improved symptoms. Arguably then, future interventions will produce simi-
larly disappointing results, and it is to be expected that improved adherence to 
antipsychotic medications may simply not always do very much for reducing 
psychotic symptoms. Possibly, it may influence emotion and behaviour rather 
than psychotic symptoms persé, which may explain the observed benefits of 
an improved adherence for functioning and involuntary admissions. Indeed, 
there is evidence that antipsychotic medication, when regarding the various 
dimensions of psychotic experiences, produces the largest effect on the behav-
ioural impact as well as somewhat smaller effects on cognitive preoccupation 
and emotional involvement, but that it hardly influences the conviction and 
external perspective of psychotic experiences (Mizrahi et al., 2006).
Most likely, the truth lies somewhere in the middle, and all these factors are 
combined in explaining the results to a certain extent.
Adherence is not a sufficient treatment goal or clinical outcome by itself. 
Interventions for improving adherence are only useful if they in the end help 
patients feel or function better. Adherence is a tool to achieve goals (Weiden, 
2007). Life goals, such as improved quality of life and achieving – or preventing 
the loss of – valued relationships and social roles, are relevant outcomes for 
patients. Obstacles in achieving these goals are useful treatment targets, which 
may or may not include psychiatric symptoms, and adherence is only a useful 
aim when viewed within this context.
10.5 Considerations
In Chapter 1, it was argued that a lot of effort is being put into developing 
better antipsychotic medications, and that perhaps more effort should be made 
to increase adherence. However, these two issues are related to each other in 
various ways. For example, if a new antipsychotic agent would appear on the 
market that produces direct pleasurable effects, the problem of non-adherence 
might be less prominent. Also, if antipsychotic medications would reach a level 
of effectiveness in which all of the symptoms – positive and negative – of schizo-
phrenia are very much reduced, without any side-effects, then being adherent 
would produce a lot more benefit for patients. Alongside this, the amount of 
stigma attached to schizophrenia would likely make a dramatic drop, because 
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patients would look and behave as all others when e.g. extrapyramidal side-
effects would be absent. And without stigma, another reason for non-adherence 
disappears. Any improvement along these lines may have a significant influence 
on the issues of adherence in psychosis.
However, it is also known that adherence in other fields of health care is 
problematic just the same, e.g. hypertension and diabetes. More effectiveness 
and fewer side-effects, therefore, are unlikely to completely solve the problem 
of non-adherence in these patients.
As mentioned before, adherence to medication does not improve short-term 
quality of life. Besides the stated implications for the way in which patients may 
be motivated for adherence, this also means that being adherent to antipsychotic 
medication is not enough to achieve substantial improvements for desired goals 
and satisfaction in life. Also, better adherence may worsen somatic side-effects, 
reduce frontal grey matter in the brain, and increase mortality—consequences 
of long use of antipsychotic medication (Weinmann & Aderhold, 2010).
Considering this, a certain conclusion is becoming more and more discern-
ible: achieving adherence to antipsychotic medication is not the holy grail in treat-
ing psychosis. We should always be aware that for some patients antipsychotic 
medication may not really be helpful, despite the possible presence of severe 
symptoms and high risk of re-admission. Also, even when the medication is 
helpful, severe adverse effects stress the need to minimize long-term use and 
doses, and other interventions and efforts are often needed to support patients 
to more fully recover from their psychosis and regain a desired level of func-
tioning and quality of life. This highlights the need for strategies such as the 
involvement of family, cognitive behavioural therapy, rehabilitation strategies, 
treatment of co-morbid disorders, and other interventions that explore personal 
life meanings of psychotic experiences (Weinmann & Aderhold, 2010; Stainsby 
et al., 2010).
10.6 limitations
Some important limitations of our study should be considered. First, the sample 
size was not large, which may have limited the power to detect effects of TAT on 
secondary outcomes and mediators.
Second, our research design distributed attention unevenly between the 
two treatment allocations, which may have produced a bias. The effects we 
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observed may have been caused simply by giving the patients in the TAT group 
more attention. We can therefore not confirm that the therapeutic contents of 
TAT were in fact the actual effective ingredients.
Third, our measure of compliance consisted of the SES plus a one-item 
rating scale. This latter measure has not been validated, and may not be the 
best available. However, measuring compliance is difficult, and a gold standard 
is certainly lacking (Kikkert et al., 2008). As well as self-report and interview 
measures, methods of measuring compliance include pill counts, electronic 
methods, prescription monitoring, and saliva, plasma and urine assay tests 
(Patel & David, 2007). Each has its advantages and disadvantages. Pill counts 
are not only time-consuming, but also have great potential for inaccuracy. And 
not only are saliva, plasma, and urine tests not possible for all drugs, they are 
expensive and invasive, and may also overestimate adherence for drugs that have 
a long half-life (Fenton et al., 1997; Zygmunt et al., 2002).
Fourth, patients were referred to our study when their clinicians believed 
they were not sufficiently adherent. They have probably not detected all cases of 
non-adherence, which may have produced a bias in the selection of our study 
sample.
10.7 ConClusions
Based on the findings in this thesis, I am positive that adherence with antipsy-
chotic medication, as well as more general service engagement, can be positively 
affected by professionals’ attitudes and interventions. However, the updated 
guidelines of the National Institute for health and Clinical Excellence (NICE, 
2009) recommend not to use any kind of adherence therapy in patients with 
psychosis. And most likely, the forthcoming update of the Dutch Multidisci-
plinary Guidelines for Schizophrenia (due 2010), will similarly advise against 
this type of intervention. I will not dispute these recommendations. They are 
correct in that inconclusive evidence exists for the various variations of adher-
ence therapy. Also, other psychosocial interventions in psychosis, not aimed 
at adherence, have produced much more conclusive evidence supporting their 
merit over the years, such as cognitive behavioural therapy and family-based 
interventions. And as these treatments are not yet available in the every-day 
practice of many mental health institutions, implementing them deserves the 
highest priority.
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However, this thesis shows that a comprehensive assessment of patient’s 
motives and capabilities can indicate what type of intervention may effectively 
support them in becoming more adherent. Treatment Adherence Therapy has 
produced significant effects (Chapter 3). And research on other strategies is 
currently underway, such as a CBT-type intervention by Peter Weiden et al., 
financial incentives by Stefan Priebe et al. (2009) as well as by Charlotte Audier 
et al., behavioural strategies in order to bypass cognitive deficits by Velligan 
et al. (2009), and an adherence coping skills therapy by Sarah Uzenoff et al. 
(2008). Combining the best strategies into an integrated approach, where each 
patient receives a tailored treatment to improve adherence, may eventually 
become an evidence-based guideline.
Adherence studies underline the need to strive to understand patients from 
their personal individual perspectives. This means giving them the opportunity 
to have their voices adequately heard. In doing so, it is hoped that the adverse 
clinical and economic impact of non-adherence may be further reduced.
10.8 reCommendations
It has become clear that non-adherence in patients with schizophrenia is a 
heterogeneous problem, and that intervention strategies should be tailored to 
patients their individual situations, ideas, and capabilities (Chapters 2, 4, & 6). 
Future research, then, can focus on the clearer assessment of patients’ individual 
reasons for non-adherence and its consequences, allowing intervention strate-
gies to be applied with more accuracy. An implication of this realisation is that 
group formats for adherence interventions are unlikely to be successful.
Future research on TAT or a similar type of intervention may use the fol-
lowing recommendations: (1) to compare its effects with a control condition in 
which an equal amount of attention is given to the patients; (2) to use various 
adherence-measurements; (3) to let patients’ own clinicians execute the inter-
vention; (4) longer or more intensive treatment; (5) longer-term follow-up; and 
(6) to distinguish between an effect on adherence itself and a positive impact of 
the medication.
Also, adherence to medications is one thing, but adherence to appoint-
ments and psychosocial treatments is similarly important for patients in order 
to achieve desired improvements. Also, when patients better adhere to appoint-
ments, it is easier to monitor adherence to medications.
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It seems practical and can probably work as a preventive measure to use the 
TAT method of medication optimization as a standard practice whenever a 
patient is given a new antipsychotic medication and is not in a too psychotic 
state to be involved in this kind of strategy. Doing so would involve patients in 
structurally monitoring symptoms and side-effects, and it would take their view 
seriously. Also, it would do justice to the fact that we never know beforehand if 
a certain antipsychotic medication or dosage is suitable. The collaborative and 
structured empirical nature of this intervention is, in my view, a realistic and 
respectful approach, and consistent with the process of shared decision making 
that we need in adherence issues (Gray et al., 2010). If non-adherence rates are 
to decrease, it will ultimately be necessary to align the incentives of the treater 
and the treated.
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11.2 summary
11.2.1 Treatment Adherence Therapy
The main objective of this research was to find ways in which to improve treat-
ment adherence in patients with psychosis. Chapters 1 and 2 constitute the 
introduction in which the literature on non-adherence in psychosis is reviewed. 
It was found that non-adherence to treatment in patients with psychotic disor-
ders is common and related to relapse, hospitalization, and suicide. Important 
predictors of non-adherence include poor social structure, cognitive deficits, 
negative medication attitude, side effects, depression, a sealing-over recovery 
style, feelings of stigmatization, denial of treatment need, and lack of insight. 
Studies on interventions to improve adherence have shown that patient edu-
cation is not fully effective, and that motivational interviewing, behavioural 
strategies, and linking a patient’s personal goals to treatment may increase 
adherence. Intervention studies have produced inconclusive results, however. 
Based on the empirical data reviewed, we formed three clusters of possible 
causes of non-adherence, each of which can be targeted by a specific module 
of our developed Treatment Adherence Therapy (TAT). These modules are: 
(1) adapted motivational interviewing, (2) medication optimization, and (3) 
behavioural training. An individual patient may benefit from one or more of 
these modules; and thus the contents of TAT vary in accordance with individual 
causes of non-adherence. Basically, TAT aims to help patients work out what 
they want regarding treatment and then support them in following this through. 
In Chapter 3, we analyzed the effects of Treatment Adherence Therapy 
(TAT) with a single-blind randomised controlled study of treatment as usual 
(TAU) versus TAU + TAT in 109 outpatients. Measurements were performed 
by masked assessors at the end of treatment and at six-month follow-up. 
Significant benefits were shown on service engagement (Cohen’s d=.48) and 
medication compliance (Cohen’s d=.43). Results remained significant at 
follow-up for medication compliance. Also, near significant effects were found 
on involuntary re-admissions (1.9% vs. 11.8%; Sig=.053), but symptoms and 
quality of life did not improve. It was concluded that Treatment Adherence 
Therapy is effective for improving engagement and compliance, and that it may 
prevent involuntary admissions. 
11.2.2 Adherence, insight, and recovery styles
Chapter 4 deals with the issue that, when patients adhere to their antipsy-
chotic medication, it is not certain whether they experience short-term 
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improved quality of life. By simultaneously reducing symptoms and increasing 
side-effects, compliance with antipsychotics may have opposing effects on a 
patient’s perceived quality of life. Using Structural Equation Modeling (SEM), 
this hypothesis was tested in 114 outpatients with psychotic disorders, using 
the baseline data of the current randomised controlled trial. It was found that 
compliance was not directly related to quality of life. The best-fitting model 
indicated that high compliance was associated with fewer psychotic symptoms 
and more adverse medication effects. Symptoms and adverse medication effects 
were both related to lower quality of life. This means that, with regard to the 
effects of medication, the balance between symptom reduction and adverse 
effects is associated with the benefit a patient perceives in terms of improved 
quality of life. Also, as quality of life generally is not higher in those who are 
adherent, patients who keep using their pills for a prolonged time, probably do 
so because they have some other short-term reason (e.g. to sleep better, to avoid 
arguments, or to reduce certain symptoms), or because they have insight in the 
long-term consequences of non-adherence, such as increased odds of relapse 
and re-admission. 
In Chapter 5, we looked at effects of insight in patients with psychosis, 
because it is known that good insight is related not only to medication compli-
ance and high service engagement, but also to depression, low self-esteem, and 
low quality of life. We investigated the possibility that the negative effects of 
good insight are moderated by perceived stigma. Again, this was done by the 
method of SEM, using the baseline data of our study sample. We found that 
good insight was associated with high service engagement and high compliance. 
Also, insight was related to depressed mood, low quality of life, and negative 
self-esteem. These latter associations were strong when stigma was high and 
weak when stigma was low. SEM showed that the detrimental effects of insight 
are moderated by stigma. A clinical implication is that when attempting to 
increase insight, perceived stigma should also be addressed. 
Another issue with insight is that while lack of insight into illness is often 
a strong predictor of antipsychotic non-adherence, there is considerable incon-
sistency in the literature that has not been adequately explained. In Chapter 6, 
we investigated the hypothesis that verbal memory deficits may be an important 
moderator in the association between insight and adherence, because memory is 
an essential link needed to change intent to action. Results showed that insight 
was associated with compliance in patients without, but not in patients with 
severe verbal memory deficits. Thus, in patients with verbal memory deficits, 
compliance is unaffected by the amount of insight. If compliance is poor in 
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these patients, behavioural interventions are probably enough to overcome it, 
such as reminders, the simplification of dosing frequency and polypharmacy 
use, the involvement of family members in treatment, or the use of contingency 
management such as financial incentives. Patients without memory impair-
ments, whose insight is poor, may benefit not only from behavioural strategies, 
but also from insight-enhancing interventions such as cognitive therapy or 
motivational interviewing. 
In Chapter 7, the hypothesis is tested that low service engagement in 
immigrant patients – frequently observed – is caused by more sealing-over 
recovery styles, and that this is related to low self-esteem. Broadly defined, the 
sealing-over patient prefers not to think about psychotic experiences during 
recovery, while the integrator, by contrast, is interested in the psychotic experi-
ence and desires to place it into some coherent perspective. Results showed 
that sealing-over was associated with low service engagement, but not with low 
self-esteem. However, although first-generation immigrant patients had lower 
service engagement, they did not differ from natives with regard to recovery 
style or self-esteem, and neither did second-generation immigrants. It was 
concluded that sealing-over predicted low service engagement, but that lower 
service engagement in immigrant patients than in natives was not attribut-
able to sealing-over or low self-esteem. Low self-esteem may contribute to the 
development of schizophrenia in a relatively high number of immigrants, but 
after onset, it may be equally common in native patients, and not lead to more 
sealing-over in immigrants. Their low service engagement may be related to 
other factors, such as non-Western views or a different attitude towards the need 
to keep appointments. 
Finally, we were interested in the way that patients’ recovery styles con-
tributed to remission of schizophrenia. In Chapter 8, we used data of 103 
patients on recovery style, insight, therapeutic alliance, and symptoms. At 
twelve months, remission status was assessed. Results showed that having an 
integrating recovery style increased the odds of remission 5.66-fold (95% C.I.: 
1.65-19.40). Insight and therapeutic alliance were not predictive. While remis-
sion was also predicted by positive symptom levels at baseline, this did not 
influence the effect of recovery style. These findings provide support for the 
development of interventions such as motivational interviewing and cognitive 
therapy, designed to promote psychological adjustment to psychosis. 
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11.2.3 Financia incentives for improving adherence
In Chapter 9, we describe a pilot study in which five patients received financial 
incentives for a duration of one year to improve adherence to medication. 
Results showed that the percentage of accepted depot injections increased from 
an average of 44% in the previous year to 100% in the year when financial 
incentives were offered. And while patients had been hospitalised for an average 
of 100.2 days in the previous year, only one was re-admitted during the year of 
the intervention, which was for 17 days.
11.2.4 Conclusions and recommendations
In Chapter 10, the findings are discussed in the light of the literature and 
future directions. The guidelines of the National Institute for health and 
Clinical Excellence (NICE, 2009) recommend not to use any kind of adherence 
therapy in patients with psychosis. And most likely, the forthcoming update 
of the Dutch Multidisciplinary Guidelines for Schizophrenia (due 2010), will 
similarly advise against this type of intervention. However, the findings of this 
thesis suggest that adherence with antipsychotic medication, as well as service 
engagement, can be positively affected by professionals’ attitudes and interven-
tions. A thorough assessment of patient’s individual situations can indicate what 
type of intervention may effectively support them in becoming more adherent. 
Other research on specific strategies is currently underway in various countries. 
Combining the best strategies into an integrated approach, where each patient 
receives an individually tailored treatment to improve adherence, may turn 
out to be the most effective method. However, at this moment, there is still 
insufficient evidence that interventions aimed at improving adherence result 
in better treatment outcomes, and widely implementing such interventions in 
standard mental health care is not yet advisable.
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11.3 samenvatting
11.3.1 Treatment Adherence Therapy
Het belangrijkste doel van dit onderzoek was het ontwikkelen van manieren 
om de therapietrouw te verbeteren in patiënten met psychoses. Hoofdstukken 
1 en 2 vormen de introductie waarin de stand van zaken in de literatuur over 
therapie-ontrouw bij patiënten met psychoses wordt geschetst. Er is gevonden 
dat therapie-ontrouw veel voorkomt en gerelateerd is aan terugval, rehospitalisa-
tie en suïcide. Predictoren voor therapie-ontrouw zijn weinig sociale structuur, 
cognitieve stoornissen, een negatieve houding ten opzichte van medicatie, bij-
werkingen van de medicatie, depressie, een toedekkende copingstijl, gevoelens 
van stigmatisatie, ontkenning van de behandelnoodzaak, en laag ziekte-inzicht. 
Studies naar interventies om therapietrouw te verhogen laten zien dat psycho-
educatie geen effect heeft, maar dat motiverende gespreksvoering, gedragsstrate-
gieën en het koppelen van behandeling aan persoonlijke doelen van een patiënt, 
allemaal een effect kunnen hebben. Echter, de bestudeerde interventies hebben 
tot nu toe zeer wisselende successen laten zien.
Op basis van deze empirische gegevens hebben we drie clusters van moge-
lijke oorzaken van therapie-ontrouw vastgesteld, en voor ieder cluster is een 
specifieke module gemaakt. Deze therapie hebben we Treatment Adherence 
Therapy (TAT) genoemd. De modules zijn: (1) motiverende gespreksvoering, (2) 
medicatie optimalisatie en (3) gedragstraining. Een individuele patiënt kan baat 
hebben bij één of meer van deze modules, en de inhoud en duur van de totale 
interventie variëren dus afhankelijk van de individuele oorzaken van therapie-
ontrouw. TAT helpt patiënten bij het uitzoeken van wat ze willen met betrekking 
tot behandeling, en steunt ze vervolgens bij het gevolg geven daaraan.
In Hoofdstuk 3 hebben we de effecten geanalyseerd van Treatment Adhe-
rence Therapy (TAT) met een enkel-blind gerandomiseerde gecontroleerde 
studie waarbij in 109 ambulante patiënten treatment as usual (TAU) werd ver-
geleken met TAU + TAT. Metingen werden verricht direct na de interventie en 
na een follow-up van zes maanden. Er werden significante resultaten gevonden 
op behandelmedewerking (Cohen’s d = .48) en medicatietrouw (Cohen’s d = 
.43). Deze resultaten bleven significant na de follow-up periode voor medica-
tietrouw. Daarnaast werd een bijna significant effect gevonden op gedwongen 
opnames (11,8% versus 1,9%; Sig=.053). Echter, symptomen en kwaliteit van 
leven verbeterden niet. Treatment Adherence Therapy blijkt dus effectief te 
zijn in het verbeteren van de behandelmedewerking en de medicatietrouw, en 
mogelijk voorkomt het gedwongen opnames.
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11.3.2 Therapietrouw, inzicht en copingstijlen
Hoofdstuk 4 gaat over de kwestie dat indien patiënten trouw hun antipsy-
chotische medicatie gebruiken, het niet duidelijk is of ze op korte termijn wel 
een betere kwaliteit van leven ervaren. Door het tegelijkertijd verminderen 
van symptomen en het veroorzaken van bijwerkingen, kan therapietrouw 
aan antipsychotica tegengestelde effecten hebben op de kwaliteit van leven. 
Met Structural Equation Modeling (SEM) is deze hypothese getoetst in 114 
ambulante patiënten met een psychotische stoornis, waarbij gebruik is gemaakt 
van de baseline gegevens van de huidige studie omtrent TAT. We vonden dat 
therapietrouw niet direct gerelateerd was aan kwaliteit van leven. Het meest 
passende model liet zien dat goede therapietrouw samenhing met minder 
psychotische symptomen en meer bijwerkingen van de medicatie. Sympto-
men en bijwerkingen hadden allebei een negatief effect op de kwaliteit van 
leven. Dit betekent dat met betrekking tot de effecten van antipsychotische 
medicatie, de balans tussen symptoomreductie en bijwerkingen geassocieerd is 
met de verbetering die een patiënt ervaart in diens kwaliteit van leven. Verder, 
aangezien de kwaliteit van leven in het algemeen niet hoger is in patiënten die 
therapietrouw zijn, zullen de persoonlijke redenen om medicatie langdurig te 
blijven gebruiken waarschijnlijk op andere gebieden liggen dan een verhoogd 
welbevinden, zoals b.v. op korte termijn beter slapen, ruzies voorkomen, of 
bepaalde symptomen reduceren, of op lange termijn het verkleinen van de kans 
op terugval en heropname.
In Hoofdstuk 5 hebben we gekeken naar de effecten van ziekte-inzicht, 
aangezien het bekend is dat goed inzicht niet alleen gerelateerd is aan medicatie-
trouw en algemene medewerking aan behandeling, maar ook aan depressie, lage 
zelfwaardering en lage kwaliteit van leven. We hebben onderzocht of de nega-
tieve effecten van ziekte-inzicht gemodereerd worden door ervaren stigma. Dit 
is wederom met SEM gedaan, op basis van de baseline gegevens. We vonden dat 
goed inzicht inderdaad gerelateerd is aan hogere behandelmedewerking en medi-
catietrouw. Echter, goed inzicht was ook gerelateerd aan depressieve stemming, 
lage kwaliteit van leven en negatieve zelfwaardering. Deze laatste verbanden 
waren sterk wanneer er stigma werd ervaren, en zwak wanneer er geen stigma 
werd ervaren. SEM liet zien dat de negatieve effecten van inzicht gemodereerd 
worden door de hoeveelheid stigma die wordt ervaren. Een klinische implicatie 
is dat, wanneer pogingen worden ondernomen om het ziekte-inzicht te verbete-
ren, er ook aandacht moet zijn voor het ervaren stigma of de zelf-stigmatisatie.
Een andere kwestie rondom het ziekte-inzicht is dat hoewel inzicht vaak 
een sterke voorspeller is van ontrouw aan antipsychotische behandeling, er 
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toch aanzienlijke inconsistentie in de literatuur is die nog niet is verklaard. In 
Hoofdstuk 6 hebben we de hypothese onderzocht dat problemen in het verbale 
geheugen een belangrijke moderator zijn voor de relatie tussen inzicht and 
therapietrouw. Het geheugen is namelijk een essentiële link om van intentie te 
komen tot gedrag. De resultaten lieten zien dat inzicht sterk gerelateerd was aan 
therapietrouw in patiënten zonder ernstige problemen in het verbale geheugen, 
maar dat er geen verband was in de patiënten met dergelijke problemen. In 
patiënten met een slecht verbaal geheugen lijkt de mate van therapietrouw dus 
niet te worden beïnvloed door het ziekte-inzicht. Wanneer zij therapie-ontrouw 
zijn, zijn gedragsstrategieën waarschijnlijk voldoende om er iets aan te doen, 
zoals bijvoorbeeld het aanbieden van herinneringen, simplificatie van pil-inname 
of het aantal medicaties, het betrekken van familieleden in de behandeling, 
of contingency management zoals het aanbieden van financiële beloningen. 
Voor patiënten zonder geheugenproblemen met een laag inzicht kunnen ook 
inzicht-verhogende interventies zinvol zijn, zoals cognitieve gedragstherapie en 
motiverende gespreksvoering.
In Hoofdstuk 7 werd de hypothese getoetst dat weinig behandelmedewer-
king in allochtone patiënten – zoals vaak geobserveerd – veroorzaakt wordt 
door een toedekkende copingstijl. Breed gedefinieerd denkt de toedekkende 
patiënt liever niet na over diens psychotische ervaringen tijdens herstel, terwijl 
de integrerende patiënt, aan de andere kant, geïnteresseerd is in diens psychose 
en het wenst te plaatsen in een coherent narratief. Resultaten lieten zien dat 
toedekken gerelateerd is aan weinig behandelmedewerking, maar niet aan een 
lage zelfwaardering. Echter, hoewel de 1e generatie allochtone patiënten minder 
meewerkten met behandeling, verschilden ze niet van autochtonen in hun 
copingstijl of zelfwaardering, en dat geldt ook voor de 2e generatie. Conclu-
derend bleek dat een toedekkende copingstijl voorspellend is voor een matige 
therapietrouw, maar dat het feit dat de meeste allochtone patiënten minder met 
behandeling meewerken dan autochtone patiënten niet verklaard kan worden 
door meer toedekken of een lagere zelfwaardering. Een lage zelfwaardering 
draagt mogelijk bij aan de ontwikkeling van schizofrenie in een relatief groot 
aantal allochtonen, maar na start van de ziekte lijkt de zelfwaardering hetzelfde 
te zijn als bij autochtone patiënten en niet geassocieerd met meer toedekking bij 
allochtone patiënten. Hun lagere medewerking met behandeling heeft mogelijk 
met andere factoren te maken, zoals niet-Westerese ideeën over de stoornis, of 
een andere houding ten opzichte van het maken en nakomen van afspraken. 
We waren tenslotte geïnteresseerd in de manier waarop de copingstijl van 
patiënten zou bijdragen aan de remissie van schizofrenie. In Hoofdstuk 8 
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hebben we gegevens van 103 patiënten verzameld op de gebieden van coping-
stijl, inzicht, therapeutische relatie, en symptomen. Twaalf maanden later is 
remissie vastgesteld. Resultaten lieten zien dat het toepassen van een integre-
rende copingstijl de kans op remissie met 5,66 keer vergrootte (95% B.I.: 1,65-
19,40). Inzicht en therapeutische relatie voegden niets toe aan de voorspelling. 
Ook het baseline niveau van positieve symptomen voorspelde remissie, maar 
dit had geen invloed op het effect van copingstijl. Deze bevindingen bieden 
steun voor het ontwikkelen van interventies zoals motiverende gespreksvoering 
en cognitieve therapie, gericht op het stimuleren van psychologische aanpassing 
aan een psychose.
11.3.3 Financiële prikkels om therapietrouw te verhogen
In Hoofdstuk 9 beschrijven we een pilot-studie waarin vijf patiënten, gedu-
rende een jaar, geldelijke beloningen hebben ontvangen voor het verhogen van 
de medicatietrouw aan depot medicatie. Resultaten lieten zien dat het per-
centage geaccepteerde depot-injecties van 44% in het voorafgaande jaar steeg 
naar 100% in het jaar tijdens de interventie. En terwijl de patiënten gemiddeld 
100,2 dagen waren opgenomen in het voorafgaande jaar, is slechts één patiënt 
nogmaals opgenomen tijdens het jaar van de interventie, voor 17 dagen.
11.3.4 Conclusies en adviezen
De bevindingen worden besproken in Hoofdstuk 10. De richtlijnen van de 
National Institute for health and Clinical Excellence (NICE, 2009) adviseren 
om geen gebruik te maken van enige vorm van adherence therapy in patiënten 
met psychose. En waarschijnlijk zal het binnenkort te verschijnen document 
van de Multidisciplinaire Richtlijnen voor Schizofrenie (ergens in 2010) een 
vergelijkbaar advies formuleren. Echter, resultaten in dit proefschrift wijzen erop 
dat zowel medicatietrouw als een meer algemene behandelmedewerking positief 
te beïnvloeden zijn door extra interventies. Een uitvoerig onderzoek van een 
patiënt’s individuele situatie kan bepalen wat voor type interventie effectief kan 
zijn in het verbeteren van de therapietrouw. Er wordt momenteel onderzoek 
gedaan naar specifieke strategieën in verschillende landen. Het combineren 
van de best-werkende interventies in een geïntegreerde aanpak, waardoor 
iedere patiënt een op maat gesneden behandeling krijgt om de therapietrouw 
te verbeteren, zou uiteindelijk misschien het beste kunnen werken. Tot nu toe 
is er echter onvoldoende bewijs dat interventies gericht op het verbeteren van 
therapietrouw daadwerkelijk resulteren in een verbeterde behandeluitkomst, en 
is brede implementatie van deze interventies nog niet aan de orde. 
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11.4 dankwoord
Mijn dank gaat uit naar de promotoren Niels Mulder en Mark van der Gaag. 
Beide zijn fijne en actieve begeleiders die altijd beschikbaar waren en het nooit 
te druk hadden om te antwoorden op mijn vragen of om steeds binnen korte 
tijd de geschreven stukken te lezen en te becommentariëren. Ze hebben me 
ontzettend veel geleerd en gestimuleerd, zowel in het onderzoek als in de patiën-
tenzorg. Het is dankzij hen en hun vertrouwen in mij dat ik me op professioneel 
gebied heb kunnen ontwikkelen tot waar ik nu ben. 
♣
Aan mijn promotieonderzoek hebben veel mensen meegewerkt zonder wie er 
niets van terecht zou zijn gekomen. Het gaat hierbij om de uitvoerende therapeu-
ten: Renate Nijboer, Ellen Kamphuis, Heleen van Gijssel, Greet Troost, Hanjo 
van Berkel, Dennis Bastiaansen, Marcel Vosmeer, Anje Sterrenburg, Monique 
Hiwat, Nanette Demmers, Johanna Woudstra, Marjolein van Loenhout, Julie 
van Limbergen, Regina Geerards, Pieter Claus en Astrid van Es. Zij hebben met 
veel inzet de behandeling uitgevoerd die in dit proefschrift wordt beschreven. 
En het gaat ook om de interviewers: Maimoene Weerdenburg, Leon Mirck, 
Wouter de Waal, Miranda van den Berge, Alexander van Galen, Marijk Vonk, 
Suzanne van de Laar, Soumia Aamari, Elvira van Alphen en Janneke Gilden. Zij 
hebben met veel geduld en kundigheid alle patiënten aan uitvoerige interviews 
onderworpen. Dank daarvoor! En tot slot is er een belangrijke bijdrage gegeven 
door de trainers van verschillende onderdelen van Treatment Adherence The-
rapy: mijn twee promotoren en Maarten Merkx en Cor Hoffer. Veel dank voor 
het meedenken en voor alle inzet. 
♣
Alle co-auteurs van de hoofdstukken van dit proefschrift hebben een belangrijke 
bijdrage geleverd aan het uiteindelijke geheel, waarvoor ik ze van harte bedank. 
♣
Er hebben verscheidene instellingen aan het onderzoek meegewerkt. Dit waren 
het Erasmus Medisch Centrum, Bavo-Europoort, Riagg Rijnmond, Delta Psy-
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chiatrisch Centrum, en De Grote Rivieren. Bedankt voor alle mogelijkheden en 
de medewerking die aan het onderzoek zijn geboden! 
♣
Farrid Maagdelijn en Jiska van Espelo, bedankt voor het meedenken en ontwer-
pen van de omslag van dit proefschrift. 
♣
Katja Korte, dank voor alle steun en liefde. 
♣
Tot slot wil ik alle patiënten bedanken die aan het onderzoek hebben deelge-
nomen. Ze hebben eraan meegewerkt en de behandeling ondergaan die erbij 
hoort. Ze hebben privé-informatie beschikbaar gesteld en moeilijke kwesties 
met ons besproken. Veel dank!
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11.5 over de auteur 
Anton B.P. Staring werd op 20 februari 1979 geboren te Venlo. Hij behaalde in 
augustus 1997 zijn VWO-diploma aan het Knippenberg-college in Helmond. 
Daarna heeft hij een jaar de opleiding tot wiskunde-docent gevolgd op de Fontys 
Hogeschool in Tilburg, hetgeen werd afgerond met het propedeuse-diploma. 
Hij startte in 1998 met het studeren van psychologie aan de Universiteit van 
Tilburg, alwaar hij zijn diploma behaalde in juli 2002, in de afstudeerrichting 
klinische gezondheidspsychologie. Zijn scriptie ontving de Wim de Moor scrip-
tieprijs voor sociale wetenschappen. Daarna heeft hij een jaar gewerkt als junior 
onderzoeker / beleidsmedewerker bij GGZ Groep Europoort te Rotterdam, en 
vervolgens is hij een jaar gaan reizen. In deze periode heeft hij samen met drie 
anderen De Branding opgericht, een filosofisch-ethische beweging en tijdschrift, 
met als doel om ethische en politieke discussie te voeren. Bij terugkomst in 
Nederland (eind 2004) is hij gestart met zijn promotie-onderzoek en eveneens 
als behandelend psycholoog bij het huidige Bavo-Europoort in Rotterdam, 
waar hij op dit moment nog steeds werkt. In de periode van 2005 tot 2008 heeft 
hij de opleidingstrajecten tot GZ-psycholoog (RINO) en cognitief gedragsthe-
rapeut (VGCt) gevolgd en afgerond. Sinds 2009 is hij gecertificeerd docent 
bij Kenniscentrum Phrenos (voorheen Schizofrenie Stichting), van waaruit hij 
cognitieve gedragstherapie bij psychoses doceert. Hij geeft soms les in opdracht 
van de RINO, Cure and Care Development, en andere scholing-organisaties in 
de gezondheidszorg. Ook heeft hij in de Verenigde Staten gewerkt als trainer 
voor een project van het National Institute of Mental Health. 
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11.7 Phd Portfolio
Summary of PhD-training and teaching
Name PhD student: A.B.P. Staring
Erasmus MC Department: Psychiatry
Research School: O3 Research Center
PhD period: May 2005 – Aug 2010
Promotor 1: Prof.dr. C.L. Mulder
Promotor 2: Prof.dr. M. van der Gaag
1. PhD training Year Workload
General courses 
- Psychiatric Epidemiology (NIHES)
- English scientific writing (O3 Research Centre)
- Regression Analyses (NIHES)
- Clinical Trials (NIHES)
- Bridging science and clinical practice (ZonMW)
2006
2006-2007
2007
2007
2008
26 
12 
45 
20 
21
Specific courses (e.g. Research school, Medical Training)
- WHO-CIDI training, DSM-IV en ICD-10 diagnoses
- Motivational interviewing
2005
2005
20
40 
Seminars and workshops
- Seminars at O3 Research Centre, Erasmus MC
- Seminars at the Platform Psychiatry and Philosophy, VvP
2005-2010
2009-2010
30
20
Presentations
- Various presentations at research seminars and mental health 
institutions
2005-2010 200
(Inter)national conferences
- The Schizophrenia International Research Society Congress, 
Florence, Italy
- Schizofrenie Congres, Zwolle (oral presentation)
- The International Congress for the Psychological Treatments 
of Schizophrenias and other Psychoses, Kopenhagen, Den-
mark (two oral presentations)
- Werken met moeilijke mensen. Nieuwe interventies en instru-
menten in de Openbare GGz, Poortugaal (oral presentation)
- Najaarscongres van de Vereniging voor Gedragstherapie en 
Cognitieve therapie (VGCt), Veldhoven (oral presentation)
- 36e Voorjaarscongres van de Nederlandse Vereniging voor 
Psychiatrie, Amsterdam (oral presentation)
- (F)ACT bemoeizorg-congres, Amsterdam (oral presentation)
- Schizofrenie Congres, Zwolle (poster presentation)
- International Congress on Schizophrenia Research, Colorado 
Springs, USA
- Doorbraakproject Schizofrenie, Zutphen (oral presentation)
- Symposium Samenwerking in behandeling, Amsterdam (oral 
presentation)
2010
2009
2009
2009
2008
2008
2008
2007
2007
2006
2005
30
30
70 
20
20
20
20
30
32 
20
20
2. Teaching
Supervising Master’s theses (two theses) 2006-2008 100
- Consultation and training for the research team of Prof.dr. P.J. 
Weiden at the University of Illinois in Chicago (UIC), in light 
of the ‘Cognitive Behavioural Therapy Adherence Interven-
tion Program,’ financed by the National Institute of Mental 
Health (NIMH, R34 MH080978). 
- Various courses and workshops in motivational interviewing 
for mental health institutions, general practicioners, and the 
Radbout University Nijmegen. 
2009
2007-2010
50
100
TOTAL 996 hours
